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A new convergent methodology has been developed for the synthesis of the anti-
malarial lead compound ADAM (24). A series of 41 derivatives were successfully 
synthesized, 35 of which were new compounds; all of which related to ADAM (24). All 
the synthesized derivatives were screened against in vitro Plasmodium falciparum K1, of 
which 11 showed significant activity in the low micromolar range, including compound 
(46) (IC50 0.3 g/ml), (80) (0.7 g/ml). and (88) (1.4 g/ml). A preliminary structure 
activity relationship analysis study was performed, which suggested that while 4,6-
diaminopyrimidine analogs are inactive, if one of the two amines are alkylated then anti-
malarial activity is returned. In order to generate a more thorough analysis, more 
compounds need to be synthesized by modifying the side chain. The SAR study also 
suggests that the heteroatom nitrogens in the pyrimidine ring are required for anti-malarial 
activity. The entire range of derivatives based on 5-benzoyl-4,6-dichloropyrimidine are 
inactive. The replacement of the phenyl substituent with an isopropyl group resulted in 
good anti-malarial activity but less than the parent compound.  
Novel synthetic dimerising methodology mediated by thallium(III) trifluoroacetate 
has been developed for the synthesis of biindoles. The methodology included the 
development of 2,2’- and 2,7’-biindoles, and 2,7’,7,7’’-triindole. A series of 41 new indole 
derivatives were synthesized and screened for anti-malarial activity, of which three showed 
significant anti-malarial activity. During this study, the dimerisation of indole mediated by 
 xii 
triflic anhydride was demonstrated for the first time. There are two other interesting 
synthetic results were observed, the triflic anhydride-mediated bi-pyrroloindole formation 
and the formation of the 1,2-dihydropyridineindole.  
Most compounds synthesized here were further tested in a series of additional 
biological assays, and a number of them showed activity against HIV reverse transcriptase, 
integrase, tuberculosis, anti-fungal and anti-cancer. In particular, the biaryl derivatives 
showed moderate activity against tuberculosis and fungal, which may be able to investigate 

















Malaria is a serious endemic disease that has resisted all efforts of eradication, 
and control for over a century. The disease is a growing, and is a major threat to public 
health in more than 100 countries including, Africa, Asia, Oceania, Latin and South 
Africa (Figure 1.1).1 Malaria affects more than 500 million people per year, with an 
associated 2.7 million deaths,2 three-quarters of which are children under the age of 
five years. The economic toll of malaria is tremendous with an estimation that the 
African continent alone has forgone almost $100 billion in lost Gross Domestic Product 
over the last 35 years due to the disease.2 Today, in the United States and Western 
Europe, most malaria infections are imported by travellers and with the increasing 
globalization of commerce, the number of travellers to areas of high risk is increasing 
each year.3  
 





Figure 1.1: Global distribution of malaria.1   
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1.2 Malaria – the parasite 
Malaria is caused by the protozoan parasite, Plasmodium, a member of the 
phylum Apicomplexan. There are four species that infect humans: P. falciparum, P. 
vivax, P. malaria, and P. ovale of which P. falciparum, and P. vivax is widespread.  
Immature young erythrocytes are invaded by P. vivax and P. ovale malaria, whereas P. 
malaria infect mature cells and P. falciparum infects cells of all stages4 and the parasite 
disease results in severe infections and is responsible for the malarial-related deaths. P. 
malariae occurs widely and causes the least severe but persistent infections, whereas P. 
ovale is mainly confined to Africa.  
 
1.3 Life cycle 
1.3.1 Hepatocyte Invasion 
Malaria infection is initiated by the bite of an infected Anopheline mosquito.5 
Infective forms of the parasite named sporozoites are carried into the human host in the 
saliva of the mosquito and are rapidly carried to the liver where they invade liver 
hepatocytes via a receptor ligand mediated adhesion of the parasite (Figure 1.2).6 The 
parasite establishes as an infection in the liver hepatocytes within a period of ten days, 
and in the case of P. falciparum multiply from a single parasite to approximately 
10,000 organisms. This species possesses one of the fastest DNA replication rates of all 
















See the hard copy for the picture 
 
Figure 1.2: Malarial parasite life cycle.8 
 
1.3.2 Erythrocyte Invasion 
Upon maturation to merozoites, the parasites are released from the liver and 
invade human erythrocytes (Figure 1.2), again via a receptor mediated process.6,9 The 
merozoite invades the red cell generating a vacuolar membrane containing both host 
and parasite derived lipids and proteins. Once inside the infected cell, the parasite 
begins its replication cycle over a 48 hour period, with the parasite multiplying from a 
single merozoite to 20 new daughter merozoites or schizonts, each of which is capable 
of invading a new red cell. The process of intracellular maturation to schizonts is called 
schizogony. The development of the schizont progresses from the initial ring-form 
stage to the trophozoite stage to the schizont stage. Within a few days in a non-immune 
host, the number of parasites can reach 1011 parasites. All of the symptoms, including 
fever, anemia, cerebral malarial, and the morbidity and mortality of the disease are 
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associated with the erythrocyte stage of the infection.10 To complete the cycle, a subset 
of the parasites in infected red cells follow a different developmental pathway and form 
gametocytes (Figure 1.2). Once taken up by a mosquito blood meal, gametes are 
released and fertilization occurs in the mosquito mid gut (Figure 1.2). The zygote 
parasite differentiate into a motile form and migrate across the gut wall where it 
develops into an oocyst, undergoing reduction division and then replication to produce 
approximately 10,000 oocyst from a single zygote (Figure 1.2). It is during this 
sporozoite portion of the life cycle that genetic exchange can occur between different 
parasites. The obligate sexual exchange, which occurs at each transmission cycle, is 
thought to play a major role in the rapid spread of traits such a drug resistance 
throughout parasite populations. 
 
1.4 Traditional treatment of malaria 
The most prevalent drug treatments against malaria still used today, have their 
origins in a natural plant called the cinchona. Exploitation of the cinchona bark, first 
discovered in Peru, began in the 17th century by the Jesuits. The history of the 
discovery of its curative effects is not clear but the first recorded shipments of the bark 
to Rome were in 1631, 1632 and again in 1645.11 
A successful treatment for malaria was used by Robert Talbor in the 17th 
century, an apothecary's apprentice in the English marshes, to treat Essex smugglers 
and European Royalty. The basis of this cure is identified as quinquina from the bark of 
the South American Cinchona tree.12 
The powdered cinchona bark was administered in various forms and through 
various means remained the main anti-malarial agent until 1820, when two French 
pharmacists, Pierre Joseph Pelletier and Joseph Bienaimé Caventou, succeeded in 
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separating its active ingredients, which they named quinine and cinchonine.11 This was 
the basis for the subsequent development of quinine and its derivatives, which are still 
in widespread use today. A Chinese plant, Artemisia annua L., was also known to be 
used for curing ‘ague’, as malaria was then known, and compounds derived from this 
source have also been developed as anti-malarial drugs.4 
 
1.5 Present drugs and treatment of malaria 
Other anti-malarials are gaining importance as resistance mounts to cinchona 
alkaloids. Several classes of drugs are widely used both therapeutically and 
prophylactically in the treatment of malaria. There are a number of measures to reduce 
the possibility of bites13 to travellers and inhabitants of high-risk areas. Prophylaxis is 
achieved with the use of mosquito repellents and insecticide impregnated nets, or drug 
regimes started before and after finishing travelling to a malaria endemic region.14  
Vector control was previously effective in controlling malaria. However, it is 
now largely ineffective due to insecticide-resistant mosquitoes. As alternatives to these 
mainstays of control, an intensive effort to develop subunit vaccines targeted at various 
stages of the malarial life cycle has been undertaken. One such vaccine, directed 
against the sexual and sporogonic stages and referred to as a transmission-blocking 
vaccine, offers the hope of controlling malaria in geographically isolated areas.13 
Since the 1940s, two major classes of anti-malarial drugs have been used. The 
antifolates, which inhibit DNA synthesis and include DHFR (dihydrofolate reductase 
inhibitors) and the sulfa drugs.15 The cinchona alkaloids or quinoline containing drugs 
like quinine and its derivatives (chloroquine, amodiaquine and mefloquine) are more 
frequently used.15 Other important anti-malarials include the tetracyclines and the 
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artemisinin derivatives. Details about the most common prophylactic and therapeutic 
drugs for malaria are presented in following sections. 
 
1.5.1 Artemisinin Derivatives  
Significant anti-malarial activity against both P. falciparum and P. vivax has 
been identified from the traditional Chinese plant Artemisia annua.16 The active 
ingredient in the plant extract was identified as artemisinin,17 a naturally occurring 
sesquitterpene lactone peroxide, which has been used in traditional Chinese medicine 
for the treatment of fever since A.D. 341.18,19 Structurally, artemisinin (1) (Figure 1.3) 
is unrelated to any other anti-malarial and problems associated with high rates of 
recurrence of the disease, its low solubility, short plasma half life and poor oral 
bioavailability prompted investigations into the discovery of other derivatives with 
better physiochemical properties.20,21 These included -arteether (2),22 -artemether (3), 
and -sodium artesunate (4),18 (Figure 1.3) all of which have in vitro and in vivo 









(1) R = =O, artemisinin
(2) R = OCH2CH3, ß-arteether
(3) R = OCH3,ß-artemether
(4) R = OCOCH2CH2COONa, α-sodium artesunate  
Figure 1.3: Artemisinin and some of its derivatives 
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Artemisinin-related compounds are concentrated in parasite-infected 
erythrocytes and the bridging endoperoxide group appears to be crucial for anti-
malarial activity of the drug.18 Critical for parasite survival is the anti-oxidant effect of 
the erythrocyte. It appears that the anti-malarial activity of the artemisinin compounds 
is mediated by increasing levels of activated oxygen radicals.18,23 Artemisinin-related 
compounds are quick acting and reduce parasitemia and, therefore, are important in 
treating severe cerebral malaria. However, it is uncertain whether these compounds will 
decrease mortality with severe malaria.18 There are also high recurrence rates when this 
family of drugs is administered alone. The combination of artemisinin and 
mefloquinine (e.g. artesunate) is more effective than artesunate monotherapy as it 
decreases the rate of recurrence and improves the overall cure rate (90-100%).24 
Derivatives of artemisinin, including new trioxanes (5),25,26 novel ring derivatives (6) 
and trioxane ethers (5a)26 (Figure 1.4), are potent in vitro 21,27 and are as effective as 

















      (5)               (6) 
  
Figure 1.4: Other derivatives of trioxane derivatives and their anti-malarial activity 
IC50 8.3 nM (5), 12-allyldexoartemisinin (6), and trioxane ethers (5) 
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1.5.2 Antimetabolites 
Anti-metabolites are divided into two types, based on mode of action, and exert 
their activity on the folic acid cycle. Essential to the parasite survival is their ability to 
carry out pyrimidine synthesis de novo, as they are unable to scavenge preformed 
pyrimidines from their host using a salvage pathway.29 
The type 1 antifolates, including sulfa drugs sulphonamides and sulphones 
(dapsone), sulfamethoxazole (7), and sulfisoxazole (8) (structure see Figure 1.5), 















            (7)                (8) 
   sulfamethoxazole                      sulfisoxazole  
Figure 1.5: Type one antifolates are sulfanilamides acting through the inhibition of 
PABA 
  
Type 2 antifolates, pyrimethamine (9) and cycloguanil (10) (a metabolite of 
proguanil), compete with dihydrofolate and inhibit DHFR (dihydrofolate reductase).29 
The sulfa drugs alone have weak anti-malarial activity and are used in combination 
















   (9)            (10)                      
   pyrimethamine                  proguanil 
Figure 1.6:  Type 2 antifolates which act through inhibition of DHFR (dihydrofolate 
reductase) 
 
1.5.3 Aminoquinolines  
Quinine has been used for centuries in treating malaria, and it is still used to 
control P. falciparum malaria. Chloroquine (12) is a derivative of quinine (11); other 


























     (11)    (12)    (13) 












                        (14)        (15) 
      Mefloquine          Halofantrine 
Figure 1.7: Quinine, chloroquine and its derivatives, amodiaquine (13), mefloquine 
(14), and halofantrine (15). 
 
These drugs are blood schizonticides and accumulate by a weak base 
mechanism in the acidic food vacuoles of trophozoite-infected cells, thereby preventing 
hemoglobin production in the organelle.33 The quinolines inhibit the heme polymerase 
enzyme resulting in specific toxicity during the parasite development.33 
Quinine is a cinchona alkaloid derived from the bark of the cinchona tree and 
remains an important anti-malarial drug due to the emergence of chloroquine resistance 
and multi-drug resistant (MDR) strains of malarial parasites. Quinine monotherapy is 
now associated with a failure rate of 40-70% in SE Asia and Africa.17 Quinidine is the 
dextrarotatory diastereomer of quinine and is more active and more toxic than quinine. 
Mefloquine (14)31 is a 4-aminoquinoline methanol structurally related to quinine. It is 
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administered orally and possesses a long half life which has resulted in the emergence 
of drug resistance.17 Mefloquine was first used clinically in 1975 and, like chloroquine, 
appears to act by inhibiting the heme polymerase, similar to chloroquine. It has been an 
effective agent against drug resistant P. falciparum. Mefloquine is selectively active 
against the intraerythrocytic mature forms (trophozoite and schizonts) of malaria and 
has no activity against gametocytes.34 However, in vitro and in vivo resistance has been 
reported in malaria endemic regions. The mechanism of resistance may involve the P. 
falciparum MDR gene family. Cross resistance can be expected between mefloquine, 
halofantrine and maybe quinine.  
Related to mefloquine (14) is halofantrine (15),32 a phenanthrene methanol 
analog which is a recent addition to the anti-malarial drugs to treat  multidrug resistant 
P. falciparum. Cure rates varied and high recurring rates were observed. Also, recent 
reports have raised serious questions concerning its safety.24,35 Cardiotoxicity has 
become a major concern during treatment with this anti-malarial drug. Lengthening of 
the QTc (Q and T wave correction in cardiac cycle) and severe cardiac arrhythmia have 
been observed.35 
 
1.5.4 Antibiotics  
The use of antibiotics in the treatment of malaria is a well-established therapy 
that has recived renewed interest with the appearance of chloroquine-resistant malaria. 
The antibiotic doxycyclin is related to tetracycline and inhibits parasite mitochondrial 
protein synthesis.36 It is an effective agent when used prophylactically against MDR P. 
falciparum. 37 Azithromycin (16) is a semisynthetic azalide antibiotic (Figure 1.8) used 
as a broad spectrum anti-bacterial agent.38 It is also used as a prophylactic agent for 
malaria. It concentrates in tissues and demonstrates significant activity against the 
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exoerythrocytic stage of malaria (liver). Its anti-malarial activity is probably due to 













          (16) 
     Azithromtcin 
Figure 1.8:  Azithromycin is a macrolide semisynthetic azalide antibiotic 
 
1.5.5 Other Drug Classes  
The chalcones (17) and (1,3-diphenyl-2-propen-l-one) (18) (Figure 1.9) have 
been identified as novel potential anti-malarials.39 A series of these compounds were 
screened in vitro and showed nanomolar activity against both chloroquine sensitive and 
resistant strains of P. falciparum.39 Recently, licochalocone A (19) (Figure 1.9),40 
isolated from Chinese licorice roots, was also reported to possess in vitro and in vivo 
























     (19) 
                   licochalocone A 
Figure 1.9: Chalcones identified as a novel potential anti-malarials, compounds (17), 
(18), and (19) showed anti-malarial activity at micromolar range. 
 
1.5.6 Malarone 
Malarone is a new synergistic drug combination of proguanil (10) and 
atovaquonone (20).41 Atovaquinone (20) is an analog of hydroxylnaphthoquinone, and 
is an inhibiter of protozoan transport.24 However, administration of atovaquinone alone 
induces rapid resistance. The drug combination has undergone several clinical trials and 
has been found to be 95% effective in otherwise drug resistant P. falciparum malaria.42  
 
 








Figure 1.10: Atovaquone (20) is an analog of hydroxynaphthoquinone used in malarial 
treatment combination with proguanil (10) 
 
1.6 Drug resistance  
Over the past three decades, the emergence of drug resistance in P. falciparum 
has been increasing. It has spread from limited geographic foci to the current global 
distribution such that in 1998 the majority of the P. falciparum infection showed 
reduced susceptibility to at least one drug. Furthermore, the parasites have become 
resistant to multiple drug therapies.3 As each new drug is introduced into wide spread 
clinical and field use, resistance has appeared, often within a few years. Thus, in many 
areas where P. falciparum is endemic, parasites are resistant to multiple drugs. This 
presents an acute clinical problem, namely the severe limitation of effective drugs in 
many malaria endemic areas. Drug resistance is not unique to malaria but is a problem 
in the treatment to most bacterial infections and many neoplasias (cancer). The problem 
is more acute for malaria due to the limited number of anti-malarial drugs, although the 
situation with certain bacterial infections is rapidly converging with that of malaria, 
namely the emergence of resistance to all available drugs. The traditional approach to 
the drug resistance has been the introduction of a new drug, either a completely new 
drug or one designed to be effective against resistant organisms. This approach has 
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been effective for the past four decades however it has served to concentrate drug 
development efforts on a small number of well-defined targets and a limited set of 
compounds. The emergence and spread of resistance to anti-malarial drugs has 
highlighted the need for the discovery and development of novel anti-malarials agents. 
To achieve this goal, anti-malarial drug research, needs to identify new drug candidates 
and new drug targets. 
 
1.7 Malarial plasmodia genome and the implications for new drug 
therapies 
The completion of the Plasmodium falciparum genome sequence43 heralds a 
new era in the efforts to identify all the parasites genes along with cellular functions. 
The 23-megabase nuclear genome consists of 14 chromosomes, encoding for about 
5300 genes. Many of the enzymes involved in a number of major metabolic processes 
have been identified. The genome sequence provides the foundation for future studies 
of this organism, and is being exploited in the search for new drugs and vaccines to 
fight malaria. 
 
1.8 Potential chemotherapeutic targets 
New anti-malarial targets are required to allow for the discovery of chemically 
diverse and effective drugs. The search for such new targets and new drug chemotypes 
is likely be helped by the arrival of functional genomics and structure-based drug 
design. The targets can be used as the basis for screening compounds in order to 
identify new leads. Potential chemotherapeutic targets in the malaria parasite can be 
broadly classified into three categories: those involved in processes occurring in the 
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digestive vacuole, enzymes involved in macromolecular and metabolite synthesis and 
those responsible for membrane processes and signalling. Details about some of the 
potential targets are given below. 
 
1.8.1 Processes in the digestive vacuole 
These primarily include hemoglobin digestion and heme detoxification. 
Antioxidant defence mechanisms also take place in the digestive vacuole as well as in 
the cytoplasm of both the parasite and the host cell, both of which represent potential 
chemotherapeutic targets. The digestive vacuole (an acidic, lysosome-like organelle) 
undertakes key processes. Once the digestive vacuole is formed, it appears to be the 
primary site of hemoglobin degradation. Vesicles bud from the cytostome transport 
hemoglobin to the vacuole where their outer membrane fuses with the single 
membrane-delimited vacuole. The vesicle is then lysed and hemoglobin is hydrolysed. 
The lack of nonproteolytic acid hydrolysis in digestive vacuoles suggests that, during 
their relatively short intraerythrocytic cycle, parasites may not need to degrade and 
recycle macromolecules other than hemoglobin and that digestive vacuoles may be 
specialized for that purpose. 
One important target for anti-malarial drugs has been the process of hemoglobin 
digestion, which appears to be essential for parasite growth. During the 
intraerythrocytic, the host cell cytoplasm is consumed and an estimated 60-80% of the 
hemoglobin is degraded. Hemoglobin proteolysis releases heme and generates amino 
acids. The heme moiety does not appear to be metabolized or recycled but instead, is 
stored as an inert polymer known as the malaria pigment hemozoin. Amino acids 
derived by hydrolysis are incorporated into parasite proteins and also appear to be 
available for energy metabolism. Hemoglobin proteolysis may be essential for survival, 
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because Plasmodium has a limited capacity for de-novo amino acid synthesis. In 
contrast to other metabolic pathways, the parasite seems to have difficulties in finding 
alternative processes for hemoglobin utilization and heme detoxification. As a result, 
quinine and aminoquinoline anti-malarials, which are thought to act principally by first 
binding to heme,10 have enjoyed a long life span of effective use relative to other drugs 
(e.g. folate inhibitors). The consequence of this binding of drug to heme molecule may 
be inhibition of heme polymerization and consequent toxicity. Resistance has emerged 
via drug accumulation/extrusion mechanisms at the digestive vacuole membrane level44 
rather than by mutation at the binding site of putative protein drug target, which if it 
exists, is as yet unknown. 
 
1.8.2 Hemoglobin digestion and proteinases 
To date, virtually all the hemoglobin-degrading capability is ascribed to two 
aspartic proteinases plasmepsin I and plasmepsin II (analogous to cathepsin D) and one 
cysteine proteinase, falcipain (analogous to cathepsin L). Inhibition of these enzymes 
has been shown to block hemoglobin degradation and kill the parasite in culture 
systems.45 Therefore, these three enzymes are potential targets for new drug 
development. 
The first aspartic proteinase (plasmepsin I) makes a single cleavage in the 
hemoglobin in a hinge region, unraveling the molecule for further proteolysis (Figure 
1.12). A second aspartic proteinase (plasmepsin II) has preferential activity on acid 
denatured globin (Figure 1.11). The two aspartic proteinases are present in the 
digestive vacuole at different time in the parasite cycle. Plasmepsin I plays important 
role at the ring stage, whereas plasmepsin II acts on trophozoite and young schizonts.  
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Hemoglobin 
      Plasmepsin I and II 
Heme release           Large fragments 
 Polymerisation     Falcipain 
 
Hemozoin          Small peptides    Amino acids (cytoplasm)  
Figure 1.11: Proposed simplified pathway for hemoglobin degradation in P. 
falciparum 
 
The plasmepsin generates hemoglobin fragments that can not be further 
catabolized without cysteine protease (falcipain) action (Figure 1.11). Inhibition of 
falcipain results in osmotic swelling leading to vacuoler functions being impaired, with 
parasite death ensuing.46 This enzyme might also be a potential target for new drug 
development. 
Validation of the vacuolar proteinases as essential targets, their specificity, and 
the potential for compound screening and drug development must all be considered. 
Firstly, there is sufficient evidence to support the validity of the vacuolar proteinases as 
chemotherapeutic targets. Inhibitors of these enzymes have been shown to block 
hemoglobin degradation and kill the parasites in culture, although the results of in vivo 
experiments are less encouraging. 
Secondly, available data suggest that the specificity of proteinase inhibitors 
towards parasite, but not host, enzymes can be achieved. The degree of homology with 
respect to the human counterparts is low enough to allow the design of specific 
inhibitors of the parasite enzymes. For instance, there are five related aspartic 
proteinases present in humans and other vertebrates. Some are in the gastrointestinal 
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system, either secreted in gut (gastricin and pepsin) or intracellular cathepsin E, and 
this will be a clear potential stopper with orally administered compounds. Rennin, 
which is produced by the kidneys and a few other tissues, is the least likely to be 
affected by inhibitors of plasmodium aspartic proteinases. 
Thirdly, molecular screening is now possible, although not yet at the desired 
high throughput level, in particular for falcipain. The genes for the three vacuolar 
proteinases have been cloned and the recombinant proteins expressed and human 
enzymes are available for in vitro screening to assess compound specificity.47  
 
1.8.2.1 Oxidative stress  
Whether compounds directed at the parasite’s antioxidant defense could be a 
valid chemotherapeutic approach is still a matter of debate.47 However, it is generally 
accepted that oxidative stress is an important mechanism for destruction of malaria and 
other intracellular parasites. It is commonly accepted that since intra-erythrocytic (and 
hepatic) stage malaria parasites must encounter reactive oxygen species (ROS), which 
are produced either by themselves, the erythrocyte or host immune cells, they must 
build antioxidative defense against ROS.48,49 It is also generally accepted that in order 
to prevent oxidant damage, the parasite would both commandeer host enzymes and 
produce its own antioxidant enzymes. 
The erythrocyte itself has potent antioxidant defenses to counteract the constant 
production of ROS by oxidation of hemoglobin (Fe2+) to methahemoglobin (Fe3+). In 
the erythrocytic, heme iron is almost entirely in the ferrous state. Upon degradation in 
the parasite digestive vacuole, the iron is oxidized to the ferric ion. Electrons liberated 
by this oxidation combine with molecular oxygen to produce reactive oxygen (O2-), 
hydroxyl radical (OH·) and H2O2.50 This appears to be a major source of oxidative 
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stress to the parasite. Anti-malarials with a peroxide bridge, like the artemisinin (1) 
family of compounds and the trioxanes (5) are believed to act by inducing oxidative 
stress. The proposed mechanism for these drugs involves heme binding which leads to 
drug activation of free radical intermediates that in turn alkylates essential parasite 
proteins, leading to loss of enzyme function.23,51,52 
 
1.8.3 Glycolysis  
The erythrocytic malarial parasite depends primarily on glycolysis for its energy 
generation.53 The NAD+ (Nicotinamide Adenine Dinucleotide) consumed during 
glycolysis is regenerated by the fermentation of pyruvate in cell cytoplasm and/or 
through the electron transport chain in the mitochondrian. Contrary to mammalian cells 
and most aerobic organisms, plasmodia pyruvate does not enter the citric acid cycle and 
lactate is the end-product of the glycolytic pathway. Lactate dehydrogenase (LDH) 
catalyses the reduction of pyruvate by NADH to lactate. Although this may represent a 
potential target, and there are no known lead compounds at present, despite the current 
screening of compounds.    
 
1.8.4 Nucleic acid metabolism  
Nucleic acids are activated precursors of DNA and RNA, and are intermediates 
in many biosynthetic pathways. They take part in many biochemical processes in the 
mammalian host, as well as in the parasite, especially those involving energy transfer 
and biosynthesis. However, major differences exist between plasmodial and the 
corresponding human pathways. This parasite differs from mammalian cells in that it 
lacks the ability to synthesize purines through the de novo pathway. 53 Instead, it relies 
solely on the purine salvage pathway, thus relying on pre-formed host purine 
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precursors. Conversely, they cannot salvage either pyrimidine bases or nucleosides so 
they must synthesize pyrimidine nucleotides de novo,53 whilst mammalian cells can 
either salvage or synthesize de novo pyrimidine nucleotides. The parasite relies on de 
novo synthesis of folate cofactors, although exogenous folates can be salvaged. 
The biosynthesis of purines, pyrimidines and folates and mitochondrial electron 
transport is intimately linked. 
 
1.8.4.1 Purine pathways 
The parasite reliance on host purines for nucleic acid synthesis and energy 
metabolism can theoretically be exploited as a means of chemotherapeutic attack. 
Hypoxanthine salvage is a potential target for new drug discovery. Although ATP is the 
predominant purine in RBCs (red blood cells), there is considerable evidence that 
hypoxanthine, formed during ATP catabolism is the primary source of purines for P. 
falciparum. The parasite-specific enzyme for salvage is hypoxanthine-guanine 
phosphoribosyltransferase (HGPRT). Purine salvaging is also funnelled through purine 
nucleoside phosphorylase (PNP)54 and adenosine deaminase (ADA). HGPRT and PNP 
may be essential, as also indicated by the fact that antisence nucleotides targeting 
HGPRT mRNA kill parasites in vitro. Indeed, inhibitors must be selective, as humans 
also posses HGPRT: severe genetic deficiency result in Lesch-Nyhan syndrome, and 
moderate deficiency result in the gut. So far, it is unclear whether HGPRT can ever 
qualify as a drug target for anti-malarial drug screening. Immucillin H (Figure 1.12) is 
the first known PNP inhibitor with specificity for the malarial enzyme.54 
 
 










OH OH  
   (21) 
immucillin-H 
Figure 1.12: Immucillin-H is new PNP inhibitor with Kd value 860 pM for P. 
falciparum. 
 
1.8.4.2 Pyrimidine metabolism and electron transport  
Unlike mammalian cells, which have the ability for both de novo synthesis of 
pyrimidine nucleic acids and the salvage of preformed pyrimidines, the malaria parasite 
cannot scavenge preformed pyrimidine nucleic acids and must synthesise pyrimidine 
via the de novo path way.53,55 
In human cells, dihydroorotate dehydrogenase (DHODH) is localized in the 
mitochondria and catalyzes the rate limiting step of UMP formation in the pyrimidine 
biosynthetic pathway. Sequence analysis of the malarial DHODH gene reveals that it 
belongs to the mitochondrial type membrane enzyme. DHODH has been purified56 and 
various inhibitors have been synthesised and tested.57  
Moreover, subsequent enzymes in the pathway, oratate 
phosphoribosyltransferase, and orotidine 5’-phosphate decarboxylase differ 
significantly from the host enzymes.56  
Parasite DHODH is a mitochondrial enzyme linked to an electron transport 
chain terminating in cytochrome oxidase.58 The last two enzymes exist as separate 
proteins on P. falciparum, while they exist as bifunctional proteins in the host.59  5-
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Fluorooratate60 is a DHODH inhibitor. Atovaquone (20) (Figure 1.10) is a 
naphthaquinone derivative inhibitor of cytochrome bc1 complex and dissipater of 
mitochondrial membrane potential. Hence, the hybrid pyrimidine and respiratory chain 
system is an attractive target for malaria chemotherapy.  
 
1.8.4.3 Folate pathway  
Tetrahydrofolate (H4 folate tetrahydropteroylglutamate), a carrier of activated 
one carbon groups, is a key coenzyme in amino acid and nucleotide metabolism. In P. 
falciparum, it can be synthesized either via a de novo or salvage pathway.61,62 The 
folate pathway is linked to the purine salvage via GTP. GTP Cylcohydrolase is the first 
enzyme in the de novo synthesis pathway.61 
Four enzymes of this pathway are traditional anti-malarial targets. These are 
dihydropteroate synthase (DHPS), 2-amino-4-OH-6-OH-methyldihydropteridine 
pyrophosphokinase (PPPK), dihydrofolate reductase (DHFR) and thymidylate synthase 
(TS). Unlike mammalian cells, these enzymes exists in the malaria parasite as a bi-
functional enzyme.63 It has been shown that mutations in DHPS are responsible for 
sulfone/sulfonalimide resistance.64  
Some of the most widely used anti-malarials inhibit folate metabolism, they are 
sufonamides and sulfones used in combination with pyrimethamine (9) or biguanides 
(10) (DHFR inhibitors) (Figure 1.6). 
 
1.8.5 DNA and RNA synthesis  
DNA appears to be replicated at a minimum of five discrete points during the 
plasmodium life cycle. Two such events occur in the mammalian host. In the case of P. 
falciparum, one round of replication in the liver and several cycles are in intra-
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erythrocytic stage schizogony. Several proteins are involved in this process. In 
particular, attention has been focused on DNA replicating enzymes, such as DNA 
polymerase, RNRase (Ribonucleotide reductase) and topoisomerases. It may be 
difficult to see how to achieve selectivity because of the close proximity between host 
and parasite. However, some differences have been reported between the parasite and 
human cells that may open new avenues for research. So far, there is no clear evidence 
that DNA polymerase will serve as a viable target. 
Ribonucleotide reductase (RNRase) is one of the DNA replicating enzymes that 
may be a target of iron chelation therapy. The potential of this enzyme as a target for 
anti-malarial therapy is shown by artemisinin and oligonucleotides.65 
 
1.8.5.1 DNA Topoisomerases  
Topoisomerase I and topoisomerase II are essential nuclear enzymes that enable 
DNA to untwist for replication and transcription. Parasitic topoisomerase properties are 
similar to the eukaryote enzyme, so plasmodium topoisomerases are not good targets 
for anti-malarials. However, fluoroquinolines (14) (Figure 1.7)66 and 9-anilinoacridine 
(21) (Figure 1.13) derivatives,67,68 which are topoisomerase II inhibitors, have been 





Figure 1.13: 9-Aminoacridine is a topoisomerase II potent inhibitor 
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1.8.6 Mitochondria functions   
Sexual blood stage Plasmodium parasite have undeveloped mitochondria 
lacking cristae of the inner membrane,69 as well as the TCA (tricarboxylic acid) cycle 
(krebs cycle) enzymes, NADH dehydrogenase and ATP synthetase. While erythrocytic 
stage malaria parasites use glycolysis for energy production, mitochondrial functions 
such as electron transport and protein synthesis, appear to be essential for survival and 
constitute a potential target for anti-malarial chemotherapy. Drugs which target these 
functions include 8-aminoquinoline, hydroxynaphthoquinones70,71 and antibiotics 
(tetracycline).36,72 Atovoquinone (20) (Figure 1.10) appears to act by inhibiting 
mitochondrial electron transport by depolarizing mitochondria.73 Asexual blood stage 
malaria parasites are also sensitive to prokaryotic ribosomal protein synthesis 
inhibitors, but are insensitive to classical mitochondrial inhibitors, such as antimycin A 
and myxothiazole.73 
 
1.8.7 Biosynthesis  
1.8.7.1 Phospholid metabolism 
The lipid content of an infected erythrocyte is significantly higher than that of 
normal erythrocytes as they possess, in addition to the erythrocyte outer membrane of 
the parasite, the parasitophorous vacuole membrane. Growing and dividing malaria 
parasites therefore need large amounts of phospholipids that are synthesized from 
plasma fatty acids and polar heads. In plasmodia, phosphotidylcholine (PC) is the 
major parasite phospholipid. De novo synthesis from choline via the CDP-choline 
pathway accounts for 60-80% of PC. In addition, PC is also obtained in part from 
ethanolamine via the phosphotidylethanolamine N-methyltransferase pathway.74  
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Compounds are being designed to target the parasite’s supply of PC. High in 
vitro activity with low nanomolar range, which extends to multi resistant isolates, is 
achieved with quaternary ammonium and bis-ammonium salts especially those 
quaternary salts with one long lipophilic alkyl chain and those bis-ammonium salts 
linked by a long alkyl chain. Members of this family of compounds also prove effective 
in vivo in experimental studies involving animals and are being further investigated. 
Much remains to be studied concerning phospholipid biosynthesis in plasmodia in the 
search for new molecular targets. 
 
1.8.7.2 Tubulin assembly  
It is still unclear whether tubulin may represent a target for anti-malarial 
chemotherapy, despite preliminary findings that taxol (22), an antitumor agent derived 
from the yew tree Taxus brevifolis, and its butyloxycarbonyl-substituted derivative 
taxotere, is known to act by binding to polymerized tubulin and inhibiting 
depolymerization in cancer cells. Taxotere (23) (Figure 1.14) is shown to act on 
schizonts at the nanomolar level possessing an IC50 value for P. faciparum in vitro 
which was 1000 times lower than peak plasma values obtained in humans for cancer 
chemotherapy.75 Similar results were obtained with taxol (Figure 1.14) both in-vitro on 
P. falciparum and in-vivo on P. chabaudi at dosage levels used and tolerated in 
humans.76 
 





































Figure 1.14: Taxol (22) and taxotere (23), shown to act at nanomolar level IC50 for P. 
falciparum in vitro  
 
1.8.8 Membrane processes and signaling  
1.8.8.1 Trafficking  
Intra-erythrocytic parasites induce profound changes in the membrane of 
infected erythrocytes, which, among other things, allow for increased permeability to 
secure nutrients from the environment. Theoretically, it is  possible to use such a 
transport system to facilitate the selective entry of anti-malarial compounds into 
infected erythrocytes or to prevent key nutrients from being internalized.77 Researchers 
have attempted to address this from different angles, and a variety of transport systems, 
often difficult to reconcile, have been reported. 
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1.8.8.2 Signal transduction 
Signal transduction pathways are involved in a number of essential cellular 
processes, and data on cancer cells indicate that this approach holds some promise in 
drug development for malaria.78 However, current knowledge of signaling pathways in 
Plasmodium is fragmentary79 and data is mostly in connection with gametocytogenesis, 
although such mechanisms are predicted to play a key role in a variety of parasite 
processes. As such mechanisms are abundant in the host, development of compounds 
with selectivity appears to be a substantial hurdle. 
 
1.8.9 Telomeres and telomerase 
With the rapidly increasing information from genomic and “post-genomic” 
research, many potential chemotherapeutic targets are being identified. Telomerase is 
one of the targets surfaced from genomic research. Telomerase activity has been 
reported in the human malaria parasite, P. falciparum,80 with the most pronounced 
expression in the early ring stage (Figure 1.2).81 It is a specialized cellular reverse 
transcriptase (RT), that helps to stabilize the length of telomeres by adding TTAGGG 
repeats onto the telomeres enabling unlimited division of the cell.82 Cells that fail to 
activate telomerase cannot undergo replication. Consequently, these cells have a limited 
number of cell divisions.83 Telomeres are the DNA-protein complexes of chromosomes 
and differ notably from other DNA sequences in both structure and function. 
Telomeres, the ends of linear chromosomes, preserve genome stability and cell viability 
by preventing aberrant recombination and degradation of DNA.84  
In the adult human, few cells express telomerase.85 The enzyme has not been 
detected in adult somatic tissues with the exception of tissues containing stem cells, 
ganadal, and cancer cells. The presence of the enzyme is increasingly being used as an 
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indicator of abnormal cellular activity such as cancer.86 In contrast, malarial cells 
undergoing schizogony reproduce at an extraordinarily high rate, requiring the 
telomerase enzyme to be active. This differential expression means that it is 
theoretically possible to target the telomerase enzyme in a parasitic cell, with minimal 
effect on the host.  
Many factors suggest that the telomerase enzyme would be a good anti-malarial 
drug target: the short length of P. falciparum telomeres, the high A-T content of the 
Plasmodium genome, and the immediate subtelomeric DNA all appear to render 
Plasmodium vulnerable to telomerase inhibition. Already some reports have been 
published regarding selective inhibition of Plasmodium telomerase enzyme, e.g. 
berberine selectively inhibits the P. falciparum enzyme at 30 µM.87,88 This clearly 
indicates malarial telomerase might be a potential target for future malaria 
chemotherapy. 
Telomerase can be defined as an unusual ribonucleoprotein reverse transcriptase 
whose RNA template is an intrinsic part of the enzyme.84 Sequence alignment of the 
four telomerase genes revealed features similar to reverse transcriptase (RT).89 The 
similarities found between HIV-1 reverse transcriptase and telomerase enzymes have 
been documented and provide a link leading to the possible targeting of this enzyme 
using known HIV-1 inhibitors.90 Malarial telomerase is known to be inhibited by HIV-
1 nucleoside analogues.88 These inhibitors, however, have many drawbacks, as they 
interact with all processes that require nucleosides in both the host and the parasite. 
Similarities between RT and telomerase provided the basis for the creation of partial 
models of the protozoan Euplotes aediculatus telomerase enzyme, based on the 
structure of HIV-1 reverse transcriptase within the region containing the conserved 
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motifs. Four partial telomerase structures were successfully produced, based on 
different conformations of the highly flexible reverse transcriptase enzyme.91  
These telomerase models showed that a form of the non-nucleoside inhibitor-
binding pocket could exist within the E. aediculatus telomerase enzyme. Analysis of 
sequence conservation within the secondary structure forming the pocket suggested that 
variations of the same structure could be present in all telomerase enzymes.91 Although 
most of the residues comprising the pocket are conserved, there is some sequence 
variation within the secondary structure forming the pocket, providing a basis for the 
potential selectivity of non-nucleoside type inhibitors targeted at telomerase. Based on 
the creation of partial telomerase (E. aediculatus) models only, the potential use of 
telomerase-targeted non-nucleoside inhibitors to treat malaria looks promising.  
 
1.9 Anti-malarial new lead generation  
As part of a current research program at the University of Wollongong 
investigating new structural entities as potential non-nucleoside inhibitors of HIV-1 
reverse transcriptase,92  a series of a pharmacophores were generated for database 
mining.93 Utilizing the National Cancer Institute (NCI) database (123,219 compounds) 
and a novel pharmacophore filtering technique,94 15 compounds were selected for 
testing. Stemming from an interest in developing biaryl-based substrates as core entities 
for novel potential non-nucleoside inhibitors of HIV-1 RT, the filtering process was 
weighted towards structural entities that were either of this type or relatively close to it. 
Results from an HIV-1 RT assay indicated that the selected compounds showed no 
activity against this target. At that moment in time, the opportunity arose to send 
samples for testing as potential anti-malarials in a random screening process. In a 
serendipitous result, of the fifteen compounds tested, seven were found to be active 
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against malaria. One of the major outcomes of these drug design studies is that the 
pharmacophores generated, in combination with the novel filtering system,94 have been 
shown to predict, in a surprisingly accurate manner, structures that display anti-malarial 
activity. The compounds identified were essentially lipophilic aromatic entities, with a 
electronegative functional groups (such as methoxy, chloro, and hydroxyl).95 Further, 
the compounds that emerged displayed a surprising degree of structural diversity. 
From these active anti-malarial compounds, a lead compound (24) was chosen, 
based on activity (0.88 M) (Figure 1.15) and synthetic assessability. It is an 
alkenyldiarylmethane (ADAM), a class of compounds with known RT inhibiting 










      (24) 
Figure 1.15: Lead compound (24) from NCI database with 0.88 M anti-malarial 
activity 
 
1.10 The development of 2,2’-biindoles as potential anti-malarial 
agents  
From previous work, biaryl compounds have been identified as potential 
NNRTIs against HIV-RT.92 Therefore, the hypothesis is proposed that the biaryl moiety 
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may be able to be used as an advanced scaffold targeting the telomerase enzyme with 
special reference to the malarial telomerase. There is some evidence to support such a 
hypothesis in that gossypol (25) is an anti-malarial compound (Figure 1.16) as well as 
being a known HIV-1 RT non-nucleoside inhibitor. Gossypol is highly toxic 
compound. A bioisosteric structural analog was drawn based on gossypol core unit 
(Figure 1.16). The current research program partly established a new 2,2’-biindole 
synthesis based on highly functionalized indole monomers,98 and therefore, offered a 
route to synthesize a range of 2,2’-biindole analogs, which will be tested for anti-
















 gossypol (25) 
 
Figure 1.16: Lead optimization (a) is a scaffold from central binapthyl unit of gossypol 
(25). An indole scaffold dimerised at position 2 may be analogous to the binapthyl 
dimer of gossypol.  
 
1.11 Project Aims 
A project was proposed to optimize the anti-malarial activity based of the lead 
molecule (24) and biindoles. The aim of this project was to develop novel synthetic 
methodology for lead compound synthesis and to then apply it to prepare synthetic 
   
 33 
analogues for biological screening. The work was to involve a high degree of chemical 
synthesis and subsequent structural characterisation of the resulting derivatives, using 
spectroscopic methodsThe results could be used in the further generation of analogs. It 
was envisioned that a detailed structure activity relationship studies will be established.




































As previously stated in Chapter 1 the lead compound (24) was chosen for 
investigation into its anti-malarial activity, via the synthesis of (24) and a series of 
analogues, with subsequent testing for activity. This chapter outlines the strategies 










Figure 2.1: The chosen lead compound ADAM (24), which shows 0.8 M anti-
malarial activity 
 
2.1.1 Synthesis of the ADAM (24) 
The lead compound ADAM (24) has been synthesized and was reported in the 
literature in 1971.99,100 It started with commercially available isobutyrophenone (26) 
(Scheme 2.1) which was subjected to Kneovenagel condensation with malononitrile 
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giving (28), followed by cyclisation with PPA (polyphosphoric acid) yielding lactone 
(29). Subsequent dehydration using phosphorous oxychloride (POCl3) gave (30), and 
subsequent hydrolysis and lactone heteroatom exchange via ring opening and ring 
closing produced the corresponding 2-amino-4,5-dihydro-3-carboxamide (31). The 
treatment of (31) with ethyl ortho formate yielded the dihydrofurano pyrimidine (32). 
The chlorination of (32) with POCl3 and acetic acid produced (33). Subsequent 
nucleophilic displacement of the chloro substituent of (33) was performed via heating 
with 30% aqueous ammonia in a sealed tube to give (34) (Scheme 2.1), followed by 
displacement of the second chloro substituent with (35) yielding the ADAM (24) in 
36% yield.99,100  
Analysis of this strategy implicates a lack of convergence. Only the synthesis of 
ADAM (24) is reported and no analogs. The synthesis of intermediate (33) was 
achieved through the construction of the pyrimidines ring that required additional steps 
(Scheme 2.1). 
 Further, most of the intermediates, including the target compound (24), 
reported in the literature are characterized based on only elemental analysis, IR and 
physical data; no 1H NMR or 13C NMR data has been published.99,100  


































































Scheme 2.1 The literature procedure for the synthesis of ADAM (24)99 
 
The anti-malarial testing results of (24) have been previously reported,99,100 
however most of these intermediates, including the lead compound (24), proved to be 
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inactive in vivo, while screened at 640 mg/kg.99 However, when this lead compound 
(24)94,95 was recently screened by Keller et all against Plasodium falciparum K1 the 
most virulent strain of malaria in vitro, it was found to be active at 0.8 µM. The 
investigation of the lead compound (24) was therefore undertaken in this project to 
produce a range of derivatives for testing and optimization of this lead and to confirm 
the activity of (24) itself. 
Therefore, the synthetic aims included the design, development, synthesis and 
derivatisation of (24) with different substitution patterns at the highlighted A, B, C, D, 
and E areas (Figure 2.2). Further, the development of a convergent synthetic route will 
enable the generation of a range of more potent and novel derivatives, such that a 
detailed SAR study could be performed. Current literature99,100 methodology does not 
easily allow different functional group manipulations at C, B, and E in a convergent 
fashion (Figure 2.2). Further details are given below.  
Position (A): A series of derivatives could be accomplished by varying chain the 
length at site 1 (Figure 2.3), by changing the stereochemistry around the stereogenic 
atom at site 3, and by varying the R-groups at the tertiary-amine (site 2) (Figure 2.3). 
Additionally, the sidechain could be completely replaced with alternatives, e.g. 
allylamine, dimethylamino, and propanolamine types. 
Position (B): This position (B) can be easily varied by starting from the 
unsubstituted aryl derivative and undergoing numerous different substitutions using 
conventional electrophilic substitution reactions. 
Position (C): At this position the investigation would be with various 
substituents including symmetrical and non symmetrical alkyl groups. 
Position (D): Where the amine may be further alkylated.  
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Position (E): Position C2 of pyrimidine (E) is known to undergo substitution 
reactions. Therefore, it should be easy to introduce a variety of alkyl groups e.g. 




























Figure 2.3: The three sites on the side chain at position (A) where variations could be 
possible   
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2.1.2 Retro-synthetic analysis of target molecule 
The retro-synthetic analysis of a general form of the target compound (40) 
(Scheme 2.2) suggests a series of possible synthetic routes, and therefore criteria need 
to be established to evaluate these strategies. A synthesis may follow a convergent or a 
linear strategy. In the former, two or more fragments of the molecule are assembled 
separately and are then brought together at a late stage in the synthesis. With the latter, 
the molecule is constructed in a stepwise fashion. A convergent strategy is more 
favourable, not only for the synthesis of the parent ADAM (24), but to allow an 
efficient access to a range of derivatives. Step by step retro-synthetic analysis of the 
target molecule reveals that it can be efficiently prepared in a few steps from the two 
following strategies A and B. 
Strategy A: The reaction that will convert the starting materials (36) and (37) 
into alcohol (38) is a nucleophilic addition. A lithiated species of (37) (R = Li) can be 
prepared from the corresponding bromo compound by halogen metal exchange or 
proton abstraction using LDA. Analysis of R1, R2 and R6 (Scheme 2.2) functional 
groups on (37) reveals that their influence on lithiation at position 5 is important. If R1 
and R2 are chlorine atoms, these could be further substituted by nucleophilic 
displacement. Conversion of the alcohol (38) to ketone (39) (Scheme 2.2) could be 
easily achieved by oxidation. Alternatively, the synthesis of (39) could be directly 
achieved by Stille coupling between (36) and (37) with the appropriate substitution at 
R7. Transformation of ketone (39) to alkene (40) is thought to be achievable using 
Wittig or McMurry reactions or by nucleophilic alkyl addition with subsequent 
dehydration. If R3 and R4 are non symmetrical groups it would be likely the resultant 
alkene will show cis/trans geometrical isomerism.  
 


























R1 = NHCH2CH(OH)CH2N(Et)2, Cl, H
R2 = Cl, NH2, H
R3 = CH3, alkyl chain, H, CN
R4 = CH3, alkyl chain, H, CN
R5 = Cl, H
R6 = Cl, alkyl 
R7 = Li, Sn(R)3, Br





(36) and (37) are commercially
 available or easily synthesised
 
Scheme 2.2: Retro synthetic strategy for ADAM (24) and its analog generation 
 
Strategy B: Disconnecting the bond between the alkene and pyrimidinyl C5 of 
(40) gives a synthetic alternate strategy (Scheme 2.3). The step could be executed by 
using various conditions including Heck, Stille, organolithium addition reactions and 

























Scheme 2.3: Disconnection of the C5 pyrimidine and alkene bond gives an alternate 
synthetic strategy.  
   
 41 
Retrosynthetic analysis of the 3-(diethylamino)-2-hydroxypropylamine side 
chain (R1) would allow for the preparation of a number of possible derivatives (Scheme 
2.4). There are three possible sites on side chain where changes can be made. The first 
site is where chain length (n) can be varied. The second site is on the side chain, where 
R and R1 could be varied by opening the epoxide with a range of alkyl amines. The 
third site importantly controls the stereochemistry around the hydroxyl group. This 
could be achieved by selective epoxidation using Sharpless technology or in some 












Scheme 2.4 Retro synthesis strategies for side chain synthesis 
 
2.2 The synthesis of ADAM (24) – Strategy A 
It was expected that a convergent total synthesis of ADAM (24) could be 
accomplished using a versatile intermediate (47) (Scheme 2.5), which would be further 
utilized to synthesize analogs of (24). The synthesis of (45) could be achieved by the 
reaction of benzaldehyde with 4,6-dichloropyrimidine as shown in scheme 2.5. 
Subsequent oxidation of (45) would lead to ketone (46), which could be transformed 
into the alkene (47) using a Wittig reaction or other suitable reactions. 
 


















(43) (44)           (45)
   (46)(47)  
Scheme 2.5: The proposed scheme for the synthesis of intermediate (47) 
 
Once the synthesis of the basic molecular skeleton is achieved (Scheme 2.6), 
further manipulation should allow the synthesis of the target ADAM (24) and 
additional derivatives. This strategy could be achieved in a number of ways and is 
outlined in scheme 2.6. Route (A) requires (47) to be treated with allylamine to obtain 
(66). The next steps involve selective epoxidation and ring opening using diethylamine, 
with subsequent amination and chlorination producing (24). Route (B) requires a chloro 
substituent to be displaced by the required side chain, followed by para-chlorination of 
the phenyl, and amination processes. Route (C) inverts this process with aromatic 
chlorination followed by nucleophilic displacement by the side chain, followed by 
amination. 
 















































Scheme 2.6: Alternative routes for the conversion of ADAM (24) and its derivative 
from intermediate from (47). 
 
2.2.1 Pyrimidines historical background and reactivity 
The pyrimidine moiety is a key component of the target structure. Further, it is a 
great biological significance as it is an integral component of genetic material, and is of 
paramount importance in nucleic acid chemistry. Pyrimidine derivatives include uracil, 
thymine, adenine and guanine which are fundamental building blocks for 
deoxyribonucleic acid (DNA) and ribonucleic acid (RNA).101 Vitamin B1 (thiamine) is 
another well-known example of a naturally occurring pyrimidine. Synthetic pyrimidine-
containing compounds occupy a prominent place in the pharmaceutical arena. For 
examples, pyrimethamine is a dihydrofolate reductase inhibitor, and is effective in 
combination with sulfanilamide.102 In an additional example, trimethprim is also an 
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anti-malarial drug, widely used as a general systematic anti-bacterial agent in 
combination with sulfamethoxazole. 
The pyrimidine parent structure (51) (Figure 2.4) is the systematic name for 
1,3-diazine, where two meta-oriented CH units in benzene have been replaced by 
nitrogen atoms. Its chemical behaviour is comparable to that of 1,3-nitrobenzene or 3-
nitropyridine. Pyrimidine has one axis of symmetry and three different pairs of bond 
lengths with four different bond angles. Accordingly, in 1H and 13C NMR spectrum, the 
1H- and 13C-nuclei are found at three different chemical shifts. Pyrimidine is -deficient 
due to the electronegative N-atoms.103 Consequently, the electron densities at the C2 
and C4/C6 positions are depleted, and these positions become strongly electrophilic.104 
The electron density at the 5-position is only slightly depleted. The ring retains 
benzenoid properties at this position, and therefore, electrophilic substitution occurs at 









Figure 2.4: The structure of the parent pyrimidine (51) 
 
The electron density at the N-atoms is greatly enhanced; the N-atoms constitute 
the basic and nucleophilic centres in pyrimidine.103 One or more electron-donating 
substituents on the pyrimidine ring are required for electrophilic substitution to occur. 
Formation of regioisomers can be controlled at C2, C4 and C6 by reaction conditions, 
usually temperature and time.103 Generally, chloride substituents are more easily 
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displaced at the 4-position than the 6-position or 2-position. Nucleophilic amination 
reactions of these halogenated pyrimidines are commonly and regioselectively carried 
out with varying conditions.103 
 
2.2.2 Synthesis of model target compound 
To establish a synthetic route that leads to the key intermediate (47), the 






        (52) 
Figure 2.5: Model target compound (52) selected for synthesis to establish reaction 
conditions. 
 
In order to accomplish the synthesis of (52) the process started with the 
synthesis of 5-benzoylpyrimidine (Scheme 2.7). To a cold solution of 5-
bromopyrimidine in THF was added slowly n-BuLi at -116 °C. After stirring for 30 
min, benzaldehyde was added and upon workup, the alcohol (54) was isolated in 50% 
yield. Subsequent oxidation of (54) with pyridinium chlorochromate gave 5-
benzoylpyrimidine in 70% yield, which was subsequently converted to the alkene (52) 
in 70% yield by the Wittig reaction using isopropyl triphenylphosphonium iodide and 
n-BuLi (Scheme 2.7). Analysis of 1H NMR spectrum of compound (52) showed a 
singlet at 8.99 ppm assigned to H2, as well as singlet at 1.79 ppm assigned to the 
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dimethyl substituents on the alkene. This compound’s structure was also verified by the 
presence of the M+1 peak in the ES mass spectrum at m/z 211. The 13C NMR spectrum 
showed the absence of carbonyl peak at 188.9 ppm that was present in the starting 























     isopropyltriphenyl





Scheme 2.7: Synthesis of the model compound (52)  
 
The mechanism for the formation of compound (52) typically arises when an 
ylide is generated by a reaction between n-BuLi and isopropyltriphenylphosphonium 
iodide. This ylide reacts with 5-benzoylpyrimidine (55) to form a cyclobutane 
(betaine)-type intermediate which spontaneously gives olefin (52) and 
triphenylphosphonium oxide (Scheme 2.8). 
 















Scheme 2.8:  Mechanism for the Wittig reaction 
 
The McMurry coupling was investigated as an alternative to the Wittig reaction. 
It was expected to give a higher yield of (52) under more facile conditions. The reaction 
was attempted using TiCl4/Zn and acetone; however, only starting material was 
isolated. When the same reaction was attempted on benzophenone, the alkene (56) was 
obtained (Figure 2.6) in 60% yield. The compound (56) was spectroscopically identical 
to that reported in the literature.105 
 
 
       (56) 
Figure 2.6: Compound (56) was synthesized via McMurry coupling 
 
The mechanism of the McMurry coupling reaction consists of two steps. The 
reductive dimerization of the ketone, with subsequent deoxygenation of the 1,2-diolate 
intermediate, spontaneously yielding the alkene (Scheme 2.9).106,107 One of the possible 
reasons for the failure in the synthesis of (52) is that, the TiCl4/Zn coordinated with the 
pyrimidine nitrogens. Excess reagent did not overcome the problem. The pyrimidine 
may be deactivating the ketone which fails to form pinacol intermediate, whereas 
Wittig reaction worked on the same ketone (55).  



























Scheme 2.9: The mechanism of the McMurry coupling 
 
After the successful synthesis of the model target compound (56), the 
investigation focused towards the synthesis of the key target intermediate (40). The 
central objective for performing model studies was to establish reaction conditions for 
the transformation of ketone to alkene. The intermediate (40) requires substitutions at 
R1 and R2.  
 
2.2.3 Synthesis of intermediate (47)  
In order to accomplish the synthesis of the dichloro intermediate (47) the 4,6-
dichloro-5-benzoylpyrimidine (46) was needed, which would be transformed into the 
corresponding alkene (47) (Scheme 2.10). It was synthesized, according to a literature 
procedure,108 by nucleophilic addition of 5-lithiated-4,6-dichloropyrimidine (Scheme 
2.10) to benzaldehyde. To a cold solution of 4,6-dichloropyrimidine in THF was added 
slowly freshly prepared LDA at -78 ºC. After stirring for 1.5 hour, benzaldehyde was 
added and upon workup, the alcohol (45) was isolated in 50% yield. Subsequent 
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oxidation of (45) using PCC produced the ketone (46) (Scheme 2.10). The spectral and 















(43) (44)           (45)







Scheme 2.10: Nucleophilic addition of (44) to benzaldehyde (43) gave alcohol (45) and 
subsequent oxidation of (45) gave (46). 
 
During the lithiation of 4,6-dichloropyrimidine with LDA at -78 ºC, the 
formation of compound (57) was observed (Scheme 2.11). The generation of (57) was 
verified by analysis of the mass spectrum (ES) with a peak at 261 (35Cl) assigned as a 
M+1 peak. The 1H NMR spectrum showed a doublet at 8.82 and a doublet at 7.50 ppm 
both with J = 5.4 Hz, assigned to the H4 and H5, and peak at 8.90 ppm representing 
H2’. The presence of (57) may be due to the self attack on the 2-position by another 
pyrimidine as a nucleophilic addition followed by in situ aromatization producing (57). 
The formation of (57) occured when the temperature was raised from -78 °C to -25 or -
40 °C. At this temperature the lithiated species is excessively reactive. There is the 
disappearance of one of the two chloro substituents from compound (57) was observed, 
and is probably due to an exchange under lithiation conditions. 
















                 (57) 
Scheme 2.11: Formation of (57) during lithiation of 4,6-dichloropyrimidine 
 
Various trials were attempted for the transformation of ketone (46) to the 
corresponding alkene (47) including Wittig and Grignard reactions, addition of 




In the first instance a Wittig reaction was used in an attempt to synthesize (47) 
starting from 4,6-dichlorobenzoylpyrimidine (46). The reaction did not proceed 
(Scheme 2.13), probably due to the large size of the ylide involving steric hindrance 





     isopropyltriphenyl









Scheme 2.12: Attempted Wittig reaction on (47)  
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Grignard and organometallic reactions 
The failure of the Wittig reaction prompted the alternative Grignard and 
organometallic strategies to be considered. Therefore, to a solution of (46) in diethyl 
ether at -78 ºC was added dropwise isopropylmagnesium chloride under a dry nitrogen 
atmosphere. The reaction was then warmed to room temperature. Upon workup, (58) 
was obtained in a yield of 60% (Scheme 2.13). The generation of (58) was verified 
with a peak in the mass spectrum (ES) at m/z 295 (35Cl) assigned as a M+1 peak and 2 
sets of doublets at 7.8 and 7.5 ppm with coupling constant of J = 8.1 Hz each assigned 
to the phenyl protons ArH2 and 6, ArH3 and 5, which is indicative of aromatic para-
disubstitution. Additional confirmation was provided by analysis of gHMBC NMR 
spectrum which showed that the isopropyl peaks correlated with the aromatic phenyl 
protons. The molecular formula of (58) has been also confirmed by high resolution 
mass spectrum (ES-HRMS m/z: [M+1]+ calcd for C14H13 35Cl2N2O 295.0404; found 
295.0405). 
This is an unusual outcome and is all the more remarkable as it does not require 
forcing conditions; the alkylation proceeded in diethyl ether solution at room 
temperature. It is interesting to note that although nucleophilic substitution is possible 
at either C2 or C4 of pyrimidines, there was no evidence of such a product. An 
analogous precedent for the type of reaction has been reported (Scheme 2.14),109  
where a solution of durylphenyl ketone (59) in ether was added over a period of five 
minutes to a solution of isopropylmagnesium bromide, and after stirring for three hours, 
the para-substituted phenone (60) was isolated 38% yield. 
 
 
















       (46)           (58) 






           (59)                     (60) 
Scheme 2.14: Literature precedent published in 1949109 for para-substitution of 
phenone (59) using isopropyl magnesium bromide. 
 
Nucleophilic addition using n-BuLi 
Another nucleophilic addition was attempted using the ketone (46). n-BuLi was 
expected to react with the ketone to give corresponding alkene (61) (Scheme 2.15), as 
n-BuLi is smaller and therefore, is more likely to be able to attack the sterically 
hindered ketone. The compound (61), similar to intermediate (40) where R3 and R4 are 
nonsymmetrical n-butyl and proton substituents. If this reaction was successful it would 
be a facile route to generate analogs related to (40) where R3 and R4 are non-
symmetrical groups. 
  











    (46)              (61) 
Scheme 2.15: A propsed reaction to obatain (61) by nucleophilic addition on (46) using 
n-BuLi subsequent in situ dehydration.  
 
An equivalent model reaction was performed on benzophenone. Treatment of 
(67) with n-BuLi in diethyl ether at -78 ºC, followed in situ dehydration with thionyl 
chloride yielded (63) in 60% yield (Scheme 2.16). The alkene was spectroscopically 







      (62)     (63) 
Scheme 2.16: n-BuLi nucleophilic addition on benzophenone (62) followed by in situ 
dehydration with thionyl chloride produced (63) 
 
Based on the above mentioned reaction parameters, the same reaction were 
attempted using (51). Treatment of (46) with n-BuLi in diethyl ether at -78 ºC, followed 
by an identical in situ dehydration with thionyl chloride produced (64) in 50% yield 
with the remainder being isolated as starting material (Scheme 2.17). Generation of 
compound (64) was verified by the presence of a peak in the (ES) mass spectrum at m/z 
275 (35Cl) assigned as molecular ion. The 1H NMR spectrum of (64) showed peaks at 
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4.36, 1.56, 1.18, and 0.78 ppm which were assigned to the butyl substituent. The 
chlorine isotopic ratio in the mass spectrum also suggested that there was replacement 











      -H2O
Diethyl ether
50%  
 ̀ (46)                 (64) 
Scheme 2.17: Nucleophilic substitution of chloride at C4-position pyrimidine. 
 
The n-BuLi addition was on (46) was straightforward with the not unexpected 
pyrimidyl nucleophilic substitution taking precedent over attack on the more sterically 
hindered ketone. One of the principle reasons for the further expansions of the above 
reaction to 5-benzoyl pyrimidine was to observe the reactivity of n-BuLi with phenones 
bearing a pyrimidine ring. Therefore, the above reaction was further attempted using 
(55). The compound (65) was synthesized in 60% yield, when the ketone was treated 
with n-BuLi followed by in situ dehydration with thionyl chloride (Scheme 2.18).111 
Analysis of the 1H NMR spectrum of (65) showed a peak at 6.21 ppm assigned to the 
alkene proton, as well as a multiplet between 2.19-0.90 ppm representing alkyl chain 
protons. Additional support was provided by the disappearance of the starting material 
carbonyl peak at 193 ppm in 13C NMR spectrum. This compound (65) was also verified 
by the presence of the molecular ion in the CI mass spectrum at m/z 225. Nucleophilic 
addition to carbonyl groups sometimes leads to a mixture of stereoisomeric products. 
Out of the possible two cis and trans geometrical isomers, only one isomer was formed. 
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(55)     (65) 
       
Scheme 2.18: Nucleophilic addition of n-BuLi on (55) followed by in situ dehydration 






Figure 2.7: Trans isomer of compound (65) was confirmed by NOESY correlations 
 
Ketone conversion reactions in the presence of amines 
A new approach towards the total synthesis of (70) was conceived and is shown 
in scheme 2.19. It required the synthesis of (66) by treatment of (46) with allylamine, 
followed by Boc protection to give (67). Subsequent nucleophilic addition with 
isopropyl lithium followed by dehydration might produce (67). The above investigation 
suggests that it is difficult to react the ketone as it is sterically hindered. It was hoped 
that the allylamine functionality might increase the reactivity at the ketone due to its 
electron donating properties. The compound (67) will be selective epoxidised by using 
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Sharpless technology to obtain (69), with subsequent ring opening and Boc removal 
producing the (70). 
















































Scheme 2.19: Theoretical scheme for the synthesis of (70) 
 
Therefore, treatment of (46) with allylamine in a sealed tube gave the mono 
allylamination (46) and diallylamination (71) (Scheme 2.20) compounds in 80% and 
20% respectively. The ketone (46) exhibited 1H NMR resonances at 6.60 ppm assigned 
to NH while peaks at 5.85, 5.20, and 4.18 ppm were assigned to CH2 adjacent to the 
amine, CH and CH2 allylamine protons respectively. This compound was also verified 
by the presence of the molecular ion peak in the ES mass spectrum at m/z 274 (35Cl). 
The diallylamine (71) exhibited 1H NMR resonances at 6.67 ppm assigned to NH with 
a relative integration of two protons, while peaks at 5.85, 5.20, and 4.18 ppm were 
assigned to the CH2 next to amine with relative integration of four protons, CH and 
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CH2 protons in allylamine with relative integration to two protons and four protons 
respectively. This compound was also verified by the presence of the M+1 peak in the 
ES mass spectrum at m/z 295. 1H NMR spectral comparison between (66) and (71) 
revealed allyl peaks in the disubstituted product slightly shifted to downfield. 
Treatment of (66) with di-tert-butyldicarbonate gave (67) in 90% yield. The next step 
was the treatment of (67) with isopropyl lithium. Therefore, a solution of (67) in diethyl 
ether was cooled to -78 ºC and isopropyllithium (0.7 M solution) was added dropwise 
under dry nitrogen. After stirring for 1 hour, thionyl chloride was added slowly at -78 
ºC and the reaction was allowed to stir for an additional 1 hour while the temperature 
was brought to room temperature. The compound (72) obtained, was a 1,2-
dihydropyrimidine derivative (Scheme 2.20). The formation of 1,2-dihydropyrimidine 
was verified via ES mass spectroscopy with a peak at m/z 318 (35Cl) assigned as the 
M+1 peak. The 1H NMR spectrum exhibited a doublet at 10.0 and a triplet at 10.20 
ppm assigned to pyrimidine NH and allylamine NH respectively. A triplet at 4.88 and a 
multiplet at 2.42 ppm were assigned to the H2 and the CH of the isopropyl group 
respectively. Assignment of the H2 proton is further confirmed by analysis of gCOSY 
spectrum (Figure 2.8) indicating a correlation between H2 and CH in isopropyl. 
Interestingly, when compound (46) was reacted with the isopropylmagnesium chloride 
Grignard reagent, substitution was only observed at the para position on the phenyl 
ring (58), but with the isopropyllithium reaction on compound (67), an addition product 
(72) at the 2-position of pyrimidines was observed. Thionyl chloride was probably 
deprotecting the Boc group. The C2 position of pyrimidine is known to under go 
nucleophilic substitution reactions although the process is more facile in the presence of 
a leaving group.112,113  
 
















































Scheme 2.20: Allylamination of (46) produced (71) and (66). Boc protection of (66) 
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Ketone conversion reactions with amine present and malononitrile Knoevenagel 
condensation 
Isopropyl lithium failed to convert (67) to its alkene but added at the C2 
position of pyrimidine. We then attempted to react (67) using malononitrile by 
Knoevenagel condensation. The objective was to make compound (73) by Knoevenagel 
condensation between malononitrile and (67) using -alanine as a base.114 After stirring 
the reaction mixture overnight at room temperature the Boc deprotected compound (66) 
was isolated (Scheme 2.21). The reaction conditions probably facilitated the Boc 
























Scheme 2.21: Knoevenagel condensation between compound (67) and malononitrile in 
the presence of -alanine as a base 
 
A Knoevenagel condensation was also attempted on (46), this time using 
piperidine as base in toluene at reflux (Scheme 2.22). Under these rigorous reaction 
conditions, nucleophilic substitution of dichloride by piperidine was observed. The 
compounds (75) and (76) were obtained in a 1:1 ratio. Both the compounds were 
identified by analysis of the (ES) mass spectrum with peak at m/z 351 assigned as a 
molecular ion for (75), m/z 302 (35Cl) as a molecular ion peak for (76). Analysis of the 
1H NMR spectrum of the compound (76) showed peaks at 3.49, 1.57, and 1.46 ppm 
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with a relative integration of 4, 2, and 4 protons respectively and were assigned to the 
piperidine. Analysis of the 1H NMR spectrum of (75) showed similar peaks to those in 
(76) but with relative peak integration and a shifting of piperidine protons to upfield 
indicated 4,6-dipiperidine substitution on pyrimidines. This was further confirmed by 
the absence of chloro isotope peaks ratio in the ES mass spectrum of (75). This may be 
the same reason malononitrile anion failed to reach the ketone as it is sterically 
hindered by the two chloro substituents and the phenyl groups. The reaction conditions 
were forceful with the piperidine becoming involved in the nucleophilic displacement 



























 (46)       (74)   (75)     (76) 
Scheme 2.22: Formation of (75) and (76) by Knoevenagel condensation between 
compound (46) and malononitrile in the presence of piperidine as a base 
 
After detailed investigations on hindered ketones (46) and (66) it was concluded 
that the ketone (46) could not be transformed easily into the corresponding alkene. All 
these results are summerised in Table 2.1. It is sterically hindered by the two chloro 
substituents and a phenyl group. Therefore a different strategy for the synthesis of (24) 
was required. 
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Table 2.1: Attempt to convert ketone to alkene  
 


















































































































































































2.3 The synthesis of ADAM (24) - Strategy B 
2.3.1 Synthesis of intermediate (47) according to disconnection between phenyl 
and alkene 
The concept of a disconnection between phenyl and alkene arose from the retro-
synthetic analysis of (40) (Scheme 2.23). Disconnection of the bond between phenyl 
C1 and alkene gives an alternate strategy for the synthesis of (40) eventually leading to 























R8 = Li, Br
 
Scheme 2.23: Disconnection of the C1 phenyl and alkene bond gives an alternate 
synthetic strategy.  
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The strategy will be used to obtain (47) by nucleophilic addition of phenyllithium to 



























Scheme 2.24: Proposed scheme for the synthesis of (47) 
 
Compound (77) was prepared from 4,6-dichloropyrimidine by a Vilsmeier 
reaction using POCl3/DMF in 60% yield. The pyrimidine aldehyde (77) was identified 
by spectral and physical data which was identical to that reported in the literature.115 
The reaction of (77) with isopropylmagnesiun chloride at room temperature gives a 
moderate 55% yield of (78), which was subsequently oxidized to give (79) in 50% 
yield (Scheme 2.25). Compound (78) exhibited 1H NMR resonances at  4.99 and 3.00 
ppm assigned to the H and OH and generation of (79) was verified by the absence of 
peaks at 4.99 and 3.00 ppm that belonged to the alcohol (78). The peak at 200.3 ppm in 
the 13C NMR spectrum was assigned to the carbonyl group as well as M+1 peak in the 
CI MS at m/z 219 35Cl. 
 

























Scheme 2.25: Treatment of isopropyl magnesium chloride with (77) gave (78) 
subsequent oxidation produced (79). 
 
A nucleophilic addition attempt was made on compound (79) using 
phenyllithium (Figure 2.26), but the reaction yielded a mixture of products which were 











  (79) 
Scheme 2.26: Nucleophilic addition attempt was made on (79) using phenyllithium  
 
Failure of the above reaction prompted an alternative approach to the synthsis of 
(47). As illustrated in (Scheme 2.27), intermediate (47) could also be synthesized by 
Heck coupling using pyrimidine alkene and arylbromide. The pyrimidine alkene (81) 
was synthesized via a McMurry coupling reaction between the compound (77) and 
acetone and offered (81) in 50% yield (Scheme 2.27). Analysis of the 1H NMR of (81) 
showed a peak at 5.54 ppm assigned to the alkene CH and peaks at 1.50 and 1.23 ppm 
assigned to the dimethyl moiety. Analysis of DEPT spectrum also confirms an alkene 
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CH peak at 80 ppm as well as the assignment of C2 to the 157 ppm peak. The 
compound (81) also showed a peak in CI mass spectrum at m/z 203 35Cl assigned as 
M+1 ion. Further spectral evidence was provided by analysis of gHMBC NMR 
spectrum of (81) that indicated that the alkene proton at 5.54 correlates with C4, C6, 
























          (77)           (81)     (47) 
Scheme 2.27: McMurry coupling reaction between the pyrimidines aldehyde (77) and 









Figure 2.9: Arrows indicates gHMBC correlations of the pyrimidines alkene (81) CH 
with its surrounding carbons. 
 
The compound (81) was subjected to Heck reaction conditions with 5-
bromopyrimidine using palladium diacetate as a catalyst. After 24 hours of heating at 
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100 ºC in DMA, the starting material remained unchanged. The same reaction was also 
tried with varying reaction conditions summarized in (Table 2.2). It is not clear at this 
stage why the Heck reaction did not proceed, and needs to be further investigated.  
 
Table 2.2: Different reaction conditions attempted on Heck coupling between (81) and 
bromobenzene 
Solvent Reagents and 
conditions 


















Multiple products by 
TLC 
None isolated 
Mass spectral analysis 
suggested that the 






















Multiple products by 
TLC 
None isolated 
Mass spectral analysis 
suggested that desired 





The same pyrimidine aldehyde (77) was subjected to Knoevenagel condensation 
using malononitrile in the presence of -alanine as a base and gave good yield of (82) 
in 70% yield (Scheme 2.28).114 The structure of (82) was supported by the appearance 
of a peak at 7.89 ppm in 1H NMR spectrum assigned to the alkene H, as well as peak 
in the CI MS at m/z 225 (35Cl) assigned as the M+1 ion. 




















Scheme 2.28: Formation of (82) by Knoevenagel condensation between (77) and 
malononitrile 
 
Earlier attempts on 5-benzoyl-4,6-dichloropyrimidine (46) failed to convert it 
into (74) by using Knoevenagel condensation (Scheme 2.22). The synthesis of (74) 
from (82) was attempted as illustrated in scheme 2.29. Therefore, a Michael addition 
was attempted on compound (82) using phenyllithium. The reaction gave a mixture of 
compounds which were difficult to separate and characterize. Similarly, the same 
reaction was attempted on benzylidenemalononitrile (84) with 5-lithiated-4,6-
dichloropyrimidine (Scheme 2.29). In the same way the reaction gave a mixture of 

























Scheme 2.29: Compound (77) subjected to Micheal addition using phenyllithium 
 
 























Scheme 2.30: Nucleophilic addition tried on benzylidenemalononitrile (84) using 5-
lithiated-4,6-dichlropyrimidine. 
 
According to strategy B the attempts to convert compounds (79), (82) and (84), 
into intermediate (47) failed.  
 
2.3.2 Synthesis of intermediate (40) according to disconnection between 
pyrimidines and alkene 
If the ketone conversion of ketone (46) to the corresponding alkene worked 
smoothly, it would have been more convergent for the synthesis of analogs with 
different R3 and R4 substituents. An alternative strategy and potentially a more efficient 
one have come from the retro-synthetic analysis of (40) by disconnection of the bond 



















Scheme 2.31: Disconnection of the C5 pyrimidine and alkene bond gives an alternate 
synthetic strategy.  
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It is already known that lithiation is possible at C5 on 4,6-dichloropyrimidine 
(Scheme 2.10). Therefore nucleophilic addition of (85) was attempted with 
isobutyrophenone (86) (Scheme 2.32). A solution of freshly prepared lithium 
diisopropylamine (-78 °C) was added to 4,6-dichloropyrimidine in THF at -78 °C. 
After stirring the reaction mixture for 1 hour at this temperature the reaction mixture 
was further cooled -116 °C, before isobutyrophenone was added slowly, and stirring 
was continued for another 30 min. The resultant alcohol was purified by 
chromatography on flash silica gel yielding (80) in 33% yield (Scheme 2.32). Analysis 
of compound (80) mass spectrum (ES) indicated a peak at m/z 297 (35Cl) which was 
assigned as the M+1 ion. Analysis of the 1H NMR spectrum of (80) showed a peak at 
3.57 ppm which was the assigned to the isopropyl CH, a peak at 3.39 ppm assigned to 
OH, and a doublet at 1.07 J = 6.6 Hz assigned to isopropyl methyl protons.  
Various conditions were tried to improve the yield of alcohol. The best was 
yield obtained was 40% (Table 2.3). The optimized condition was lithiation of 4,6-
dichloropyrimidine performed at -78 ºC and isobutyrophenone added at -116 ºC. 
Further investigation is required to improve the yield of the alcohol.  
Dehydration of (80) with thionyl chloride and P2O5 was offered (47) in 80%. 
The formation of (47) was verified via CI mass spectroscopy with a molecular ion peak 
(35Cl) at m/z 279. Further confirmation was provided by analysis of the 1H NMR 
spectrum with the disappearance of peaks at 3.57 and 3.39 ppm peaks of the CH 
isopropyl and OH in alcohol (80), indicating double bond formation. The optimization 
of this dehydration reaction is summarised in Table 2.4. 
 






















Scheme 2.32: Nucleophilic addition of (85) on (86) produced (80), with subsequent 
dehydration giving (47) 
 
Table: 2.3: Reaction conditions were attempted to optimize the alcohol yield  
Butyrophenone 
addition temp 
Method 1 or 2 Yield 
-116 °C 1 40% 









-116 °C 1 25% 
-78 °C 1 20% 
-116 °C 2 15% 
 
Method 1: A solution of freshly prepared lithiumdiisopropylamine (-78 °C) 
was added to 4,6-dichloropyrimidine in THF at -78 °C, the resulting reaction 
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mixture was stirred for 1 hour, then the reaction mixture further cooled 116 ºC 
before isobutyrophenone was added slowly. 
 
Method 2: A solution of 4,6-dichloropyrimidine cooled at -78 °C, to this 
freshly prepared LDA was added dropwise. The resultant reaction mixture was 
stirred for 1 hour, and then the reaction mixture further cooled at 116 °C before 
isobutyrophenone was added slowly. 
 
Table 2.4: Reaction conditions attempted to optimize for the synthesis of alkene (47) 
Reagents Reaction time Yield of alcohol (47) 
P2O5, 3 moles 72 h 40% 
SOCl2, 5 moles 24 h 30 % 
SOCl2, 2 moles 48h 25% 
P2O5, 1 mole:SOCl2 1 mole 72 h 80% 
 
 
2.3.3 Attempts to convert (47) into key intermediate (40) 
To complete the synthesis of target compound (24) with the correct substitution 
pattern the project needed the intermediate (33) with a para-chloro substituent on 
phenyl ring. Chlorination was attempted with compound (47) using sulfuryl chloride in 
DCM, even with varying reaction conditions starting material remain unchanged 
(Scheme 2.33). The reaction was then carried out at elevated temperatures in a sealed 
tube. The resultant compound was yet to be fully characterized, but analysis of 1H 
NMR spectrum of the compound, suggested that replacement of the 2 pyrimidinyl 
chloro substituents by THF had occured. If desired chlorination was successful the 
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methodology could be extrapolated to bromination and nitration. While these reactions 
were not pursued further here, there is a multude of possible halogenation reactions that 

















Solvent Reaction temperature Product 
1 mole DCM RT Starting material 







in a sealed tube 
Starting material 
Disappeared 





Scheme 2.33: Chlorination of (47) by using sulfuryl chloride 
 
2.3.4 Synthesis of the key intermediate (40) 
Direct chlorination of (47) failed to produce desired intermediate (33). 
Therefore, the intermediate (33) was synthesized by starting with p-
chloroisobutyrophenone (87). The reaction conditions were the same as reported above. 
Nucleophilic addition of 5-lithiated-4,6-dichloropyrimidine (85) to p-
chloroisobutyrophenone (87) yielded the alcohol (88) in 25% yield, which upon 
dehydration gave (33) in 80% yield (Scheme 2.34). The generation of (88) was 
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confirmed by mass spectrometry ES with a peak (35Cl) at m/z 331 assigned as the M+1 
ion. The 1H NMR spectrum of (88) showed a peak at 3.54 ppm assigned as isopropyl 
CH, and 3.32 ppm assigned as an OH. The generation of (33) was confirmed by CI 
mass spectrometry with a peak (35Cl) at m/z 314 assigned as the M+1 ion. The 1H NMR 
spectrum of (33) showed the disappearance of peaks at 3.54 and 3.32 ppm belonging to 
its starting alcohol (88) indicating the formation of (33). The alkene (33) was also 


























Scheme 2.34: Formation of the key intermediate (33) 
 
The synthesis of (33) was achieved by using a different strategy to that already 
reported,99 being shortened to only two steps compared to the literature procedure 
which required 6 steps.99 This allows for quicker access to a range of analogs. 
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2.3.5 Aminolysis of (47) and (33) 
2.3.5.1 A new strategy for synthesis of target compound (24) 
With the successful synthesis of the alkene (33) the next step was aminolysis. 
The required side chain could be introduced by displacement of chlorine. Subsequent 
displacement of the second chlorine could then be achieved with ammonia. An 
alternative approach to the direct introduction of the side chain, is the displacement 
using allylbromide on (89). The plan was to prepare the mono allylated (90) as 
illustrated in Scheme 2.35. This would then be epoxidised (91) selectively by using 
Sharpless technology, followed by ring opening with diethylamine to give the required 
target compound (24). At this stage, ring opening could also be performed using variety 
of amines.  
The key intermediates (33) and (47) were aminated using aqueous ammonia 
after heating at 125 ºC for five hours with only mono amination being observed-(34) 
and (92). The diaminated products (89) and (93) were obtained by heating at 160 ºC 
using aqueous ammonia (Scheme 2.36). All the four mono amino and diamino 
compounds were identified by spectral and physical data identical to those reported in 
the literature.99,100  
Allylation was attempted on (89) using allylbromide, and after heating at 100 ºC 
in a sealed tube for five hours, the diallylamine compound (94) was yielded in 60% 
(Scheme 2.37). The generation of (94) was confirmed by mass spectrometry with an EI 
molecular ion peak (35Cl) at m/z 354. Additional support was provided by analysis of 
1H NMR spectrum with peaks at 6.50, 5.36, and 4.14 ppm assigned to the CH, terminal 
CH2 and CH2 of the allyl side chain. 
 



































Scheme 2.35: A proposed convergent scheme for the synthesis of (24) using 

















X = Cl, (34)





X = Cl, (89)
X = H, (93)  
Scheme 2.36: Amination of (33) and (47) gave the respective mono and diamine 
products 
 





















Scheme 2.37: Treatment of allylbromide with (89) was expected to produce (90), 
however gave (94) in 60% yield. 
 
As expected, treatment of (89) with allybromide did not give (90). Therefore, 
the investigation continued with using intermediate alkene (33). The next step was the 
introduction of the side chain (R1) 3-(diethylamine)-2-hydroxypropylamine by 
nucleophilic displacement of chlorine, with the second chloro being displaced by 
ammonia. The desired side chain synthesis starts from allylamine protected with Boc in 
presence of DMAP catalyst (Scheme 2.38). Subsequent epoxidation with MCPBA 
proceeded smoothly to give (97) (Scheme 2.38). The epoxide ring was successfully 
opened with an excess of diethylamine, followed by Boc deprotection in TFA/DCM to 
gaving (99) as a TFA salt. According to the literature procedure side chain (99), could 
also be prepared as free amine when starting from epichlorohydrin.116 The reason for 
chosing this method for the synthesis of (99) is that the protected amine allows the 
further substitution of the alcohol. 
 


























Scheme 2.38: Side chain (99) synthesis starts from allyamine protected with Boc 
followed by formation of the epoxide and then ring opening with diethylamine which 
gave (99) as a TFA salt. 
 
Nucleophilic displacement of the chlorine substituent of (33) was carried out 
using the side chain (99) as the TFA salt. Five equivalents of the side chain (99) were 
added to a THF solution of the alkene (33) in the presence of K2CO3 and the reaction 
was heated at 160 ºC in a sealed tube for 8 hours (Scheme 2.39). The role of the base 
K2CO3 is to generate the side chain as the free amine from the TFA salt. The desired 
compound (50) was isolated in 70% yield. The CI mass spectrum of (50) showed a 
peak at m/z 423 assigned as the M+1 ion (35Cl). The 1H NMR spectrum of (50) showed 
peaks as compared its starting material with additional multiplets at 4.10, 3.77, 2.99, 
and 2.92 ppm and a quartet at 1.12 ppm, assigned to the CH, NH-CH2, ethyl CH2, CH2 
and dimethyl of the side chain, respectively.  
 


















                           (50) 
Scheme 2.39: Introducing the side chain (99) on key intermediate (33) to obtain (50) 
 
The compound (70) was prepared in a similar way as compound (50) (Scheme 
2.40). The CI mass spectrum of (70) showed a peak at m/z 389 assigned as the M+1 ion 
(35Cl). The 1H NMR spectrum of (70) was showed additional (as compared to its 
starting material) multiplets at 4.09, 3.73, 2.99, and 2.80, and a quartet at 1.15 ppm 

















                      (70) 
Scheme 2.40: Introducing the side chain (99) on the intermediate (47)  
 
 
The next step involved amination at the 6-position of pyrimidine for (50) and 
(70). The amination was carried out in a sealed tube with ethanol and aqueous ammonia 
in a 1:5 ratio. The mixture was heated at 160 ºC for 24 hours. After 24 hours heating, 
   
 79 
no change was observed (Scheme 2.41). If the direct amination had worked it would 
have been a more facile route compared to that reported. Further, if the side chain was 
chiral, it would be expensive to use as a solvent and therefore it was attempted to 
develop a method using a stoichiometric amounts of the side chain whereas in the 
literature procedure side chain used as the solvent. The same method was repeated on 
compound (70), but was also unsuccessful (Scheme 2.41).  
 
(70) X = H
(50) X = Cl
Aq ammonia
160 °C
(24) X = Cl














Scheme 2.41: Direct amination on compound (50) and (70) using aqueous ammonia 
 
These unsuccessful reactions prompted us to attempt the literature method in 
which the key intermediate (34) was used. A solvent free reaction was tried on 
compound (34) by taking an excess of the side chain (99) with K2CO3 in a glass sealed 
tube heated at 200 ºC for five hours, after which the starting material disappeared and 
the formation of multiple spots was observed by TLC analysis. Mass spectral analysis 
suggested that none of the desired product was formed. 
Another attempt to substitute (34) was made, this time using an excess of side 
chain. Amination was performed in a sealed tube with DMF and heated at around 200 
ºC for 8 hours (Scheme 2.42). Interestingly, compound (101) was obtained in 50% 
yield. The generation of (101) was confirmed with a peak in the mass spectrum (ES) at 
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303 assigned as the M+1 ion peak (35Cl). Further confirmation was provided by 
analysis of the 1H NMR spectrum which revealed the appearance of additional peak at 
2.96 ppm with a relative integration of 6H assigned to the N(CH3)2. A possible 
mechanism for the aminodimethylation product may involve the reaction of DMF. 
Additionally, it is known117,118 that if DMF is heated at 200 ºC, dimethylamine and CO 
are formed, and the dimethylamine could displace the chlorine by nucleophilic 



















Scheme 2.42: The formation of compound (101) was observed when (34) and (99) 
were heated in DMF.  
 
After the above attempts failed to obtained the target compound (24), it was 
decided that the system that contained the side chain as a free amine (35) not as a TFA 
salt (99) as shown was attempted (Scheme 2.38). To achieve this, the side chain was 
synthesised in a different manner (Scheme 2.43). Treatment of epichlorohydrin with 
diethylamine produced (105), with subsequent epoxide ring opening using diethylamine 
giving the side chain as the free amine (35). The compound (35) was identical to that 
reported.116 
 










     (102)     (103)            (35) 
Scheme 2.43: Preparation of side chain as a free amine (35) starts from epichlrohydrin  
 
Synthesis of the final compound (24) was performed99 using (35) as the free 
amine (Scheme 2.44). The compound (34) and an excess of the side chain (35) was 
subjected to heating at 200 ºC for 5 hours. The ADAM (24) was purified by flash 
column chromatography using the polar solvent system 70:30:10 ethyl acetate: 
methanol: water. The solvent was evaporated to obtain the solid (24), which was 
followed by recrystallisation from benzene. The generation of (24) was verified with a 
peak (CI) at m/z 404 assigned as the M+1 ion (35Cl). Analysis of the 1H NMR spectrum 
of (24) showed a multiplet at 5.03, a singlet at 4.63, multiplets at 3.67, 3.63, and 2.48, 
and a quartet at 0.95 ppm assigned to the secondary NH, primary NH2, CH, NH-CH2, 
ethyl CH2, CH2 and dimethyl of the side chain. Additional confirmation was provided 
by spectral comparison between standard sample from the NCI and the synthesized 















    (35)                   (34)                     (24) 
Scheme 2.44: The target (24) synthesized from nucleophilic displacement chloro 
substituent on (34) by side chain (35)  
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2.3.6 Comparison between literature procedure and developed methodology for 
the synthesis of ADAM (24) 
The target compound (24) has been successfully synthesized by novel 
methodology which is different from that reported in literature. This methodology is 
potentially useful for the generation of future analogs of (24). The synthesis of the 
intermediate (33) needed 6 steps according to literature, whereas the procedure 
developed here requires only two steps. We also fully characterized all of our 
intermediates and the final target (24). 
Analysis of the 13C NMR and 1H NMR spectrum of (70), (50) and (24) (Figure 
2.10) indicates a doubling of peaks, possibly indicating atropisomerism (Figure 2.10). 
Atropisomerism is a phenomenon which results from slow rotation about a single 
bond.119,120 The nomanclature M and P stands for minus and plus rotation around the 
single bond, and is the accepted notation for the stereochemical differentiation (Figure 
2.10).  







X = Cl, R = Cl,   (50)
X = H, R = Cl  (70)

























Figure 2.10: Atropisomerism due to the barrier to rotation around the bond shown in 
compound (70), (50) and (24). Asterisk indicates restricted rotation around the single 
bond. 
 
Free rotation about a single bond converts the M isomer into its P counterpart 
and vice versa. In some cases, the substituents may be large enough to slow rotation, 
but not prevent it completely.120 In the compounds (70), (50) and (24) the side chain 
barrier may causes repulsion when the C-C bond rotates 360° (Figure 2.10). 
Compound (101), 4,6-disubstituted with dimethyl amino and amino substituents shows 
no atropisomerism. Even when one of the chloro substituent was replaced by amine 
(34) and (92) no atropisomerism was observed. Compounds (70), (50) and (24) fall 
under class of non-biaryl atropisomers.  
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2.4 Derivatisation of (40)  
After the successful synthesis of the target compound (24), the investigations focus was 
shifted to the synthesis of different ketones related to (40) for comparison into SAR 
studies on anti-malarial targets (Scheme 2.45). This is the beginning of the 
extrapolation of the methodologies established during the synthesis of the lead 
compound, to make derivatives. Therefore, derivatisation of ketone (40) was 
undertaken in this section. According to the retro-synthetic analysis of (40), the ketone 














R7 = Li, Sn(Bu)3
R = Cl, H(40)  
Scheme 2.45: The ketone (40) obtained from retro-synthetic analysis, which is adapted 
from Scheme 2.3. 
 
Therefore the pyrimidine (105) was synthesized from 2-aminopyrimidine by 
bromination with molecular bromine in presence of NaHCO3 solvent DCM/ACN (40: 
60) in 99-100% yield (Scheme 2.44) and was spectroscopically identical to that 
reported in the literature.121 2-Amino-5-bromopyrimidine was converted into 2-chloro-
5-bromopyrimidine by diazotization using NaNO2/CuCl2/NH3 in a 30% yield. The 2-
chloro-5-bromopyrimidine (106) identified by spectral data which was identical to that 
reported in the literature.122 The compound (107) (Scheme 2.46) was prepared from 
reaction between 2-chloro-5-bromopyrimidine122 and LiSn(Bu)3 in only 50% yield, and 
is stable for at least 15 days.123 Stille coupling was performed under reflux in DCE with 
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10 mol% of bis(triphenylphosphine)palladium(II) dichloride, and (108) was isolated 
after purification by column chromatography on flash silica gel. The mass spectrum of 
(108) showed a peak at m/z 219 assigned as the M+1 ion (35Cl). Additionally the 
formation of compound (108) was supported by analysis of  the 1H NMR spectrum with 




































Scheme 2.46: Formation of (108) from Stille coupling 
  
Compound (108) was further derivatized by nucleophilic substitution with an 
amine (Scheme 2.47). Therefore, a solution of (108) in excess aqueous ammonia was 
heated at 140 °C for 12 hours giving (109) in 80% yield. The formation of (109) was 
verified by an additional peak at 5.22 ppm in the 1H NMR spectrum with a relative 
integration of 2H, assigned to NH2. The amine was alkylated using allylbromide. 
Therefore, a solution of (109) in an excess of allylbromide and THF was heated at 120 
°C for 12 hours to give (110) in 90% yield. The generation of (110) was confirmed by a 
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peak in the mass spectrum (CI) at m/z 240 assigned as the M+1 ion, a multiplet at 5.98, 
a doublet of doublet at 5.31 with coupling constants J = 17.4 Hz, J = 9.0 and a triplet 























Scheme 2.47: Aminolysis of the (108) gave (109) followed allylation of (109) 
produced (110). 
 
This investigation was further expanded to a different system using 4-
nitrobenzaldehyde and uracil to generate analogs of original key ketone (40) with 2,4-
substitutions. It has been reported that compound (113) can be prepared in good yield 
by the reaction of 4-nitrobenzaldehyde with uracil in HCl (36%).124 According to the 
literature procedure should give compound (113) exclusively, but in our hands gave 
only 10% of (113)124 and 80% of (114) (Scheme 2.48). Compounds (113) was 
identified by spectral data that was identical to that reported in the literature.124 The 
generation of (114) was verified with a peak in the mass spectrum (ES) at m/z 356 
assigned as a M-1 ion and doublet at 11.12, 8.48, 7.79, and 7.27 ppm with singlet at 
5.10 ppm each assigned to the two uracil NH protons, phenyl protons, H6 pyrimidine, 
and H. 
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First few attempts to purify by chromatography proved to be difficult and it can 
be handled in only a small quantity because of its insolubility. Based on solubility of 
(113) in methanol, whereas compound (114) insoluble in methanol, the solid obtained 
in the reaction directly subjected to methanol extraction. During this procedure, 
compound (113) was methylated to give (116). The methylation probably occurs 
through the protonation of MeOH with HCl gave (116). The generation of (116) was 
confirmed by a peak in the mass spectrum (ES) at m/z 276 assigned as the M-1 ion, a 
singlet at 5.61 and 3.65 assigned to the H and methyl group in the 1H NMR spectrum. 
Oxidation of (113) using PCC the ketone (115) was produced in 70% yield. The 
generation of (115) was confirmed by a peak in the mass spectrum (ES) at m/z 260 
assigned as the M-1 ion, further confirmation was provided by the disappearance of a 













































Scheme 2.48: Acid mediated condensation of (111) with uracil (112) produced (113) 
and (114), further oxidation of (113) gave (115) and methylation produced (116) 
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The preparation of another 4,6-dihydroxy-5-pyrimidinyl phenylmethanol (117) 
was attempted in the same way using 4,6-dihydroxypyrimidine and benzaldehyde in 
water heating under reflux. However, compound (118) was obtained in good yield 
(80%) (Scheme 2.49). Compound (118) was identified by spectral data which was 






























The chemistry has been developed for the preparation of the (ADAM) 
alkenyldiarylmethanes. The total synthesis of ADAM (24) was successfully achieved. 
The strategy used for this synthesis is different from that reported in the literature. For 
example, the literature synthesis of the key intermediate (33) needed six steps, whereas 
the method used here requires only two steps. Fourty two compounds were successfully 
synthesized, thirty six of which were new compounds, all of them related to the target 
compound (24). Most of these molecules are small in size, easy to modify for the future 
investigations and have the potential to be developed as clinical drug candidates. The 
establishment of these molecules, with suitable substitution patterns, as non-biaryl 
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atropisomers has been found, e.g. compounds (70), (50) and (24). Variable-temperature 
1H NMR and 13C NMR experiments could be conducted on all these compounds, 
leading to the established of criteria for atropisomeric inducement. Further 






































A series of biaryl derivatives related to the target compound (24) (Figure 3.1) 
have been prepared, and evaluated for their activity against Plasmodium falciparum 










Figure 3.1: Target compound (24) with anti-malarial activity IC50 0.8µM, the colour 
indicates where derivatisation was performed at these areas.  
 
The anti-malarial activity of some novel biaryl analogs related to ADAM (24) 
are presented and a preliminary structure activity relationship study of more than 40 of 
the compounds against malaria was investigated. All the biaryl derivatives are divided 
into three separate series (I, II and III) and are presented in different sections (Table 
3.1, 3.2, 3.3). The assay used the microculture radioisotope technique at a starting 
concentration of 10µg/ml and was performed at the National Centre for Genetic 
Engineering and Biotechnology (BIOTEC), Pathumthani, Thailand.  
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3.2 Series I 
Series I derivatives are related to (40) with the structure and activities presented 
in Table 3.1. Compound (33) with chloro substitutions at R1, R2, and R5 showed 
moderate activity (IC50 5.4 µg/ml). Compound (52), where R1, R2 and R5 are replaced 
by protons is more active (IC50 4.5 µg/ml). All the compounds where R1 and R2 are 
amine are inactive, except for one compound (101) with a dimethyl substituted amino 
group showing moderate activity. Replacement of one or two 4,6-chlorosubstituents of 
compound (33) with amino group renders the molecules inactive, for example (34) and 
(92). Compound (47) is inactive and its mono (92) and diamine (93) derivatives are 
also inactive. Compounds (50) and (70) are closely related to the target ADAM (24) but 
both of these compounds are inactive. The target ADAM (24) was also retested to 
confirm its activity, and reproduced the similar activity as earlier (IC50 1.9 µg/ml or 
0.88 M) (Table 3.1), (Figure 3.2). Eventhough the target (24) originally reported as 
inactive when screened in-vivo against Plasmodium berghei at 640 µg/kg.99 The target 
(24) was screened twice in this project against Plasmodium falciparum and proved to 
be active. The difference in activity may be due to the different Plasmodium strain used 
in the respective screening methods. Compounds (65) and (52) are active (Table 3.1). 
Compound (65), where R3 is butyl is more active than (52). Compound (63) closely 
related to (65), is inactive. Similarly, compound (56) is inactive, whereas (52) is active. 
Both these active compounds possess aromatic nitrogen heteroatom, which may 
necessary for the anti-malarial activity. This study suggests that for the basic ADAM 
skeleton to posses anti-malarial activity, simple amino groups are not sifficient and at 
least one of the amine must be alkylated.  
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Table 3.1: The structure and anti-malarial activity (IC50) against Plasmodium 






































































































































































replacement of the side chain 
with proton loses its activity
displacement of two amine
groups with dichloro maintain
some activity, but less






Figure 3.2: Parent ADAM (24) with anti-malarial activity IC50 0.8 µM and its structure 
activity relationship.  
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3.2 Series II 
Compound (46) (Figure 3.3) is a known compound,108 however, we report here 
for the first time its anti-malarial activity at the micromolar range of IC50 0.3 µg/ml. 
Many compounds were synthesised by replacement of the 4,6-dichloro substituents, 
however, none of them proved to be active. This indicates that with this ketone 
scaffold, the 4,6-dichloride pattern is needed for activity (Figure 3.3). The activity of 
(109) suggests that it can be further substituted at 4,6 and phenyl positions. Only a 
limited number of compounds show activity. This analysis also shows that replacement 
of the phenyl group with a isopropyl group (79) results less in activity, therefore 








substitution of one chloro 
group results in inactive






replacement of the phenyl 
ring with an isopropyl group
retain the antimalarial
activity but lower at 2.7 µg/ml
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Table 3.2: The structure and anti-malarial activity (IC50) against Plasmodium 















































































































































3.2 Series III 
Compound (80) (Table 3.3) showed good anti-malarial activity of IC50 0.7 
µg/ml, but its para-chloro substituted compound (88) is less active at 1.4 µg/ml 
(Figure 3.4). The alcohol (45) is also active with an IC50 of 3.1 µg/ml. Most of the 
compounds related to (80) are active. Dehydration of compound (80) gives (47) (Table 
3.1) which is inactive, whereas dehydration of (88) is active but at lower level (Table 
3.1). If the compound (80) is to be optimized further, then possible substitutions of the 
   
 97 
isopropyl group need to be investigated. The replacement of the phenyl group with a 






surprisingly removal of 
dichloro and dehydration
still retain the antimalarial
activity but to a lesser
extent 4.5 µg/ml
hydroxy group required for anti
malarial activity (IC50 0.7µg/ml )
removal of this removes completely
the activity
p-substitution with chloro
reduces slightly the anti-malarial 
activity to IC50 1.4 µg/ml
only removal of isopropyl
group makes molecule 
less active, IC50 3.1 µg/ml
HO
 
Figure 3.4: Compound (80) showing anti-malarial activity IC50 0.7 µg/ml, its para-
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Table 3.3: The structure and anti-malarial activity (IC50) against Plasmodium 
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3.4 Miscellaneous series 
Under this miscellaneous series, only one bi-pyrimidine compound (57) showed 







       (57) 
Figure 3.5: Bi-pyrimidine (57) showed anti-malarial activity at IC50 2.6 µg/ml 
 
3.4 Conclusions 
All compounds were evaluated for their activity against Plasmodium falciparum 
K1, the most virulent strain of malaria. There are 11 compounds that showed 
significant activity against malaria with low micromolar range. A preliminary structure 
activity relationship analysis has been performed, and suggested that the basic structure 
alkenyldiaryl methane (ADAM) is required, with one of the two aryls units being a 
pyrimidine ring. This suggests that the nitrogen atoms in the hetrocycle are required for 
the anti-malarial activity. A more extensive range of derivatives need to be synthesized 
and tested for a comprehensive SAR, with optimized activity aiming for IC50 10-9 to 10-
7 molar activities. 




THALLIUM(III) TRIFLUOROACETATE MEDIATED 





Biindoles have been shown to demonstrate a variety of biological activities.127 
2,2’-Biindole (119) is present as a structural element in some anti-tumor natural 
products including the indolocarbozole Tjipanazole E (120),128 Tjipanazole B (121), 
and rebeccamycin (122) (Figure 4.1). Arcyriaflavin A (123) was isolated from the 
mould Arcyria mutans, and Fascaplycin129 (124) is an anti-cancer agent isolated from 
an Indonesian sponge. All these natural products contain 2,2’-biindole as a common 
skeleton, and further, such a skeleton can be easily transformed to different biindole 

























       (120)      (121)         (122)  
























      arcyriaflavin A   fascaplycin 
Figure 4.1: Important anti-tumor natural products containing the 2,2’-biindoles unit. 
 
The formation of 2,2’-biindoles can be achieved by the acid catalyzed 
dimerisation of 4,6-dimethoxy-3-methylindole (Scheme 4.1).130 This yielded the 
indolyl-indoline (126) as its hydrochloride salt. However, the compound could only be 
converted into the symmetrical biindole (127) in a moderate yield of 50% by heating at 
reflux in xylene for 72 hours in the presence of chloranil T (Scheme 4.1).131,132  
 































Scheme 4.1: Preparation of the 3-substituted 2,2’-biindole moiety by an acid catalyzed  
reaction to give the dihydrobiindole, with subsequent oxidation producing the 
symmetrical biindole (127). 
 
Another reported method involves the generation of N,N’-carbonyl-bis-4,6-
dimethoxyindole (128), obtained from the reaction of 4,6-dimethoxy-3-methylindole 
(125) and N,N’-carbonyldiimidazole. This then underwent palladium(II) acetate 
catalyzed oxidative coupling to give the biindolyl (129) in 65% yield, before 
subsequent reduction using an excess of LiAlH4 gave biindole (127) (Scheme 4.2).131 
 



































Scheme 4.2: Preparation of the 3-substituted 2,2’-biindole moiety by palladium(II) 
acetate oxidative coupling followed by reduction with LiAlH4 
 
2,2’-Biindolyl (131) (Scheme 4.3) can also be prepared from 2-indolinones 
(130) using phosphoryl chloride and by heating under a nitrogen atmosphere.133 The 
same compound (131) was prepared by treatment of 2-chloro-1,3-dimethylindole (132) 
with 1,3-dimethylindole  (133) in dichloromethane in the presence of boron trifluoride 
etherate at 0 ºC for 30 min, followed by stirring at room temperature for 14 hours 
providing the 2,2’-biindole (131) in 91% yield (Scheme 4.4). However, when the 
methyl substituent was replaced with an ethyl substituent, a lower yield (60%) was 
reported.134 
 


































Scheme 4.4: Synthesis of 2,2’-biindoles from coupling mediated by boron trifluoride 
diethyl etherate between (132) and (133)  
 
In previous studies, we have investigated the oxidative dimerisation of 
indoles.98 Thallium(III) trifluoroacetate (TTFA) has been successfully used as an 
oxidizing agent in biaryl synthesis,135,136 offering smooth, rapid and direct regiospecific 
(depending on substituents pattern) oxidative dehydrodimerisation to give symmetrical 
biaryls in good to excellent yield. The method is particularly useful when applied to a 
substrate in which the ring substituents are either electron donating or mildly electron 
withdrawing.  
In our studies, TTFA was utilized in the oxidative coupling of a 4,6-
dimethoxyindole that possessed substituents at both the C2 and C3 positions, yielding 
7,7’-biindoles in excellent yield (Scheme 4.5).137 
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Scheme 4.5: Formation of 7,7’-biindoles by oxidative coupling using TTFA 
 
This simple, clean and efficient procedure gave no by-products, only required 
minimal work-up and represented the quickest and most efficient route to these dimeric 
heterocycles. This work was extended to the TTFA induced oxidative dimerisation of 
4,6-dimethoxyindoles possessing a C3 substituent, yielding 2,2’-biindoles (Scheme 
4.6).98 In previous studies, the formation of 2,2-biindole derivatives was confirmed by 
1H NMR from only partially purified samples. Therefore, confirmation of the structure 
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X = p-OMePh, p-BrPh
R = PhSO2
 
Scheme 4.6: Formation of 3-aryl-2,2’-biindole by TTFA oxidative coupling 
 
   
 106 
These studies indicated that the strategy of thallium-based oxidative couplings 
could be an effective method of efficiently generating the 2,2’-biindole scaffold. 
However, the reactions were not optimized and the scope and limitations of this 
procedure had not been investigated. For example, the influence of different protecting 
groups in the formation of 2,2’-biindoles was not known, as well as the effect of 3-
substituents on 2,2’-biindole formation. Problems regarding deprotection surfaced 
during earlier investigations and needed to be resolved.98 Therefore, a detailed 
investigation was needed to address the problems associated with deprotection of the N-
protecting groups. According to current reports,138,139 it is difficult to remove alkyl 
sulfonyl protecting groups on indoles. Further investigation on the deprotection of these 
groups was also required. It is already known that having strong electron withdrawing 
substituents hinders oxidative biaryl coupling with TTFA.135  
Facile access to a range of 2,2’-biindole analogs also has the potential to feed 
into our anti-malarial drug design and development program. Our broad hypothesis of a 
‘non-nucleoside’ type pocket existing within the malarial telomerase enzyme (see 
Section 1.8.9 Chapter 1), cross fertilized with our wider anti-viral drug design program 
investigating biaryls as a scaffold for inhibitors targeting the HIV-reverse transcriptase 
non-nucleoside inhibitor pocket, emerges with the possibility that such biindole 
systems might have significant biological activity. Therefore, once the scope and 
limitation of the TTFA oxidative coupling to produce biindoles have been established, 
it was intended to produce a range of derivatives and to test their activities, not only in 
anti-malarial assays, but additionally in anti-HIV assays. Additionally, results from this 
study could feed into the broader hypothesis of the existence of a non-nucleoside 
inhibitor binding pocket on the malaria telomerase enzyme. 
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4.2 The synthesis of 3-aryl-2,2’-biindoles  
The investigation of thallium(III) trifluoroacetate (TTFA) oxidative coupling of 
indole monomers is outlined in Scheme 4.7. The substituted indole monomer (134) was 
prepared according to the literature.140 Protection of the indole NH was achieved by 
treatment of a dichloromethane solution of 4,6’-dimethoxy-3-(4-methoxyphenyl)indole 
with sodium hydride, followed by the addition of benzenesulfonyl chloride which gave 
the N-benzenesulfonyl-3-(4-methoxyphenyl)-4,6-dimethoxyindole (135) after 2 hours 
of stirring at room temperature and following recrystallization from methanol. 
Formation of protected indole (135) was confirmed by analysis of the mass spectrum 
(ES) with a peak at 424 assigned as the [M+1] peak. 1H NMR provided further 
confirmation with the disappearance of the indole NH of (134) at 8.01 ppm, and the 
appearance of resonances between 7.89-7.56 ppm assigned to the benzenesulfonyl 
substituent. The indicative upfield chemical shifts of the indole H2 and H7 aromatic 
protons from 6.90 to 7.31 ppm and 6.47 to 7.20 ppm respectively, also indicates the NH 
substitution of compound (134).  
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Scheme 4.7: Synthesis of protected 3-aryl-2,2’-biindoles (136) and deprotected 3-aryl-
2,2’-biindoles (137). 
 
Dimerisation of (135) was achieved by the treatment of an acetonitrile solution 
of N-benzenesulfonyl-3-(4’-methoxyphenyl)-4,6-dimethoxyindole (135) with a half 
mole equivalent of thallium(III) trifluoroacetate, followed by the addition of boron 
trifluoride diethyletherate. This resulted in a good yield (70%) of the 2,2’-bi-[N-
benzenesulfonyl-4,6-dimethoxy-3-(4-methoxyphenyl)]indole (136) after 1 hour of 
stirring at room temperature, followed by recrystallization from 
methanol/dichloromethane. Again, generation of (136) was confirmed by the analysis 
of the mass spectrum (ES) with a peak at m/z 845 assigned as the [M+1] ion. Analysis 
of the 1H NMR spectrum also confirmed the formation of 2,2’-biindole (136) by the 
disappearance of the peak at 7.31 ppm that was assigned to H2 in (135). The presence 
of only one set of peaks in the 1H NMR spectrum further suggest the formation of 
compound (136), indicating its symmetrical nature. Comparison of 1H NMR spectrum 
between the dimer (136) and the monomeric (135), indicates a shift in the peaks 
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assigned to the benzenesulfonyl from 7.89-7.56 to 7.53-7.30 ppm and the peaks 
assigned to the 3-aryl moved from 7.47-6.92 to 7.03-6.65 ppm. Similarly, in the 13C 
NMR spectrum, the peaks assigned to C2 shifted from 121.0 to 127.0 ppm and analysis 
of DEPT spectrum indicated that it was a quaternary carbon. Compound (136) was also 
confirmed by X-ray crystallographic analysis (Figure 4.2), showing that both phenyl 














Figure 4.2: X-ray structure of 2,2’-bi-[N-benzenesulfonyl-4,6-dimethoxy-3-(4-
methoxyphenyl)]indole (136) ORTEP plot. 
 
The mechanism of dimerisation was postulated135 to proceed via an initial one-
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thallium(III), which results in the generation of an indole radical cation (135a); 
electrophilic substitution of the indole substrate (135) by (135a) gives intermediate 







































Scheme 4.8: Postulated mechanism for the thallium(III) catalyzed aryl dimerization 
reaction. 
 
An attempt was made to remove the benzenesulfonyl protecting group in the 
presence of thionyl chloride at room temperature, but the reaction yielded a mixture of 
compounds that could not be separated. Deprotection was achieved by heating (136) at 
reflux for 4 hour in a 20% sodium hydroxide solution, giving (137) in 15% yield. 
Confirmation of the structure was provided by analysis of the mass spectrum (CI) with 
a peak at m/z 564 assigned as the molecular ion. Analysis of the 1H NMR spectrum also 
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supports the formation of (137) with the presence of a peak at 9.80 ppm assigned as the 
NH, and the disappearance of benzenesulfonyl peaks between 7.64-7.25 ppm.  
The TTFA mediated oxidative coupling reaction was further investigated with 
three more indole monomers including 4,6-dimethoxy-3-phenylindole (138), 4,6-
dimethoxy-3-(4-bromophenyl)indole (139) and 4,6-dimethoxy-3-(4-nitrophenyl)indole 
(140). Compounds (141)-(143) were prepared as described above in good yield (65 -
70%) (Scheme 4.9). Subsequent TTFA oxidative coupling of (141) and (142) gave the 
dimers (144) in 74% yield and (145) in 70% yield. Under these oxidative conditions, 
compound (143) did not successfully couple, even after a prolonged reaction time. This 
may be due to the strongly electron-withdrawing para-nitro group, resulting in the 
electron rich aromatic indole becoming electron depleted, therefore making it difficult 
to transfer an electron from the indole to thallium. Deprotection of (144) and (145) 
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(138)  X = Ph
(139)  X = BrPh





































Scheme 4.9: Formation of protected 2,2-biindoles and their deprotected 2,2’-biindole 
 
4.2.1 Synthesis of 2,2’-biindoles with alternative N-alkylsulfonyl protecting groups 
The TTFA oxidative coupling reaction was expanded to synthesize 2,2’-
biindoles with different protecting groups. The aim of this investigation was to examine 
the relative ease of removal of these alternative groups under normal deprotection 
conditions, and their influence on 2,2’-dimerisation. Already it has been noted that the 
removal of benzenesulfonyl group proved to be difficult and low yielding. The 
protection of indoles with other alkylsulfonyl chlorides was achieved as previously 
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shown using sodium hydride as a base and DCM as a solvent (Scheme 4.10) with 
subsequent TTFA oxidation providing the protected 2,2’-biindoles (154)-(158) in good 
yields (Scheme 4.10). N-4-Nitrobenzenesulfonyl-3-(4-nitrophenyl)indole (150) did not 
undergo TTFA oxidative coupling, with only starting material remaining even after 
prolonged reaction time, further supporting that an electron-withdrawing nitro 
substituent is detrimental to the oxidative coupling of indole. Deprotection of these 
dimers was attempted under a different reaction conditions, with thiophenol, DMF and 
K2CO3 at room temperature. Only (158) gave the deprotected 2,2’-biindole (137) in 
25% yield. The yield of (137) here was slightly better than deprotection of (136) was 
carried out using 20% NaOH (Scheme 4.7). All other deprotection reactions resulted in 
inseparable mixtures. Confirmation of the structure of (157) was obtained by X-ray 
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Figure 4.3: X-ray structure of 2,2’-bi-[N-methanesulfonyl-4,6-dimethoxy-(4-
bromophenyl)]indole (157) ORTEP plot.  
 
4.2.2 Thallium(III) trifluoroacetate mediated coupling of 4,6-dimethoxy-3-aryl 
indoles with other protecting groups 
The investigation of TTFA oxidative coupling of indoles was further expanded 
to three other protecting groups; N-triflate, N-acetyl, N-trifluoroacetate and N-tert-
butylcarbamate (Figure 4.6). The reason behind this investigation was to improve the 
biindole yields during the deprotection step and the influence of the protecting groups 
on 2,2-coupling. The first triflation attempt on indole NH (134) was made by the 
treatment of a DCM solution of 4,6-dimethoxy-3-(4-methoxyphenyl)indole (134) 
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which was stirred for 72 h, resulting directly in the dimerised product (137) (Scheme 
4.11), rather than the expected protected monomer (159). The dimer (137) produced 
here was spectroscopically identical to that produced earlier (Scheme 4.7). This 































Scheme 4.11: Proposed reaction to obtain the N-triflated indoles (159), but 
unexpectedly direct formation of the 2,2’-dimer (137) was observed. 
 
An acetylation attempt on the indole NH was made by the treatment of a DCM 
solution of 4,6-dimethoxy-3-(4-methoxyphenyl)indole (134) (Scheme 4.12) with 
sodium hydride, followed by the addition of acetyl chloride, which was stirred for 24 
hour resulting in no change in starting material.  
 











Scheme 4.12: An acetylation attempt was made on indole NH (134) by the treatment of 
acetyl chloride in the presence of base. 
 
A second acetylation attempt was made on (134) by treatment of a THF solution 
of (134) with pyridine, followed by the addition of acetyl chloride offering the 1,2-
dihydropyridine (160) in 50% yield (Scheme 4.13). Generation of (160) was confirmed 
by the analysis of mass spectrum (CI) with the peak at m/z 405 assigned as the 
molecular ion. The link between the acetyl and pyridine nitrogen was confirmed by 15N 
gHMBC analysis, which indicated that the indole nitrogen correlated with its own 
proton while the pyridine nitrogen correlated strongly with the acetyl and H2’ protons 
and weakly with the H6’ proton. 1,2-Dihydropyridine protons were assigned 
unambiguously based on 1H-1H correlations and irradiated decoupling proton 
experiments. The pyridine H3’ and H5’ protons appear at characteristic resonances of 
4.97 and 5.10 ppm respectively. At present, the formation of the 1,2-dihydropyridine 
compound (160) has not been investigated, however, it could be explained by the acetyl 
chloride reacting with the pyridine in aprotic THF at reflux with the inclusion of 
electron withdrawing groups, inducing a second nucleophilic addition of the indole to 
the -position of the pyridinium ion furnishes the corresponding 1,2-dihydropyridine 
(160).141 There is literature precedent for the formation of (160) (Scheme 4.14) where 
pyridine reacts with benzoylchloride to give a pyridinium ion, this induces a 
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remarkable second nucleophlic addition of an equivalent of the starting pyridine ot the 























 (134)        (160) 
Scheme 4.13: When acetylation was attempted on indole NH (134) using acetylation in 














              (161) 
Scheme 4.14: This is a literature precedent141 for the formation of 2-pyridinyl-
dihydropyridine (161)  
 
Acetylation of indole (134) was achieved using a phase transfer catalyst, 
tetrabutylammonium hexafluorophosphate, in the presence of potassium hydroxide in 
DCM, providing the N-acetylindole (162) (Scheme 4.12) in good yield (60%). 
Formation of (162) was confirmed by analysis of the mass spectrum (CI) with the peak 
at m/z 326 assigned as the [M+1] ion. Analysis of the 1H NMR spectrum provided 
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further confirmation by the disappearance of the indole NH of (134) at 8.01 ppm, and 
appearance of a peak at 2.61 ppm is indicative of an acetyl CH3 group. Analysis of the 
13C NMR spectrum shows the presence of a resonance of 169.1 ppm assigned to the 
















   (134)      (162) 
Scheme 4.15: Acetylation of 4,6-dimethoxy-3-(4-methoxyphenyl)indole using a phase 
transfer catalyst  
 
The acetylation methodology was further extended to p-nitroindole (140). 
Similarly compound (163) was prepared by using the phase transfer catalyst (Scheme 
4.16). The generation of compound (163) was verified by the presence of NH peaks at 
9.20 ppm and a shifting of H2 proton from 7.20 ppm to 7.71 ppm in the 1H NMR 
spectrum and the presence of a carbonyl peak at 149.0 ppm in the 13C NMR spectrum. 
The M+1 ion peak at m/z 341 in the CI MS was also noted. 
 















   (140)      (163) 
Scheme 4.16: Acetylation of 4,6-dimethoxy-3-(4-nitrophenyl)indole using a phase 
transfer catalyst  
 
The first protected indole (162) in this series was subjected to TTFA oxidation 
using reaction conditions as described earlier. However, the starting material remained 
unchanged. When an acetyl group was used as a protecting group on 4,6-dimethoxy-3-
(4-nitrophenyl)indole (163), oxidative dimerization with TTFA produced the 2,2’-
dimer (167) in a 60% yield (Scheme 4.17). Generation of compound (167) was 
confirmed by the analysis of 1H NMR spectrum which showed the disappearance of a 
peak at 7.71 ppm assigned to the H2 proton in the starting material. Additional support 
was provided by analysis of the 13C NMR spectrum which revealed a downfield shift of 
the acetyl carbonyl peak in the starting material from 149 ppm to 171.0 ppm and 
analysis of the DEPT spectrum also indicated the disappearance of the protonated C2 
carbon. The biindole (167) did not give the correct molecular ion peak during MS 
analysis even when using different ionization techniques (ES, CI and EI). 
Mass spectral analysis of the TTFA oxidative coupling of 4,6-dimethoxy-3-(4-
methoxyphenyl)indole with Boc (166) as a protecting group indicated the presence of 
many compounds  which were difficult to separate by column chromatography. Mass 
spectral analysis indicated the probable formation of polyindoles and demethylated 
hydroxyl compounds.  
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The starting materials (164)-(165) were prepared  according to the literature 
procedure.140 The compounds (164)-(165) were identified by spectral and physical data 
which was identical to that reported in the literature.140 TTFA oxidative coupling was 
attempted using the indoles (164) and (165). No 2,2’-biindole formation was observed 
with protected monomer (164) possibly due to the strong electron withdrawing nature 
of the trifluoroacetate group. Compound (165) gave the 2,7’,7,7’’-trimer or terindole 
(168) in 35% yield (Figure 4.17) with the remainder being isolated as the starting 
material (165) and the deprotected monomer (140).  
Identification of the trimer (168) was provided by the analysis of the mass 
spectrum (ES) with a peak at 1179 assigned as the molecular ion. Analysis of the 1H 
NMR spectrum showed singlet peaks at 6.73, 6.66, and 6.44 ppm assigned to the H5’, 
H5 and H5’’ protons. These three H5’, H5, and H5’’ protons show no coupling to their 
respective H7 protons suggesting the linking of molecule through 2,2’7,7’’-trimer. 
Additional support is provided by the absence of one H2 from the 1H NMR spectrum, 
with the other two singlets at 7.21 and 6.95 ppm assigned to the H2’ and H2’’ protons 
(Table 4.1). Additional support to the proposed structure was provided by the 
significant gHMBC, gCOSY and NOESY correlations (Table 4.1). Usually H5 and H7 
are coupled through the gCOSY and with a meta coupling constant of approximately J 
= 1.8 Hz, and is clearly absent in the terindole (168). All the carbons in the terindole are 
unambiguously assigned with help of gHMBC and protons are assigned based on 
gCOSY and NOESY (Table 4.1).  
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Scheme 4.17: Formation of compound (167) and (168) 
 
The mechanism for the formation of (168) is not clear. However, on the basis of 
current knowledge about TTFA promoted oxidations and dimerisation of 
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indoles,135,142,143 it may be due to the p-nitro group and trifluoroacetate group at the N1 
position not activating the 2-position to the same level as the previous example, thus 
allowing attack at the C7 position to become a significant competitive reaction. This 
results in the formation of the 2,7’-dimer with the reaction undergoing further oxidative 
coupling between 7,7’ yielding the 2,7’,7,7’’-trimer (168) (Scheme 4.18). Oxidative 
dimerisation of indole (165) is initiated by either one or two electron transfer to the 
TTFA from the 7-position instead of the regular 2-position, leading to an electrophilic 
species, formally cation (165a), which is susceptible to attack from the nucleophilic C2 
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Table 4.1: Compound (168) significant gHMBC, gCOSY and NOESY correlations, 




















carbon      13C              gHMBC  1H       gCOSY NOESY 
C4’’ 156.6     
C6’’ 160.2  8.24   
C6’ 157.4  8.21   
C6 156.8  7.94   
C4’ 154.8  7.66   
C4 154.0  7.55   
ArC4’’ 147.4  7.21   
ArC4’ 147.3  7.12   
ArC4 146.4  6.95   
ArC1’’ 142.0  6.73   
ArC1’ 141.1  6.66   
ArC1 140.0  6.44   
C7a’  137.2  3.95   
C7a 137.2  3.92   
C7a’’ 137.0  3.84   
15 130.4  3.81   
C2 128.0  3.79   
C3’ 124.6  3.72   
C3’’ 124.3     
19 123.0     
ArC3,C5 122.4     
C2’ 121.9     
C2’’ 121.3     
C3 121.0     
C3a’ 114.2     
C3a’’ 113.1     
C3a 112.8     
C7’ 106.2     
C7 105.5     
C7’’ 100.2     
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4.2.3 Thallium(III) trifluoroacetate mediated coupling of 4,6-dimethoxy-3-aryl 
indoles without N-protecting group 
After performing detailed investigations utilizing different N-protecting groups, 
TTFA oxidative dimerisation was expanded using indole monomers without NH 
protecting groups. When no N-protecting group is present, the optimum conditions 
involve a Lewis acid added in 3 to 5 equivalents at 0 ºC, before being continued at 
room temperature for 3 hours. The first compound (134) was dimerised by oxidative 
coupling and gave the corresponding 2,2’-dimer (137) in (35%) yield (Scheme 4.19), 
with substance remaining being starting material and other baseline material. The 
second compound, 4,6-dimethoxy-3-(4-bromophenyl)indole (139), under direct 
oxidative coupling gave 20% of 2,2’-dimer (146) with 50% of the starting material 
recovered. Interestingly, 4,6-dimethoxy-3-(4-nitrophenyl)indole gave only the 2,7’-
dimer (169) (20%) with no traces of formation of 2,2’-dimer.  
The identification of the dimer (169) followed from analysis of the 
characteristic region around 6.50 ppm in the 1H NMR spectrum, clearly showing as the 
absence of H2 and H7 protons, the presence of one uncoupled H5’ at 6.41 ppm and the 
other two H5 6.31 ppm and H7 6.57 ppm protons showed a meta coupling of J = 1.8 Hz 
confirmed through the gCOSY correlations. This is the basis for establishing the 
carbon-carbon linkage of 2,7’.  The additional support to the proposed structure was 
provide by analysis of the gHMBC, gCOSY and NOESY spectrum enabling the 
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Scheme 4.19: Attempted oxidative coupling on indoles without N-protecting group 
 
The mechanism of formation of compound (169) was proposed to occur 
similarly to the formation of compound (168). The reaction pathway could involve one 
electron transfer from indole (140) at the C7-position to TTFA giving rise to the 
cationic electrophilic species, which is susceptible to nucleophilic attack by the 2-
position of starting indole (140). The postulated mechanism is illustrated in the Scheme 
4.20. The 7-position experiences a more pronounced electron donating effect due to the 
electron deficiency of the C2-position. Compound (169) is a 2,7’-dimer in contrast to 
compound (168), a 2,7’,7,7’’-trimer. The formation of these possible arrangements (2,7 
and 2,7’,7,7’’) can be dictated by the p-nitro and/or trifluoroacetate groups.  





































Scheme 4.20: Postulated mechanism for the thallium(III) catalyzed 2,7-biindole 
formation 
 
In all oxidative coupling reactions without N-protecting groups, the reaction 
takes longer, with significant quantities of starting material remaining. The results 
clearly indicate that in order to obtain 2,2’-biindoles in reasonable yield, the indoles N1 
position must be protected with an alkylsulfonyl group. These results also suggest that 
the alkyl or aromatic sulfonyl group may help in the regiospecificity of the 2,2’-
dehydrodimerisation in TTFA oxidative coupling provided the 3-aryl substitution is 
mildly electron withdrawing or electron donating. The indole monomers (143) and 
(150) did not undergo oxidative coupling using TTFA.  
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4.3 Conclusions 
Oxidative coupling of indoles with thallium(III) trifluoroacetate gives good to 
excellent yields of 2,2’-dimers. Protecting groups such as benzenesulfonyl, tosyl or 
methane sulfonyl definitely direct formation of the 2,2’-dimer, provided that the phenyl 
para substituent is a mildly electron withdrawing or a electron donating group. If the 
phenyl para substituent is a strong electron withdrawing group, e.g. NO2, even when a 
suitable nitrogen protecting group is present, no dimerisation was observed under these 
oxidative conditions. When an attempt was made without having any protecting group 
present on the indole nitrogen with nitro phenyl para-substitution, no 2,2’-dimerisation 
was observed, but a small amount of formation of 2,7’-dimer (20%) (169) was formed. 
When a p-nitrophenyl substituent was present at the 3-position on the indole, the 2-
position was deactivated, and oxidative coupling with TTFA gave the 2,7’-dimer only. 
Having a p-nitro on the phenyl group and a trifluoroacetate group at the N1 position 
deactivates C2 and activates C7 such that the tri-indole (168) was obtained from 
oxidative TTFA coupling. A route has been found to synthesize a new 1,2-
dihydropyridineindole (160) derivative. Biindole deprotection requires further 
investigation to obtain more efficient deprotection methods for this class of compounds. 












FORMATION OF BIINDOLES 





During the investigation of 2,2’-biindoles as potential novel anti-malarial 
agents, the thallium(III) trifluoroacetate mediated oxidative coupling of N-protected 
indole was investigated (Chapter 4). The synthesis of N-triflate indoles (159) (Scheme 
5.1), followed by oxidative coupling with TTFA was expected to give triflated 2,2’-
biindoles (170), with subsequent deprotection leading to the desired symmetrical 2,2’-
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p-OMeC6H4 R = SO2CF3
 
Scheme 5.1: Unexpected formation of (137) 
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Trifluoromethanesulfonic (triflic) anhydride has broad applications in synthetic 
chemistry, primarily as a reagent for the conversion of various compounds to their 
triflates.144 More than 1000 publications concerning its chemistry have been published, 
however, attempts to fully understand chemistry of triflic anhydride is still in 
progress.145  
Application of triflic anhydride as a mild and effective activation reagent in the 
Vilsmeir-Haack reaction was similar to the intended indole transformations. It has been 
reported145 that less nucleophilic aromatics can be formylated when the classical 
Vilsmeir-Haack reagent (DMF/phosphoryl chloride) is replaced by DMF/triflic 
anhydride. The iminium salt (171) (Scheme 5.2) which is formed, even reacts with less 








Ar-CHO0 ºC 1. Ar-H
2. NaOH, H2O 25-90%
 
             (171) 
Scheme 5.2: Formylation of aromatic using DMF and triflic anhydride iminium salt 
(171). 
 
Using similar conditions, indolin-2-one was shown to convert 3-aryl-4,6-
dimethoxyindoles(138), (139) and (172) into the 2,7’-bisindolyl compounds (173) and 
(174).146 In contrast, the reaction of the indoline-2-one/triflic anhydride complex with 
3-aryl-4,6-dimethoxybenzofurans afforded the 2,2’-biindole (176) as the major product. 
The 7-substituted products  (Scheme 5.3) were obtained in low yields due to the higher 
reactivity of C2 over C7 in the 3-aryl-4,6-dimethoxybenzofuran series.147 In all cases, 
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X = O, (174) 10 - 28%
(175) 0%
X = O, (176) 37-58%
X = NH
X = O (172)
R = Ph, 4-BrPh, (138), (139)  
Scheme 5.3: Some literature examples detailing the formation of unsymmetrical 
biindoles. In all cases the iminium salt is formed from triflic anhydride and the 
carbonyl compound reacts with the even less reactive aromatic compounds (138), (139) 
and (172).145 
 
Indolin-2-one (177) reacts with the 2,3-disubstituted indole (178) in the 
presence of two equivalents of Tf2O (triflic anhydride) forming predominantly the 
7,7’:2,7’-terindoles (179).146 The mechanism is reported to involve the initial reaction 
of the iminium salt with the indole (178) to produce the 2,7’-bisindolyl system, which 
then undergoes oxidative coupling with a further equivalent of (178) (Scheme 5.4). 


























Scheme 5.4: Some literature examples detailing the formation of the unsymmetrical 
terindole. In all cases an iminium salt is formed from triflic anhydride and the carbonyl 
compound, then reacts with the even less reactive (178).145 
 
Triflic anhydride reacts with aryl diazomethane (180) to form predominately 
cis-stilbenes (181) (182) (Scheme 5.5) by electron transfer from the diazocompounds to 
the anhydride.148 With the reaction between triflic anhydride and phenyl diazomethane, 
it was anticipated that such a reaction would lead to formation of the -sulfonyl triflate 
(183) which would be formed from triflic anhydride acting in an electrophilic manner 
with the nucleophilic carbon of phenyl diazomethane. However, the expected product 
(183) was not obtained. Instead cis and trans-stilbenes were isolated in a 93:7 ratio 
(90% overall yield) (Scheme 5.5).148 This clearly demonstrates the formation a C-C 
bond using the oxidative properties of triflic anhydride (Scheme 5.5). 
 




















Scheme 5.5: Formation of cis and trans stilbenes from aryl diazomethane and triflic 
anhydride 
 
To the best of our knowledge, no literature exists detailing triflic anhydride 
mediated dimerization of indoles. This project now reports details of such reactions, 
provides characterization, and proposes a plausible unique mechanism of their 
formation.  
 
5.2 Results and Discussion 
To prepare N-triflated indole, 4,6-dimethoxy-3-(4-methoxyphenyl)indole (134) 
was treated with trifluoromethanesulfonic (triflic) anhydride in the presence of sodium 
hydride as a base (Scheme 5.6). It was initially anticipated that such a reaction would 
lead to formation of the N-triflate indole (159). However, no expected product (159) 
was detected, instead an indole 2,2’-dimer (137) was obtained in 70% without requiring 
chromatography. The reaction of 2 mol of triflic anhydride with 1 mol of 4,6-
dimethoxy-3-(4-methoxyphenyl)indole (134) in the presence of 2 mols of sodium 
hydride in CH2Cl2 gave the 2-2’dimer (137) in good yield (70%) (Scheme 5.6). 
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Compound (137) was also obtained by using thallium(III) trifluoroacetate oxidative 
coupling of 4,6-dimethoxy-3-(4-methoxyphenyl)indole with full characterization 































Scheme 5.6: Proposed reaction to get the N-triflated indoles (159), formation of N-
triflated 2,2’-dimers, and deprotection gives 2,2’-dimers (137), but the reaction was 
yielded (137) in 70%.  
 
Without base and with equimolar amounts of triflic anhydride and 4,6-
dimethoxy-3-(4-methoxyphenyl)indole (134) in CH2Cl2  the 2,2’-dimer (137) was still 
produced in 50% yield.  
A possible mechanism for the 2,2’-dimerisation involves (134) reacting with 
triflic anhydride to give the iminium salt (184) (Scheme 5.7), which undergoes attack 
by another indole monomer, and subsequent aromatization of (185) gives the 2,2’-
dimer (137). Another role of the base, sodium hydride, may be to neutralize the 
methane sulfonic acid that is formed during the reaction, pushing the reaction to 
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completion. This could explain the longer reaction times and incomplete reactions were 






































Scheme 5.7: Proposed mechanism for triflic anhydride mediated dimerisation 
 
It was expected that this technique could be applied to synthesize a variety of 
2,2’-biindoles. Therefore, the reaction was further investigated using three other 
different indoles, 4,6-dimethoxy-3-phenylindole (138), 4,6-dimethoxy-3-(4-
bromophenyl)indole (139) and 4,6-dimethoxy-3-(4-nitrophenyl)indole (140) (Scheme 
5.8). Interestingly, the bromo indole gave the 2,2’-dimer as well as the 2,7’-dimer, 
whereas the p-nitro derivative and the phenyl derivative gave only 2,7’-dimers 
(Scheme 5.8). This demonstrates the influence of a para substituent on the phenyl ring 
in the formation of the 2,7’ over 2,2’-dimer. The influence of a para substituent of 
phenyl ring for formation of 2,2’-2,7’-dimers has also been observed during the 
thallium(III) trifluoroacetate oxidative coupling of 4,6-dimethoxy indoles. The TTFA 
oxidative coupling of para nitro indole gave the 2,7’-dimer (140) in 20% yield, and was 
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discussed in Chapter 4. The triflic anhydride mediated dimerisation results are clearly 
showed that the p-OMe group is strongly 2,2’-directing. The mildly deactivating bromo 
group favoured the formation of 2,7’ and 2,2’-dimers, with p-NO2 indole and the 
derivative having no para substituent on the 3-aryl indole the triflic anhydride 





















(138) X = Ph
(139) X = p-BrC6H4
(140) X = p-NO2C6H4
 (146)
(186), (187), (169)  
 
Yield  
X 2,2’-dimer  2,7’-dimer  
ES-MS 
[M+1] 
Br 15% (146) 35% (186) 661 
H 0% 40% (187) 504 
NO2 0% 30% (169) 595 
 
Scheme 5.8: Formation of 2,2’- and 2,7’-dimers 
Purification of compound (146) proved to be problematic; due to its close 
association with other impurities. After isolation of the major compound (186) and the 
impure (146) it was treated with di-tert-butyldicarbonate. The Boc-protected 2,2’-
biindole (188) could be easily purified by flash silica gel chromatography. 























Scheme 5.9: The crude (146) was treated with di-tert-butyldicarbonate to give (188) 
 
In order to optimize the coupling reaction, different conditions were attempted. 
Initially, all were performed in the presence of triflic anhydride and in the absence of 
base. Although product formation was observed, longer reaction times were required 
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1 OMe 0 1 (137) 25% 0% 96h 
2  1 1 (137) 40% 0% 72h 
3  2-4 2-3 (137) 70% 0% 48h 
4 Br 0 1 0% (186) 15% 72h 
5  1 1  (146) 5% (186) 20% 72h 
6  2 2 (146) 15% (186) 40% 48h 
7 NO2 0 1 0% (169) 10% 72h 
8  1 1 0% (169) 20% 96h 
9  2 2 0% (169) 30% 72h 
10 H 0 1 0% (187) 15% 72h 
11  1 1 0% (187) 30% 72h 
12  2 2 0% (187) 40% 48h 
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Identification of the 2,7’-biindoles (186), (187) and (169) followed from 
analysis of the mass spectrum with peaks at m/z 661 (79Br), 504 and 595 assigned to 
their respective molecular ions. Further confirmation of the 2,7-biindoles were provided 
by analysis of the 1H NMR spectrum which showed two set of peaks indicating the 
unsymmetrical nature of the molecule as well as the disappearance of the H7 and H2 
peaks in the 6.00 to 6.60 ppm region of the spectrum. The peaks at 6.20 and 6.60 ppm 
were assigned to H5’ and H7’ whereas the peak at 6.40 ppm was assigned to H7. The 
presence of one H7 indicates the 2,7’-linking of the indole units and substitution of the 
C7’ was further confirmed provided by the analysis of the 13C NMR spectrum, which 
exhibited a downfield shift of the C7’ peak from 85.0 to 98.0 ppm. 1H-1H and 1H-13C 
correlation experiments were conducted on all these structurally important 2,7’-dimers 
in order to assign unambiguously a number of key protons and carbon resonances. The 
substituted quaternary C7’ atoms were further confirmed by gHMBC NMR, as they 
correlate with the H5’ atoms in the same indole unit. The C7’ correlations are almost 
the same in all the 2,7’-dimers. C2 carbon was confirmed by a strong gHMBC 
correlation with NH. The two indole NH groups could be differentiated by gHMBC and 
NOESY correlations (Figure 5.1) (page 268 Appendix Table.1). Some of the more 
difficult correlations were confirmed by analysis of the Boc protected compounds, 
where many of the 2D correlations (189) (190) carbon peaks were well resolved 
(Figure 5.2). 
















X = Br, H
 
Figure 5.1: Some important gHMBC correlations for the compounds 2,7’-dimers 











X = Ph (189)
X = p-NO2C6H4 (190)
 
 Figure 5.2: Boc protected compounds (189) and (190)  
 
 
A possible mechanism for the formation of 2,7’-dimers is that the iminium salt 
reacts at the 7-position instead of 2-position (Scheme 5.10) giving intermediates (191) 
and (192), which upon aromatization produces 2,7’-dimer. An acid catalyzed 
dimerisation mechanism was ruled out as there was no dihydrodimer product was 
isolated.132  
 




























X = p-BrC6H4, p-NO2C6H4, Ph
(138-140) (191)
(192)(186), (187), (169)  
Scheme 5.10: Postulated mechanism for formation of 2,7’-dimers 
 
During trial reactions investigating different solvent combinations in the 
reaction of triflic anhydride and 4,6-dimethoxy-3-(4-methoxyphenyl)indole (134) and 
4,6-dimethoxy-3-phenylindole (138) were conducted in acetone, it was serendipitously 
found that the unusual, structurally important compounds (193), (194), and (195) 
(Scheme 5.11) (Scheme 5.12) (Table 5.4) were formed. The reaction yields are 
presented in the (Table 5.4). When the experiment was performed in DCM none of 
these compounds were formed. These compounds were also formed when triflic acid 


































Scheme 5.11: The treatment of (134) with triflic anhydride in presence of sodium 

















Scheme 5.12: The treatment of (138) with triflic anhydride in presence of sodium 
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Table 5.4: Formation of different products (193), (194), and (195), when the reaction 
performed in different solvents 
Yield %  
solvent (193) (194) (195) 






Extensive 1H-1H and 13C-1H correlation studies were carried out on these 
compounds, with the structure of (194) being confirmed by X-ray crystallographic 
analysis (Figure 5.3). Full characterization of these compounds identified a series of 
compounds, with structures related to previously published work.149,150 The reagent 
used here was different to that reported in the literature and there is the potential to 
expand this work to the synthesis of other indoles and aromatic systems. Compound 
(195) was fully characterized based on spectral comparison with (194).  
Analysis of the 1H NMR spectrum of (193) exhibited only one set indole 
protons with the C2 proton missing clearly indicating the symmetrical nature of the 
structure. Mass spectral analysis identified a peak at m/z 687 which was assigned as the 
molecular ion provided further confirmation of (193). 1N NMR spectral comparison 
was performed between (193) and (194), clearly indicating the presence of a 
pyrroloindole in (193). gHSQC shows that two non equivalent methylene protons at 
3.28 ppm attached to one carbon and along with DEPT, and gHMBC shows that two 
non equivalent methyl groups present the quaternary carbon at 39 ppm.  
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Figure 5.3: X ray structure of  5,7-dimethoxy-2,3-dihydro-1-[4,6-dimethoxy-3-(4-
methoxyphenyl)indol-2-yl]-1,3,3-trimethyl-4-(4-methoxyphenyl)-1H-pyrrolo[1,2-
a]indole (194) ORTEP plot 
 
Compound (193) contains two pyrroloindoles fused together by a spiro carbon, 
but the spiro carbon position proved difficult to assign. Initially it was expected that the 
position of the spiro carbon would be the same as either (196) or (197) (Figure 5.4). 
After critical analysis of the 2D spectrum for (193) and (194) the position of the spiro 
carbon in compound (193) was determined to be at position 2, different from (196) and 
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(197) (Figure 5.4). Analysis of the 15N gHMBC of (193) and (194) (Figure 5.5) ruled 
out the possibility of the carbon bearing the dimethyl next to the nitrogen atom as an 
(196) or (197) (Figure 5.4). In compound (193) N equally correlates with two 
nonequivalent methylene protons, where as one of two non equivalent nitrogens in 
(194) and (195) correlate with the methyl of the other nitrogen which correlates with its 
own proton. 15N gHMBC, gHMBC and NOESY clearly indicates the presence of two 
methyl groups next to C3a, and two non equivalent methylene protons next to nitrogen 
in compound (193) (Figure 5.6). This is clearly substantiating the structure of (193) 





(196) (197)  



























(194)     (193) 
Figure 5.5: 15N gHMBC NMR (red colour) arrow shows correlations in the compounds 
(194) and (193). 
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Some important correlations are the spiro C2 in gHMBC (Figure 5.6), which 
correlates with two protons in the CH2 of the pyrrole but one correlates strongly and the 
other one weakly. C3a correlates with two methyl groups at C3 and it sees only one of 
its two methylene protons. The C3a (numbering shown in Figure 5.6) (146 ppm in 
CDCl3) carbon moved to a higher ppm than the normal 3-substituted 2,2’-biindoles 


























(193)     (193) 
Figure 5.6: (A) 13gHMBC (red colour) arrow shows correlations in the compound 
(194). (B)  NOESY correlations for compound (193) 
 
The mechanism of formation for compounds (193), (194) and (194) involved a 
pathway in which acetone first reacts with Tf2O to give a vinyl triflate, which then 
reacts with the indole unit. Two of these units react together to give intermediate (198) 
(Scheme 5.13). Subsequently intramolecular cyclisation gives compounds (195) and 
(195). Confusion still exists over how compound (193) was formed, analysis suggesting 
that one extra vinyl triflate involved in comparison to the formation of (194) and (195). 


























Scheme 5.13: Mechanism postulated150 for formation of (194) and (195) 
 
5.3 Biological activities 
All the compounds synthesized in this chapter were subjected to in vitro anti-
malarial screening (Table 5.5). All the compounds synthesized in this chapter were also 
subjected for screening against tuberculosis with only one compound showing 
moderate activity (187) (200 µg/ml). The assay used the microculture radioisotope 
technique at a starting concentration of 10µg/ml and was performed at the National 
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5.4 Conclusions 
There are many 2,7-biindoles reported in literature but this is the first report of a 
triflic anhydride mediated dimerisation of 3-substituted-4,6-dimethoxyindoles with the 
formation of new 2,7’-dimers. Only one partially characterized 2,7’-dimer has been 
previously reported, which had been formed by a different reagent.151 With regard to 
the pyrroloindole series, all the three compounds were previously are unreported. We 
report here the first time the anti-malarial activity of this compound class at 11.2 µM. 
The yields of some of the derivatives from both series are low despite the simplicity of 
the one step reaction and the easy purification. Compounds (137) and (186) are found 
to have good activity against malaria at IC50 2.8 µg/ml and 4.5 µg/ml. The interesting 
spiro 2,2’-bipyrroloindole (193) possesses a spiro carbon position or connectivity 
between two pyrroloindoles, and is different to related literature compounds.149 Only 
one spiro compound related to this compound exists in the literature, being published 
by Sakakibara et al 1966.152 Importantly, the reactions can be controlled to produce the 
2,2’ or 2,7’-dimers by taking suitable para phenyl substitutions. All these three active 
malarial compounds are structurally diverse biindoles, one is a 2,2’-dimer (137), the 
second one is 2,7’-dimer (186), and the third is a bi-pyrroloindole (195),  and will be 





















Random screening has been successful in producing effective lead compounds 
which are likely to be chemically diverse to the known active compounds and are 
therefore also likely to have a novel mode of action against our intened biological 
target. Once this mode of action was established, there was possibility of uncovering 
potential new targets. 
For of these reasons, a variety of the final compounds and intermediates 
synthesized in this project were sent for testing against a selection of targets including 
HIV, tuberculosis, cancer, herpes simplex virus, and fungi. These targets were chosen 
both due to the requirement of novel drugs to combat these conditions and also the 
availability of high throughput screening facilities. The primary structure-activity 
relationship and for some biological activities the minimal structural requirements for 
potency were established. Anti-HIV testing was performed at Avexa Corporation in 
Melbourne, Australia; all other assays were performed at the National Centre for 
Genetic Engineering and Biotechnology (BIOTEC), Pathumthani, Thailand. 
 
6.2 Anti-HIV biological testing 
HIV is the most significant risk factor for many opportunistic infections like 
fungal, tuberculosis, etc.153 The introduction, in 1995, of highly active antiretroviral 
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therapy (HAART) dramatically reduced the morbidity and mortality of HIV-infected 
patients.154 The virus can be markedly suppressed for a relatively long period of time 
when exposed to HAART, However despite patients longevity with HAART,  
dyslipidemias place them at risk of cardiovascular disease.155 The action of cross 
resistance to drugs has also become prevalent with numerous multi-drug resistant 
strains of HIV now appearing.156 Therefore, there is a continuing need for new anti-
HIV agents to be developed.  
 
Some of the compounds and intermediates synthesized in this project were 
tested for inhibition against two HIV enzymes, integrase and RT (reverse transcriptase). 
Results are shown in (Table 6.1) as percentage inhibition, where all testing was 
performed at 100 M. 
 
Table 6.1: Testing results against HIV integrase (In) and reverse transcriptase (RT), 
where all testing was performed at 100 M and the results are appeared as percent 
inhibition.  
 














































































































































































































































































































































































None of the compounds tested showed significant inhibition against the 
integrase or reverse transcriptase enzymes, however some of these compounds 
displayed low to moderate activity to both the enzymes. The most active compounds 
tested were compound (86) with 68% inhibition of RT. Most of these (Table 6.1) 
compounds showed selectively towards either integrase or reverse transcriptase. A brief 
structure activity analysis of the compounds tested is shown in (Figure 6.3). Most of 
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these derivatives are related to a known class of ADAM the example shown in Figure 
6.1  has high activity with IC50 0.3 µM.96 These derivatives act through inhibiting the 











Figure 6.1: A published alkenyldiarylmethane derivative with RT inhibiting activity at 
IC50 0.3 µM .96 
 
In conclusion, based on the available information, 4,6-substitution on the 
pyrimidines ring with bulky groups gives (75), (76) selectivity to moderate inhibition of 
reverse transcriptase (Figure 6.2). It is not clear whether the heterocyclic ring is 
necessary for required activity by looking at (52), (56), (72), and (74) it clearly says 
that in these compounds it looks like heterocycle ring does not play any role for 
activity. Compounds (72) and (74) are very close to reported examples (Figure 6.1) are 
but are inactive. ADAM is a known class of non nucleoside RT inhibitors.96 A known 
derivative is shown in (Figure 6.1) with good activity. Bipyrimidine rings with 
trichloro showed 46% inihibition (57) (Figure 6.2). Among the compounds showing 
anti-HIV activity (57) is different structure from all other biaryl derivatives.  
 








46% In. inhibition 






bulky substitution of dichoro 
gives selectivity to RT
p-isopropyl substition
integrase activity 47%
conversion of ketone 




Figure 6.3: Functional groups required for integrase and RT activity 
 
 
6.3 Anti-tuberculosis biological testing 
Mycobacteria are ubiquitous organisms that are becoming increasingly 
important pathogens, due to the resurgence in the number of reported cases of 
tuberculosis, along with the recent emergence of multidrug-resistance strains of 
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Mycobacterium tuberculosis. It is estimated that worldwide 100 million people are 
infected annually. Approximately ten million develop the disease, with five million of 
these progressing to the infectious stage and ultimately three million dying. 
Tuberculosis prevalence is also high among patients with HIV. Such infections 
contribute substantially to morbidity and mortality and are difficult to control with the 
current treatment regimens. Therefore, a significant need exists for the development of 
new anti-bacterial agents targeting novel mode of action.  
All the variety of compounds synthesized throughout this project were tested, 
against Mycobacterium tuberculosis via the microplate alamar blue assay (MABA). 
The test results are presented in (Table 6.2). 
The most active compounds tested against Mycobacteria tuberculosis were (88), 
(80), and (75) and one biindole (147) (Table 6.2). Compound (88) shows the highest 
anti-tuberculosis activity. Only small number of molecules is showing significant 
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Table 6.2: Compounds showing moderate activity against Mycobacterium tuberculosis 
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6.4 Anti-fungal activity 
The incidence of opportunistic fungal infections has been increasing worldwide, 
especially due to the increase in the number of hosts immunocompromised due to 
cancer chemotherapy, organ and bone marrow transplantation, and human 
immunodeficiency virus infection to none just few.157-159 Most current anti-fungal 
agents have serious limitations, such as a narrow therapeutic window, inadequate 
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spectrum of activity and rapid emergence of resistance. We describe the preliminary 
structure-activity relationship of some novel classes of anti-fungal molecules.   
Some of the compounds generated during this project were randomly selected 
and screened against anti-fungal activity. Surprisingly, some of them showed 
significant anti-fungal activity (Figure 6.4). Preliminary screening results shows IC50 
of three compounds with around 30 M range and three compounds with around 70 
M. All these are 5-substituted pyrimidines and may be different from existing anti-
fungal agents. There are hundreds of 5-substituted anti-fungal pyrimidines reported 
(Figure 6.5).160,161 Known plant fungicides trireme 250µM, fenarimol 20µM, and 
nurimol are 5-substituted pyrimidines (Figure 6.5).160,161 The compounds reported here 















       (123)        (52)          (58)   (64) 





















   (46)      (112)     (78)     (79) 
32 µM     29 µM     69 µM  68 µM 
Figure 6.4: Compounds synthesized in this project randomly screened for anti-fungal 
activity, most of them shows significant activity. 
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  trireme 250 µM          fenarimol 20 µM               nurimol 
Figure 6.5: Known plant fungicides are triarimol, fenarimal, and nurimol are related to 
compounds reported to show anti-fungal activity in this project.160,161 
 
Compound (58) shows the highest among these compounds, and was obtained 
by alkylation of (46). Compounds (58), (64) and (123) are selectively showing anti-
fungal activity. It is difficult to draw conclusions regarding the minimum structural 
requirement for the activity.  
 
6.5 Anti-cancer 
All the biindoles and some diaryl compounds generated in this project were 
screened for anti-cancer activity. All biindoles proved to be inactive. Only four 
pyrimidine compounds were screened for anti-cancer activity, with only two 


















(88)              (33) 
Figure 6.6: Two diaryl pyrimidine derivatives showing good activity against different 
cell lines compound (88) showing different cell lines IC50 0.64 g/ml (NCL-H187), 
IC50 9.61 g/ml (KB) and IC50 14.39 g/ml (BC). Whereas compound (33) showing 
IC50 4.68 g/ml (NCL-H187 
 
6.6 Conclusions 
5-Substituted pyrimidines are synthesized during this project were subjected to 
random biological screening and revealed a number of interesting results. A brief 
structure activity relationship study was performed on the compounds showing anti-
fungal and anti-HIV activity. This study reveals that para-phenyl substitution or 2-
substitution on pyrimidine in 5-benzoylpyrimidine may result in potent anti-fungal 
activity. Further investigation may be needed in this area, so that detailed structure 
activity studies can be performed. For anti-tuberculosis activity it is not clear which 
groups are influencing the activity even though a couple of compounds showed 











CONCLUSIONS AND FUTURE DIRECTIONS 
____________________________________________________ 
 
A new convergent methodology has been developed for the synthesis of ADAM 
(24), i.e. and for alkenyl diarylmethane derivatives when one of the two aryl units is a 
pyrimidine. A series of 41 derivatives were successfully synthesized, 35 of which were 
new compounds; all of them related ADAM (24). All the synthesized derivatives were 
subjected to screening against in vitro Plasmodium falciparum K1. There are 11 
compounds showed significant activity with low micro molar range including 
compounds (46) IC50 0.3 g/ml, (80) IC50 0.7 g/ml and (88) IC50 1.4 g/ml. A 
preliminary structure activity relationship analysis was performed on these derivatives. 
The SAR study suggests that in order for the ADAM skeleton to possess antimalarial 
activity, simple unsubstituted amino groups alone are not sufficient and at least one of 
the amines must be alkylated. 
Due to the time restrictions investigations related to modification of the side 
chain (R1) (Figure 7.1) were not completed. Therefore future work could investigate a 
variety of derivatives based upon changes at R1 side chain length, stereochemistry at 
the stereogenic atom, substitutions at the tert-nitrogen, and substitutions on the 
hydroxyl group. The SAR study also suggested that the heteroatom nitrogen in 
pyrimidine is required for anti-malarial activity. These future directions related to 
Series I summarised in Figure 7.1. 
 









with a variety of alkyl groups






replacement with variety 






halogens, OMe, Me etc
 
Figure 7.1: Parent ADAM (24) with anti-malarial activity IC50 0.8 µM and suggestions 
for future work. 
 
The SAR analysis of Series II suggests that possible variations involve only 
replacement of the phenyl with various groups, as the 4,6-dichloro scaffold is needed 
for the anti-malarial activity. Further, there is the possibility of making analogs at 








(46) IC50 0.3 µg/ml  
Figure 7.2: Future works involved in Series II.  
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A novel oxidative dimerisation methodology mediated by thallium(III) 
trifluoroacetate has been developed for the synthesis of biindoles. The methodology 
includes the development of 2,2’-biindoles and 2,7’biindoles and 2,7’,7,7’’-terindole. A 
series of 41 new indole derivatives were prepared and screened for anti-malarial 
activity. Only three biindoles showed significant anti-malarial activity. During this 
study, the dimerisation of indole by triflic anhydride was shown for the first time. 
Future directions for the thallium oxidative coupling are based around, the 
deprotection methods of the indole nitrogen. Only three derivatives showed moderate 
anti-malarial activity, therefore, in order to perform a comprehensive SAR, further 












R = OMe 2.8 µg/ml
when R = OMe anti-malarial
activity 2.8 µg/ml; therefore future 
work could the involve the use of
electron donating e.g. ethyl, phenyl,allyl
 
Figure 7.3: Future work could involve the use of various R groups on the 2,2’-biindole  
 
Different 2,7-biindoles could be synthesized by replacing the bromine group 
with CN, COOH, CHO, and CF3. These groups are considered to be 2,7’-directing 
polar functional groups (Figure 7.4). 
 






X = Br 4.5 µg/ml
when X = Br anti-malarial
activity is 4.5 µg/ml, therefore future 
work could involve the use of different







Figure 7.4: Future work will involve replacing X groups with electron withdrawing 
groups 
 
A large number of the compounds synthesized in this project were randomly 
screened against number of biological assays. This screening revealed activity against 
HIV reverse transcriptase, HIV integrase, tuberculosis, fungal, and cancer. Some of 
these compounds showed significant activity against tuberculosis, fungi, and cancer cell 
lines. 
More than 100 compounds were synthesized in this project, around 76 of which 
are new structures. Around 17 of these showed significant anti-malarial activity in the 

























8.1 General Procedures 
 
Compound names for new compounds have been italicized. Solvents and 
reagents were purchased as reagent grade and used without further purification unless 
otherwise stated. THF and ether were dried over KOH and distilled from sodium using 
benzophenone as indicator. DCM was distilled from CaCl. All reactions were carried 
out in standard glassware under an inert nitrogen atmosphere unless otherwise stated. 
Melting points (mp) were determined using a Gallenkamp (Griffin) melting 
point apparatus. Temperatures are expressed in degrees Celsius (ºC) and are 
uncorrected.  
Nuclear magnetic resonance (NMR) spectrum was determined with a Varian 
Unity 300 MHz spectrometer. Proton NMR (1H NMR) spectrum were acquired at 300.0 
MHz. 13C NMR were acquired at 75.4 MHz. Spectra were recorded in deuterated 
chloroform (CDCl3), (DMSO d6), (CD3CN), (CD3COCD3) and (CD3OD) with 0.5% 
trimethylsilane (TMS), obtained from Cambridge Isotope Laboratories Inc., using TMS 
( 0.00 ppm) as the internal standard, unless otherwise specified. Chemical shifts () 
are expressed in ppm relative to TMS internal standard and coupling constant (J) are 
expressed in hertz (Hz) also relative to the internal standard. Multiplicities are 
expressed as singlet (s), broad singlet (bs), doublet (d), doublet of doublets (dd), 
doublet of doublet of doublets (ddd), triplet (t), quartet (q) and multiplet (m). Each peak 
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is presented in the following order: chemical shift, integration, multiplicity, coupling 
constant, and assignment.  
Electrospray ionization (ES) mass spectra (MS) were performed with VG 
Quattro-triple quadruple. Chemical ionization (CI) mass spectra (MS) were done using 
a Shimadzu QP 5000 MAT-44 Quadrapole spectrometer. CI and ES were both 
performed via direct insertion with an electron beam of 70 eV at source temperature 
<200 ºC. The major ion peaks m/z values are stated with their relative intensities in 
parentheses. ES-HRMS were performed using a Q-Tof mass spectrometer. CI high 
resolution mass spectrum (HRMS) and electron ionization (EI) HRMS were performed 
by using a Fison/VG Autospec-TOF mass spectrometer. 
Analytical thin layer chromatography (TLC) was carried out using Merck Silica 
Gel F254 aluminum supported sheets (cat no. 1005554). Flash column chromatography 
was performed using Merck silica gel (230-400 mesh), under gravity, unless otherwise 
specified. All chromatographic solvents proportions are volume for volume. 
X-ray crystallography studies performed by using a Bruker SMART CCD 
diffractometer using omega scan at a temperature of 150 ºK. Absorption corrections 
applied using the multiscan method with the program SADABS. 
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8.2 Synthesis of biaryl compounds 
1-[[6-Amino-5-[1-(4-chlorophenyl)-2-methylpropenyl]-4-pyrimidinyl]-3-
(diethylamino)-2-propanol 99 (24) 
A mixture of 4,6-dichloro-5-[2-methyl-1-(4-chlorophenyl)-1-
propenyl]pyrimidine (34) (0.20 g, 0.7 mmol) and 1-amino-3-
diethylamino-2-propanol (35) (2 ml) was heated at 200 ºC for 
5 hours. The reaction mixture was cooled, the gummy 
residue was treated with between water and extracted with 
dichloromethane (3 x 50 ml). The combined organic extracts were dried over MgSO4 
and concentrated. The compound was purified by flash silica gel chromatography 
(70:20:10 ethyl acetate:methanol:water) affording (24) (0.11 g, 40%) as pale yellow 
solid. mp 127-129 °C. 1H NMR (300 MHz CDCl3) : 8.10 (1H, s, H2), 7.27 (2H, d, J = 
8.7 Hz, ArH2’ and 6’), 7.19 (2H, d, J = 8.7 Hz, ArH3’ and 5’), 5.03 (1H, m, NH ), 4.63 
(2H, m, NH2), 3.67 (1H, m, CHOH), 3.63-3.2 (2H, m, NHCH2CHOH), 2.48 (4H, m, 
CH2N(CH2CH3)2), 2.35 (2H, m, CH2N(CH2CH3)2), 1.94 (3H, s, C=C(CH3)2), 1.76 (3H, 
s, C=C(CH3)2), 0.95 (6H, t, CH2N(CH2CH3)2). 13C NMR (CDCl3) : 159.7 (ArC6), 
159.2 (ArC4), 156.9 (ArC2), 139.5 (C=C(CH3)2), 138.1 (ArC1’), 132.9 (ArC4’), 130.5 
(ArC2’ and 6’), 128.6 (ArC3’ and 6’), 125 (C=C(CH3)2), 99.9 (ArC5), 67.1 (CHOH), 
56.5 (CH2N(CH2CH3)2), 47.4 (CH2N(CH2CH3)2), 44.8 (CH2N(CH2CH3)2), 22.4 
(C=C(CH3)2), 22.1 (C=C(CH3)2), 12.1 (CH2N(CH2CH3)2), 11.9 (CH2N(CH2CH3)2). CI-






















To a solution of (4-chlorophenyl)-1-(4,6-dichloro-4-
pyrimidinyl)-2-methyl-1-propanol (88) (1.00 g, 3.0 mmol) 
in dichloromethane (10 ml) was slowly added thionyl 
chloride (0.35 g, 3.0 mmol, 0.22 ml). After stirring for 48 h 
at room temperature (25 °C), water was added slowly. The organic layer was separated 
and aqueous layer further partitioned with DCM (2 x 50 ml). The combined organic 
layers were washed with water (2 x 50 ml), dried over MgSO4, the solvent evaporated 
under reduced pressure. The resultant residue purified by chromatography on silica 
(90:10 hexane:ethyl acetate) to give (33) (0.74 g, 80%) as a white solid. mp 100-103 
°C. 1HNMR (300 MHz CDCl3) : 8.70 (1H, s, H2), 7.31 (2H, d, J = 8.7 Hz, ArH2’ and 
6’), 7.22 (2H, d, J = 8.7 Hz, ArH3’ and 5’),  1.90 (3H, s, C=C(CH3)2), 1.67 (3H, s, 
(C=C(CH3)2). 13CNMR (CDCl3) : 162.1 (C4 and 6), 156.4 (C2), 139.1 (C=C(CH3)2), 
136.7 (ArC1’), 134.9 (C5), 133.4 (ArC4’), 131.1 (ArC2’ and 6’), 128.5 (ArC3’ and 5’), 
126.7 (C=C(CH3)2), 22.3 (C=C(CH3)2), 21.7 (C=C(CH3)2). CI-MS m/z: 316 ([M+1]+ 
37Cl, 20%), 314 ([M+]+, 35Cl, 95), 277 (65), 241 (50), 89 (100); EI-HRMS m/z: calcd 




A suspension of 4,6-dichloro-5-[2-methyl-1-(4-
chlorophenyl)-1-propenyl]pyrimidine (33) (1.00 g, 3.2 
mmol) in aqueous ammonia 20 ml (25%) was heated at 140 
°C for 5 hours in a glass sealed tube. The reaction mixture 
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benzene produced (34) (0.70 g. 75%) as white crystals, mp 208 °C. 1H NMR (300 MHz 
CDCl3) : 8.29 (1H, s, H2), 7.29 (2H, d, J = 8.7 Hz, ArH2’ and 6’), 7.19 (2H, s, ArC3’ 
and 5’), 5.23 (2H, s, NH2), 1.96 (3H, s, C=C(CH3)2), 1.72 (3H, s, C=C(CH3)2); 13C 
NMR (CDCl3) : 162.1 (C4), 158.9 (C6), 157.0 (C2), 139.3 (C=C(CH3)2), 137.9 
(ArC4’), 130.6 (ArC1’), 130.7 (ArC2’ and 6’), 128.7 (ArC3’ and 5’), 125.8 
(C=C(CH3)2), 119.0 (C5), 22.5 (C=C(CH3)2), 22.1 (C=C(CH3)2); ES-MS m/z: 294 
([M+1]+, 35Cl, 50%), 260 (40), 241 (30).  
 
4,6-Dichloro-5-pyrimidinylphenylmethanol108 (45) 
A solution of lithium diisoproylamide was prepared by treating 
diisopropylamine (0.70 g, 6.7 mmol) in anhydrous THF (10 ml) 
with n-butyllithium (4.1 ml, 6.7 mmol, 1.6 M) in hexane with 
stirring at -80 °C under dry argon. The solution was stirred for 1 h at -80 °C and then a 
solution 4,6-dichloropyrimidine (1.0 g, 6.7 mmol) in THF (5 ml) was added dropwise. 
Stirring was continued for 1.5 h at -80 °C and finally a solution of the benzaldehyde 
(0.7 g, 6.7 mmol) in THF (5 ml) was added, and the mixture stirred for a further 1 h at -
80 °C. The mixture was immediately hydrolyzed by the addition of a mixture of water 
and THF (20 ml), and extracted with dichloromethane (3 x 50 ml). The combined 
organic extracts were dried over MgSO4, the solvent removed under reduced pressure. 
The residual product was purified by column chromatography on alumina using 
hexane/dichloromethane (2:1) as a eluent to give (45) (0.84 g, 50%) as a white solid. 
mp 127 °C. 1H MNR (300 MHz CDCl3) : 8.73 (1H, s, H2), 7.39-7.28 (5H, m, ArH2’, 
3’, 4’, 5’, and 6’), 6.59 (1H, d, J = 9.3 Hz, CHOH), 3.39 (1H, d, J = 9.3 Hz, OH). 1C 




OH Cl  
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(ArC2’ and 6’), 128.3 (ArC4’), 125.5 (ArC3’ and 5’), 71.1 (CH-OH); CI-MS m/z: 257 
([M+1]+ 37Cl, 65%), 255 ([M+1]+, 35Cl, 100), 237 (30), 177 (10). 
 
4,6-Dichloro-5-pyrimidinephenylmethanone108 (46) 
A solution of   4,6-dichloro-5-pyrimidinylphenylmethanol (45) 
(1.0 g 3.9 mmol) and pyridinium chlorochromate (0.80 g, 3.9) in 
anhydrous chloroform (10 ml) was stirred at room temperature for 
12 h. The solvent removed under reduced pressure, and the residual product was 
purified by silica gel column chromatography to give (46) (0.70 g, 70%) as white solid. 
mp 110 °C. 1H MNR (300 MHz CDCl3) : 8.92, (s, H2) 7.85-7.52, (5H, m, ArH2’, 3’, 
4’, 5’, and 6’). 13C NMR (CDCl3) : 188.9 (CO), 158.7 (C4 and 6), 158.5 (C2), 135.5 
(ArC4), 134.5 (C5), 132.1 (ArC1), 129.7 (ArC2’ and 6’), 129.6 (ArC3’ and 5’). CI-MS 




To a solution of phenyl-1-(4,6-dichloro-4-pyrimidinyl)-2-
methyl-1-propanol (80) (1.00 g, 3.4 mmol) in dichloromethane 
(10 ml) was slowly added thionyl chloride (0.4 g, 3.4 mmol, 
0.25 ml). After stirring for 48 h at room temperature (25 °C) 
water was added slowly. The organic layer was separated and aqueous layer was further 
partitioned with DCM (2 x 50 ml). The combined organic layers were washed with 
water (2 x 50 ml), dried over MgSO4, and the solvent evaporated under reduced 
pressure. The resultant residue was purified by flash silica gel chromatography (90:10 
hexane:ethyl acetate) to give (47) (0.76 g, 80%) as white solid.  mp 73-75 °C. 1H NMR 
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(3H, s, C=C(CH3)2), 1.68 (3H, s, (C=C(CH3)2). 13C NMR (CDCl3) : 162.1 (C4 and 6), 
156.4 (C2), 138.4 (C5), 138.2 (C=C(CH3)2), 135.4 (ArC1’), 129.8 (ArC2’ and 6’), 
127.8 (ArC3’ and 5’), 127.5 (ArC4’), 126.5 (C=C(CH3)2), 22.3 (C=C(CH3)2), 21.7 
(C=C(CH3)2). CI-MS m/z: 281 ([M+1]+ 37Cl, 65%), 279 ([M+1]+, 35Cl, 100). EI-HRMS 
m/z: calcd for C14H1335Cl2N2 279.044452; found 279.045579. 
 
4-(Allylamino)-6-chloropyrimidinyl-5-phenylmethanone (66) 
A solution of 4,6-dichloro-5-pyrimidinephenylmethanone (46) (1.0 
g, 3.9 mmol) and allylamine (0.22 g, 3.9 mmol) in dry THF was 
heated at 120 °C for 5 hours. The solvent was removed and the 
resultant residue purified by flash silicagel column 
chromatography (80: 20 heaxane:ethyl acetate) to give (66) (0.75 g, 65%) as a white 
solid. mp 99-100 °C. 1H NMR (300 MHz CDCl3) : 8.44 (1H, s, H2), 7.82-745 (5H, 
ArH2, 3, 4, 5, and 6), 6.60 (1H, m, NH), 5.85 (1H, m, NHCH2CHCH2), 5.20 (2H, m, 
NHCH2CHCH2), 4.18 (2H, m, NHCH2CHCH2). 13C NMR (CDCl3) : 195.4 (CO), 
162.0 (C6), 158.5 (C2), 158.0 (C4), 138.0 (ArC1’), 134.2 (NHCH2CHCH2) 133.9 
(ArC4’), 129.0 (ArC2’ and 6’), 128.5 (ArC3’ and 5’), 117.9 (NHCH2CHCH2), 102.2 
(C5), 44.0 (NHCH2CHCH2). ES-MS m/z: 276 ([M+1]+ 37Cl, 40%), 274 ([M+1]+, 35Cl, 









O Cl  





A suspension of 4,6-dichloro-5-(2-methyl-1-phenyl-1-
propenyl)pyrimidine (47) (1.00 g, 3.2 mmol), 1-amino-3-
diethylamino-2-propanol (99) (2.33 g, 16.0 mmol) and 
potassium carbonate ( 0.44 g, 3.2 mmol) in THF (20 ml ) was 
heated at 160 ºC for 12 hours in a sealed glass reaction tube. 
The mixture was cooled, and the THF was evaporated to dryness. The residue was 
partitioned between water and dichloromethane (3 x 50 ml). The combined organic 
extracts were dried over MgSO4 and concentrated, and purified by flash silicagel 
column chromatography (80: 20 ethyl acetate: methanol) to yield (50) (0.98 g, 70%) as 
a white hygroscopic solid. 1H NMR (300 MHz CDCl3) : 8.25 (1H, s, H2), 7.30 (2H, d, 
J = 8.7 Hz, ArH2’ and 6’), 7.24 (2H, d, J = 8.7 Hz, ArH3’ and 5’), 6.05 (1H, t, J = 5.7 
Hz, NH), 4.10 (1H, m, CHOH), 3.77-3.39 (2H, m, NHCH2CHOH), 2.99 (4H, m, 
CH2N(CH2CH3)2), 2.92-2.47 (2H, m, CH2N(CH2CH3)2), 1.93 (3H, s, C=C(CH3)2), 1.72 
(3H, s, C=C(CH3)2), 1.12 (6H, t, CH2N(CH2CH3)2).  13C NMR (CDCl3) : 161.1 
(ArC6), 157.3 (ArC4), 156.6 (ArC2), 140.7 (C=C(CH3)2), 137.0 (ArC1’), 137.2 
(ArC5), 133.0 (ArC4’), 130.8 (ArC2’ and 6’), 128.5 (ArC3’ and 6’), 125.1 
(C=C(CH3)2), 65.8 (CHOH), 56.4 (CH2N(CH2CH3)2), 48.2 (CH2N(CH2CH3)2), 44.4 
(CH2N(CH2CH3)2), 22.3 (C=C(CH3)2), 21.8 (C=C(CH3)2), 9.5 (CH2N(CH2CH3)2); ES-
MS m/z: 425 ([M+1]+ 37Cl, 65%), 423 ([M+1, 35Cl]+, 100). ES-HRMS m/z: calcd for 
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5-[2-Methyl-1-phenyl-1-propenyl]pyrimidines (52) 
A cold (-80 ºC) solution of isopropyltriphenylphosphonium iodide 
(2.34 g, 5.4 mmol) in dry THF (20 ml) was added slowly n-
butyllithium (3.4 ml, 5.4 mmol, 1.6 M). The solution was stirred 
for 2 h at –80 ºC and then a solution of 5-pyrimidinylphenylmethanone (55) (1.0 g, 5.4 
mmol) in THF (5 ml) was added dropwise. The reaction was then heated at reflux for 
17 h under argon atmosphere. The mixture was allowed to cool to room temperature 
and water was then added slowly. The solvent was removed under reduced pressure. 
The resultant residue was partitioned between water and DCM (3 x 50 ml), the 
combined extracts were dried over (MgSO4), and the solvent was removed in vacuo. 
The crude product was purified by flash silicagel column chromatography (ethyl 
acetate:hexane, 25:75) to yield (52) (0.80 g 70%) as a white solid. mp 40-43 °C. 1H 
NMR (300 MHz CDCl3) : 8.99 (1H, s, H2), 8.47 (2H, s, H4 and 6), 7.27-7.04 (5H, m, 
ArH2’, 3’, 4’, 5’, 6’), 1.79 (6H, s, 2 x CH3). 13C NMR (CDCl3) : 157.5 (C4 and 6), 
156.5 (C2), 141.4 (ArC1’), 136.7 (C5), 135.8 (C=C(CH3)2), 130.6 (C=C(CH3)2), 130.0 
(ArC2’ and 6’), 128.5 (ArC3’ and 5’), 127.1 (ArC4’), 22.8 (C=C(CH3)2), 22.5, 
(C=C(CH3)2). ES-MS m/z: 211 ([M+1]+, 100%), 194 (20), 184 (25), 167 (20); ES-
HRMS m/z: calcd. for [M+1]+ C14H14N2 211.1244; found 211.1235. 
 
Phenyl-5-pyrimidinylmethanol162 (54) 
To stirred cold solution of 5-bromopyrimidine (1.0 g, 6.3mmol) in 
anhydrous THF and diethylether (50:50) (20 ml) was slowly added 
n-butyllithium (3.9 ml, 6.3 mmol, 1M) at -116 °C. The solution 
was stirred for 20 min and then benzaldehyde (0.68 g, 6.3mmol) in THF (5 ml) slowly 
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reaction mixture was quenched with saturated ammonium chloride, followed by being 
partitioned with dichloromethane (5 x 50 ml). The combined organic layers were 
evaporated in vacuo and the residue was purified by  silica gel column chromatography 
(hexane:ethyl acetate 50:50) give (54) (0.84 g, 70%) as a yellowish liquid. 1H NMR  
(300 MHz CDCl3) : 8.80 (1H, s, H2), 8.56 (2H, s, H4 and 6), 7.27 (5H, m, ArH2’, 3’, 
4’, 5’, and 6’), 5.74 (1H, s, CHOH). 13C NMR (CDCl3) : 157.1 (C2), 155.2 (C4 and 6), 
142.5 (C5), 137.6 (ArC1), 129.1 (ArC2 and 6), 128.5 (ArC-4), 126.8 (ArC3 and 5), 
72.3 (CHOH). CI-MS m/z: 187 ([M+1]+, 100%), 153 (10), 106 (5). 
 
Phenyl-5-pyrimidunylmethanone162 (55) 
A solution of phenyl-5-pyrimidinylmethanol (54) (1.0 g 5.4 mmol) 
and pyridinium chlorochromate (1.16 g, 5.4 mmol) in anhydrous 
chloroform (10 ml) was stirred at room temperature 12 hour. The 
solvent was removed in vacuo, and the residual product was purified by silica gel 
column chromatography on silica using hexane/ethyl acetate (70:30) as a eluent to give 
(55) (0.80 g, 70%) as a white solid. mp 101-102 °C. 1H NMR  (300 MHz CDCl3) : 
9.40 (1H, s, H2), 9.11 (2H, s, H4 and 6), 7.85-7.33 (5H, m, ArH2’, 3’, 4’, 5’, and 6’). 
13C NMR (CDCl3) : 193.0 (CO), 161.0 (C2), 157.9 (C4 and 6), 136.0 (C5), 134.1 
(ArC4), 133.3 (ArC1), 130.2 (ArC3’ and 5’), 129.1 (ArC2’ and 6’). CI-MS m/z 185 
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4,6-Dichloro-5-(4-chloropyirimidinyl)pyrimidines (57) 
A cold solution of lithium diisopropylamine (prepared from 
diisopropylamine (3.40 g, 33.0 mmol) and n-BuLi (20.90 ml 33.0 
mmol of 1.6 M) in THF (10 ml) at -78 °C), was added to solution of 
4,6-dichloropyrimidine (5.00 g, 33.9 mmol) in THF    (3 ml) at -78 
°C. The reaction was stirred for 1 h at same temperature. The reaction mixture was 
quenched with saturated ammonium chloride. The organic layer was separated, and the 
aqueous layer was partitioned with dichloromethane (3 x 50 ml). The combined organic 
layers were evaporated under reduced pressure. The compound was subjected to 
column chromatography (85:15 hexane:ethyl acetate) to give (57) (4.42 g, 50%) as a 
pale yellow solid. mp 225-228 °C. 1H NMR (300 MHz CDCl3) : 8.85 (1H, s, H2), 
8.82 (1H, d, J = 5.4 Hz, H4’), 7.50 (1H, d, J = 5.4 Hz, H5’). 13C NMR (CDCl3) : 162.3 
(C5), 161.7 (C2’), 160.5 (C4 and 6), 159.1 (C4’), 158.1 (C2), 131.2 (C6’), 121.8 (C5’). 
ES-MS m/z: 262.9 ([M+1+ 37Cl, 70%), 260.9 ([M+1]+, 35Cl, 80), 129 (100); ES-HRMS 
m/z: calcd for [M+1]+ C8H4N435Cl3 260.9508; found 260.9502. 
 
4,6-Dichloropyrimidinyl-5-(isopropylphenyl)methanone (58) 
A solution of 4,6-dichloro-5-pyrimidinephenylmethanone 
(46) (1.0 g, 4.0 mmol) in anhydrous diethylether (10 ml) was 
cooled to -80 °C. Isopropylmagnesium chloride in pentane 
(0.27 g, 2.0 ml, 2M, 4.0 mmol) was then added slowly under a nitrogen atmosphere. 
The reaction mixture was brought to room temperature slowly over 3 hours, quenched 
with saturated ammonium chloride, and partitioned with dichloromethane (3 x 50 ml). 
The combined organic layers were dried over MgSO4 and the solvent removed under 
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chromatography with hexane:ethyl acetate (80:20) as a eluent to give (58) (0.60 g, 
50%) as a white solid. mp 65-66 °C. 1H NMR (300 MHz CDCl3) : 8.91 (1H, s, H2), 
7.76 (2H, d, J = 8.1 Hz, ArH2’ and 6’), 7.40 (2H, d, J = 8.1 Hz, ArH3’ and 5’), 3.01 
(1H, m, CH(CH3)2), 1.28 (3H, s, CH(CH3)2). 13C NMR (CDCl3) : 188.5 (C=O), 158.8 
(C4 and 6), 158.3 (C2), 157.5 (C5), 132.4 (ArC1’), 132.3 (ArC4’), 130.1 (ArC2’ and 
6’), 127.7 (ArC3’ and 5’), 34.7 (CH(CH3)2), 23.7 (CH(CH3)2). ES-MS m/z: 297 
([M+1]+ 37Cl, 6%), 295 ([M+1]+ 35Cl, 10), 260 (12), 230 (100), 188 (55), 150 (50);  ES-
HRMS m/z: [M+1]+ calcd for C14H13 35Cl2N2O 295.0404; found 295.0405. 
 
5-Benzoyl-4-n-butyl-6-chloropyrimidine (64) 
A solution of 4,6-dichloro-5-pyrimidinephenylmethanone (46) 
(1.0 g, 3.9 mmol) in anhydrous diethyl ether (10 ml) was cooled 
to -80 °C and n-butyllithium in hexane (0.24 g, 2.4 ml, 1.6M, 3.9 
mmol) was added slowly under a nitrogen atmosphere. The 
reaction was stirred for one hour at the same temperature, followed by the slow 
addition of thionylchloride (0.40 g, 3.6 mmol). The reaction mixture was quenched 
with saturated ammonium chloride, and partitioned with dichloromethane (3 x 50 ml). 
The combined organic layers were dried over MgSO4, the solvent removed under 
reduced pressure and the residual product purified by silica gel column chromatography 
on silica with hexane: ethyl acetate (80: 20) as a eluent to give (64) (0.50 g, 50%) 
yellowish liquid. 1H NMR (300 MHz CDCl3) : 8.63 (1H, s, H2), 7.83-7.45 (5H, m, 
ArH2’, H3’, H4’, H5’, and H6’), 4.36 (2H, t, CH2CH2CH2CH3), 1.56 (2H, m, 
CH2CH2CH2CH3), 1.18 (2H, m, CH2CH2CH2CH3), 0.78 (2H, t, CH2CH2CH2CH3). 13C 
NMR (CDCl3) : 191.0 (CO), 158.2 (C2), 135.9 (C4), 135.4 (C6), 134.6 (ArC1’), 129.5 
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(CH2CH2CH2CH3), 30.5 (CH2CH2CH2CH3), 18.9 (CH2CH2CH2CH3), 13.7 
CH2CH2CH2CH3). ES-MS m/z: 277 ([M+1]+ 37Cl, 65%), 275 [M+1]+ 35Cl 100); ES-




To a solution of 5-pyrimidinephenylmethanone (55) (1.0 g, 5.4 
mmol) in anhydrous diethylether (10 ml) at -80 °C was added n-
butyllithium (3.4 ml, 5.4 mmol, 1.6 M) the reaction was stirred for 
30 min at the same temperature, this was followed by the slow 
addition of thionyl chloride (0.73 g, 5.4 mmol), and the reaction mixture was stirred for 
another 30 min. The reaction mixture was quenched with saturated ammonium 
chloride, partitioned with dichloromethane (3 x 50 ml), and dried over MgSO4. The 
solvent was removed under reduced pressure, and the residual product purified by silica 
gel column chromatography (hexane/ethyl acetate 80:20) as a eluent to give (65) (0.72 
g, 60%) as a colourless liquid  . 1H NMR (300 MHz CDCl3) : 9.05 (1H, s, H2), 8.57 
(2H, s, H4 and 6), 7.45-7.14 (5H, m, ArH2’, 3’, 4’, 5’, and 6’), 6.21 (1H, t, C=CH), 
2.19 (2H, m, C=CH-CH2-CH2-CH3), 1.52, (2H, m, C=CH-CH2-CH2-CH3), 0.93 (3H, t, 
C=CH-CH2-CH2-CH3). 13C NMR  CDCl3 : 156.9 (C2), 154.9 (C4 and 6), 137.9 
(C=CH-CH2-CH2-CH3) 136.1 (C5), 135.9 (ArC1’), 133.9 (ArC4’), 129.8 (ArC2’ and 
6’), 128.8 (ArC3’ and 5'), 127.8 (C=CH), 32.1 (C=CH-CH2-CH2-CH3), 23.2 (C=CH-
CH2-CH2-CH3),  14.2 (C=CH-CH2-CH2-CH3). CI-MS m/z: 225 ([M+1]+, 80%), 187 
(60), 171 (30), 147 (25), 123 (70), 97 (50), 81 (100); ES-HRMS m/z: calcd for [M+1]+ 











A solution of 4-(allylamino)-6-chloropyrimidinyl-5-
phenylmethanone (66) (1.0 g, 3.9 mmol), di-tert-butyldicarbonate 
(0.84 g, 3.9 mmol), and DMAP as catalyst in dichloromethane (10 
ml) was stirred for 1 hour at room temperature before being 
washed with water (2 x 50 ml). The solvent was removed under vacuum and the 
resultant residue recrystallised from methanol to give (67) (1.30 g, 90%) as a white 
solid.  mp 160-163 °C. 1H NMR (300 MHz CDCl3) : 8.44 (1H, s, H2), 7.82-745 (5H, 
ArH2, 3, 4, 5, and 6), 5.85 (1H, m, NHCH2CHCH2), 5.20 (2H, m, NHCH2CHCH2), 
4.18 (2H, m, NHCH2CHCH2). 13C NMR (CDCl3) : 195.4 (CO), 162.0 (C6), 158.5 
(C20), 158.0 (C4), 156.5 (CO), 138.0 (ArC1), 134.2 (NHCH2CHCH2) 133.9 (ArC4), 
129.0 (ArC2 and 6), 128.5 (ArC3’ and 5’), 117.9 (NHCH2CHCH2), 102.2 (C5), 44.0 
(NHCH2CHCH2); 28.3 (C(CH3)3). ES-MS m/z: 276 -Boc (([M+1]+, 37Cl, 40%), 274 




A suspension of 4,6-dichloro-5-(2-methyl-1-phenyl-1-
propenyl)pyrimidine (47) (1.00, g, 3.6 mmol), 1-amino-3-
diethylamino-2-propanol (99) (2.62 g, 18.0 mmol) and 
potassium carbonate ( 0.50 g, 3.6 mmol) in THF (20 ml) was 
heated at 160 ºC for 12 hours in a sealed glass reaction tube. 
The mixture was cooled, and the THF was evaporated to dryness. The residue was 
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extracts were dried over MgSO4, concentrated, and purified by flash silica gel column 
chromatography using (80: 20 ethyl acetate: methanol) to yield (70) (1.00 g, 72%) as a 
colourless gummy substance. 1H NMR (300 MHz CDCl3) : 8.23 (1H, s, H2), 7.32-29 
(5H, m, ArH2’, 3’, 4’, 5’, and 6’), 4.09 (1H, m, CHOH), 3.73-3.33 (2H, m, 
NHCH2CHOH), 2.99 (4H, m, CH2N(CH2CH3)2), 2.80-2.40 (2H, m, CH2N(CH2CH3)2), 
2.00 (3H, s, C=C(CH3)2), 1.92 (3H, s, C=C(CH3)2), 1.15 (6H, t, CH2N(CH2CH3)2). 13C 
NMR (CDCl3):  162.4 (ArC6), 161.6 (ArC4), 156.2 (ArC2), 139.3 (C=C(CH3)2), 
139.0 (ArC1’), 138.9 (ArC5), 127.7 (ArC2’ and 6’), 126.3 (ArC3’ and 5’), 125.4 
(ArC4’), 124.3 (C=C(CH3)2), 63.3 (CHOH), 60.5 (CH2N(CH2CH3)2), 55.7 
(CH2N(CH2CH3)2), 44.8 (CH2N(CH2CH3)2), 21.4 (C=C(CH3)2), 21.3 (C=C(CH3)2), 8.7 
(CH2N(CH2CH3)2); CI-MS m/z: 391 ([M+1]+ 37Cl, 70%), 389 ([M+1, 35Cl]+, 100). EI-
HRMS m/z: calcd for C21H30N4O35Cl 389.2113; found 389.2120. 
 
4,6-Di(allylamino)-5-pyrimidinylphenylmethanone (71) 
A solution of   4,6-dichloro-5-pyrimidinephenylmethanone (46) 
(1.0 g 3.9 mmol) and allylamine (0.22 g, 3.9 mmol) in dry THF (10 
ml) was heated at 120 °C for 5 hours. The solvent was removed 
and the resultant residue purified by flash silica gel column 
chromatography (80:20 hexane:ethyl acetate) to give (71) (0.10 g, 
10%) as a colourless liquid. 1H NMR (300 MHz CDCl3) : 8.23 (1H, s, H2), 7.66-7.45 
(5H, ArH2, 3, 4, 5, and 6), 6.67 (1H, m, NH), 5.80 (1H, m, NHCH2CH=CH2), 5.04 
(2H, m, NHCH2CH=CH2), 4.14 (2H, m, NHCH2CH=CH2). 13C NMR (CDCl3) : 195.4 
(CO), 162.0 (C4 and 6), 160.5 (C2), 140.0 (ArC1’), 134.2 (NHCH2CH=CH2), 133.9 
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(C5), 44.0 (NHCH2CH=CH2). ES-MS m/z: 295 ([M+1]+, 100%), ES-HRMS m/z: calcd 
for [M+1]+ C17H19N4O 295.1563; found 295.1559. 
 
4-Allylamino-2-isopropyl-1,2-dihydropyrimidine-5-phenylmethanone (72) 
A solution of 4-(N-allyl-N-tert-butoxycarbonylamino)-6-
chloropyrimidinyl-5-phenylmethanone (67) (1.0 g, 3.6 mmol) 
in anhydrous diethylether (10 ml) was cooled to -80 °C and 
isopropylithium in hexane (0.17 g, 3.2 ml, 0.7 M, 3.6 mmol) 
was added slowly under a nitrogen atmosphere. The reaction was stirred for one hour at 
the same temperature, followed by the slow addition of thionyl chloride (0.40 g, 3.6 
mmol). The reaction mixture was quenched with saturated ammonium chloride, and 
partitioned with dichloromethane for (3 x 50 ml). The combined organic layers dried 
over MgSO4, the solvent removed under reduced pressure and the residual product was 
purified by flash silica gel column chromatography with hexane:ethyl acetate (80:20) as 
a eluent to give (72) (0.69 g, 60%) as a pale yellowish solid. mp 82-85 °C. 1H NMR 
(300 MHz CDCl3) : 10.20 (1H, d, J = 4.5 Hz, H3), 10.06 (1H, t, J = 5.1 Hz, 
NHCH2CH=CH2), 7.57-7.43 (5H, m, ArH2’, 3’, 4’, 5’, and 6’), 5.92 (1H, m, 
NHCH2CH=CH2), 5.46 (1H, d, J = 17.4 Hz, NHCH2CH=CH2), 5.33 (1H, d, J = 10.2 
Hz, NHCH2CH=CH2), 4.88 (1H, m, H2), 4.31 (2H, m, NHCH2CH=CH2), 2.42 (1H, m, 
CH(CH3)2), 1.20 (3H, d, J = 6.6 Hz, CH(CH3)2), 1.14 (3H, d, J = 6.6 Hz, CH(CH3)2). 
13CNMR (CDCl3) : 193.5 (CO), 156.3 (C6), 155.3 (C4), 139.7 (ArC’1), 132.7 
(ArC4’), 130.6 (NHCH2CH=CH2), 128.5 (ArC2’, 3’, 5’, and 6’), 118.4 
(NHCH2CH=CH2), 95.2 (C5), 68.4 (C2), 45.5 (NHCH2CH=CH2), 31.6 (CH(CH3)2), 
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35Cl, 100) 282 (20), 247 (10); ES-HRMS m/z: calcd for [M+1]+ C17H21N3O35Cl 
318.1375; found 318.1373. 
 
Phenyl(4,6-di(piperidinyl)-5-benzoylpyrimidinyl)methanone (75) 
 A solution of 4,6-dichloro-5-pyrimidinephenylmethanone (46) 
(0.50 g, 19.9 mmol), malononitrile (0.13 g, 19.90 mmol), and 
piperidine (0.16 g, 20.0 mmol) in THF (15 ml) was stirred at 
reflux for 4 h. The reaction mixture was evaporated under 
reduced pressure, water was added to the residue and was then 
partitioned with dichloromethane (3 x 30 ml). The combined organic layers were 
evaporated to dryness and purified by silica gel column chromatography (20:80 ethyl 
acetate:hexane) to give (75) (1.70 g, 25%) as a yellow solid. mp 176-178 °C. 1H NMR 
(300 MHz CDCl3) : 8.27 (1H, s, pyrimidine H2), 7.53-7.34 (5H, m, ArH2, 3, 4, 5, and 
6), 3.37 (8H, m, H2’,6’), 1.48 (12H, m, H3’,4’,5’). 13C NMR (CDCl3) : 191.9 (CO), 
166.0 (pyrimidine C4 and 6), 157.1 (pyrimidine C2), 140.5 (ArC1), 131.9 (ArC4), 
129.0 (ArC2 and 6), 128.3 (ArC3 and 5), 115.0 (pyrimidine C5), 50.7 (C2’ and 6’), 
26.0 (C3’and 5’), 24.5 (C4’ and 4’’). ES-MS m/z 351.5 ([M+1]+, 100%), 302.4 (5); ES-
HRMS m/z: calcd for C21H27N4O 351.2183; found 351.2185. 
 
Phenyl[6-chloro-4-(1-piperidinyl)-5-pyrimidinyl]methanone (76) 
4,6-Dichloro-5-pyrimidinephenylmethanone (46) (0.50 g, 19.9 
mmol), malononitrile (0.13 g, 19.9 mmol), and piperidine (0.16 g, 
19.9 mmol) in THF (10 ml) was stirred at reflux for four hours. 
The reaction mixture solvent evaporated under reduced pressure. 
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30ml). The combined organic layers were evaporated to dryness and purified by flash 
silicagel column chromatography (20:80 ethyl acetate:hexane) to give 4-(piperido-1-
yl)-5-benoyl-6-chloropyrimidine yield (0.13 g, 25%) as a pale yellow solid, mp 200-
202 °C. 1H NMR (300 MHz CDCl3) : 8.27 (1H, s, pyrimidne H2), 7.53-7.34 (5H, m, 
ArH2, 3, 4, 5, and 6), 3.49 (4H, m,  H2’and 6’), 1.57 (1H, m, H4’), 1.46 (4H, m, 
H3’and 5’). 13C NMR (CDCl3) : 193.7 (CO) 160.0 (pyrimidine C4 and 6), 157.4 
(pyrimidine C2) 136.7 (ArC1), 134.4 (ArC4), 129.6 (ArC2 and 6) 129.3 (ArC3 and 5), 
114.0 (pyrimidine C5), 48.6 (C2’,6’), 25.5 (C C3’,5’), 24.4 (C4’). ES-MS m/z 304 
([M+1]+ 37Cl, 65%), 302 ([M+1]+, 35Cl, 100); ES-HRMS m/z: calcd for [M+1]+ 
C16H1735ClN3O 302.1056; found 302.1060. 
 
1-(4,6-Dichloropyrimidin-5-yl)-2-methyl-1-propanol (78)  
 
To a solution of 4,6-dichloropyrimidine-5-carboxyaldehyde (77) (1.0 
g, 5.6 mmol) in anhydrous diethylether (10 ml) at -80 °C was added 
slowly isopropyllmagnesium chloride, (0.27 g, 2.0 ml, 2 M, 4.0 
mmol) and the mixture was allowed to come to room temperature slowly over 3 h. It 
was then quenched with saturated ammonium chloride, and partitioned with 
dichloromethane (3 x 50 ml). The combined organic layers were dried over MgSO4 and 
the solvent removed under reduced pressure. The residual product was purified by flash 
silicagel column chromatography (hexane:ethyl acetate 80:20) as a eluent to give (78) 
(0.60 g, 50%) as a colourless liquid. 1H NMR (300 MHz CDCl3) : 8.65 (1H, s, H2), 
4.99 (1H, d, J = 15 Hz, CHOH), 3.00 (1H, s, CHOH), 2.50 (1H, m, CH(CH3)2), 1.23 
(3H, s, CH(CH3)2), 0.88 (3H, s, CH(CH3)2).  13C NMR (CDCl3) : 162.0 (C4 and 6), 
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A solution of   1-(4,6-dichloropyrimidin-5-yl)-2-methyl-1-propanol 
(78) (1.0 g, 4.5 mmol) and pyridinium chlorochromate (0.98 g, 4.5 
mmol) was taken in anhydrous chloroform (10 ml). The mixture was 
stirred at room temperature (25 °C) overnight. The solvent removed in vacuo, and the 
residual product was purified by flash silicagel column chromatography using 
hexane:ethyl acetate (70:30) as a eluent to give (79) (0.60 g, 60%) as a colourless 
liquid. 1H NMR  (300 MHz CDCl3) : 8.80 (1H, s, H2), 3.25 (1H, m, CH(CH3)2), 1.14 
(3H, s, CH(CH3)2), 1.12 (3H, s, CH(CH3)2). 13C NMR (CDCl3) : 200.3 (CO), 158.1 
(C2), 158.0 (C4 and 6), 133.9 (C5), 42.1 (CH(CH3)2), 19.5 (CH(CH3)2). CI-MS m/z: 
221 ([M+1]+ 37Cl, 80%), 219 [M+1]+, 35Cl, 100), 201 (10), 178 (20), 167 (30); CI-
HRMS m/z: calcd for [M+1]+ C8H9N2O37Cl2 221.0061; found 221.0062. 
 
1-(4,6-Dichloro-4-pyrimidinyl)-2-methyl-1-phenyl-1-propanol (80)  
To a cold solution of freshly prepared lithium diisopropylamine 
prepared from diisopropylamine (3.40 g, 33.0 mmol) and n-BuLi 
(20.90 ml 33.0 mmol of 1.6 M) in THF (10 ml) at -78 °C), was 
added a solution of 4,6-dichloropyrimidine (5.00 g, 33.9 mmol) was dissolved in THF 
(3 ml) at -78 °C under nitrogen atmosphere. After stirring the reaction mixture for one 
1h at the same temperature, the temperature was lowered to -116 °C and 
isobutyrophenone (5.0 g 33.9 mmol) was added slowly, and stirring was continued for 
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chloride. The organic layer was separated, and the aqueous layer partitioned with DCM 
for (3 x 50 ml). The combined organic layers were first washed with dilute HCl, dried 
over MgSO4 and evaporated under reduced pressure. The compound purified by flash 
silicagel chromatography (85:15 hexane:ethyl acetate) to give (80) (3.0 g, 33%) as a 
white solid. mp 66-68 °C. 1H NMR (300 MHz CDCl3) : 8.56 (s, H2), 7.46 (2H, d, J = 
6.9 Hz, ArH2’ and 6’), 7.35-7.26 (3H, m, ArH3’, 4’, and 5’), 3.57 (1H, m, CH(CH3)2), 
3.39 (1H, s, OH), 1.07 (3H, d, J = 6.6Hz CH(CH3)2), 0.95 (3H, d, J = 6.6Hz 
CH(CH3)2). 13C NMR (CDCl3) : 161.2 (C4 and 6), 154.7 (C2), 143.4 (C5), 137.9 
(ArC1’) 128.2 (ArC2’ and 6’), 127.8 (ArC4’), 126.7 (ArC3’ and 5’), 82.4 (C-OH), 34.8 
(CH(CH3)2), 18.5 (CH(CH3)2) 17.6 (CH(CH3)2). ES-MS m/z: 299 ([M+1]+ 37Cl, 65%), 
297 ([M+1]+, 35Cl, 100), 279 (20), 242 (25); ES-HRMS m/z: [M+1]+ calcd for C14H15 




To a cold suspension of Zn granules (0.18 g, 2.8 mmol) in THF (20 ml) 
was added TiCl4 (0.54 g, 2.8 mmol) in sealed tuble, then the reaction 
mixture was heated to 60 °C for 30 minutes. The sealed with its contents 
cooled to room temperature then added pyrimidine aldehyde (77) (0.5 g, 2.8 mmol) and 
acetone (0.34 g, 5.6 mmol). The reaction mixture was subjected to heating at 100 °C for 
12 hours. The solvent was removed under reduced pressure, the resultant residue 
partitioned between water and DCM (5 x 50 ml). The compound was purified by flash 
chromatography to obtain (81) as a colourless liquid (0.28 g, 50%). 1H NMR (300 MHz 
CDCl3) : 8.71 (1H, s, H2), 5.54 (1H, s, -H), 1.65 (3H, s, CH=C(CH3)2), 1.58 (3H, s, 
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(CH=C(CH3)2), 81 (CH=C(CH3)2), 29.8 (CH=C(CH3)2), 27.8 (CH=C(CH3)2). CI-MS 





To a solution of 4,6-dichloropyrimidine-5-carboxyaldehyde (77) 
(1.0 g, 5.6 mmol), malononitrile (0.37 g, 5.6 mmol) and 3-
aminopropionic acid was added (-alanine) (0.50 g, 5.6 mmol) in 
anhydrous acetonitrile (20 ml). The reaction mixture was stirred for 
24 hour under a nitrogen atmosphere, then poured into water (100 ml) and partitioned 
with dichloromethane (3 x 50 ml). The combined organic layers were dried over the 
MgSO4 and the solvent was removed under vacuum. The resultant residue was 
recrystallised from methanol to give (82) (0.87 g, 70%) as an orange solid, mp 128-130 
°C. 1H NMR (300 MHz CDCl3) : 8.99 (1H, s, H2), 7.89 (1H, s, -H). 13C NMR 
(CDCl3) : 160.5 (C4 and 6), 159.6 (C2), 151.8 (-C), 124.6 (C5), 111.3 (CN), 110.1 
(CN), 96.2 (C(CN)2); CI-MS m/z: 227 ([M+1]+ 37Cl, 80%), 225 ([M+1]+, 35Cl, 100) 174 





To a cold solution of freshly prepared lithium 
diisopropylamine (prepared from diisopropylamine (3.40 g, 
33.0 mmol) and n-BuLi (20.9 ml 33.0 mmol of 1.6 M) in 
THF (10 ml) at -78 °C), was added solution of 4,6-dichloropyrimidine (5.00 g, 33.9 
mmol) in THF (3 ml) added at -78 °C under nitrogen atmosphere. After stirring the 
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116 °C and isobutyrophenone (6.9 g, 33.9 mmol) was added slowly, and stirring was 
continued for another 30 min. The reaction mixture was quenched with saturated 
ammonium chloride. The organic layer was separated, and the aqueous layer 
partitioned with DCM for (3 x 50 ml). The combined organic layers were first washed 
with dilute HCl, dried over MgSO4 and evaporated under reduced pressure. The 
compound purified by flash silicagel chromatography (85:15 hexane:ethyl acetate) to 
give (88) (2.7 g, 25%) as a white solid. mp 93-95 °C. 1H NMR (300 MHz CDCl3) : 
8.58 (1H, s, H2), 7.41 (2H, d, J = 8.7 Hz, ArH2’ and 6’), 7.31 (2H, d, J = 8.7 Hz, 
ArH3’ and 5’), 3.54 (1H, m, CH(CH3)2), 3.32 (1H, s, OH), 1.07 (3H, d, J = 6.6 Hz, 
CH(CH3)2), 0.93 (d, J = 6.6Hz, CH(CH3)2). 13C NMR (CDCl3) : 161.2 (C4 and 6), 
154.7 (C2), 141.9 (C5), 137.9 (ArC4’), 133.7 (ArC1’) 128.4 (ArC2’ and 6’), 128.2 
(ArC3’ and 5’), 82.0 (C-OH), 34.8, CH(CH3)2; 18.5, CH(CH3)2; 17.6, CH(CH3)2. ES-
MS m/z: 333 ([M+1]+ 37Cl, 100%), 331 ([M+1]+, 35Cl, 100); ES-HRMS m/z: calcd for 
[M+1]+ C14H14 35Cl3N2O 331.0178; found 331.0172. 
 
4-Amino-6-chloro-5-(2-methyl-1-phenyl-1-propenyl)pyrimidine100 (92) 
A suspension of 4,6-dichloro-5-(2-methyl-1-phenyl-1-
propenyl)pyrimidine (47) (1.00 g, 3.6 mmol) in aqueous ammonia 
(20 ml) (25%) was heated at 140 °C for 5 h in a glass sealed tube. 
The reaction was cooled, the solid collected, washed with water and air dried. 
Recrystallisation from benzene produced (92) (0.69 g, 80%) as a white crystals. mp 193 
°C. 1H NMR (300 MHz CDCl3) : 8.25 (1H, s, H2), 7.33-7.21 (5H, m, ArH2’, 3’, 4’, 
5’, and 6’), 5.66 (2H, s, NH2), 1.96 (3H, s, C=C(CH3)2), 1.72 (3H, s, C=C(CH3)2); 13C 
NMR (CDCl3) : 162.5 (C6), 158.6 (C4), 156.7 (C2), 138.8 (C=C(CH3)2), 138.5 (C5) 
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(C=C(CH3)2), 99.9 (C5), 22.5 (C=C(CH3)2), 22.1 (C=C(CH3)2). ES-MS m/z: 262 





A suspension of 4,6-dichloro-5-[2-methyl-1-(4-chlorophenyl)-
1-propenyl]pyrimidine (33) (1.00 g, 3.2 mmol) in aqueous 
ammonia (20 ml) (25%) was heated at 160 °C for 24 hours in 
a glass sealed tube. The reaction was cooled, the solid 
collected, washed with water and air dried. Recrystallisation from benzene produced 
(89) (0.61 g, 80%) as a white solid. mp 261 °C. 1H NMR (300 MHz CDCl3) : 8.05 
(1H, s, H2), 7.25 (2H, d, J = 8.7Hz, ArH2’ and 6’), 7.19 (2H, s, ArC3’ and 5’), 4.80 
(4H, s, NH2), 1.96 (3H, s, C=C(CH3)2), 1.72 (3H, s, C=C(CH3)2). 13C NMR (CDCl3) : 
160.3 (C4 and 6), 157.1 (C), 139.0 (C=C(CH3)2), 137.9 (ArC4’), 130.6 (ArC1’), 130.4 
(ArC2’ and 6’), 128.7 (ArC3’ and 5’), 125.8 (C=C(CH3)2), 99.9 (C5), 22.5 
(C=C(CH3)2), 22.1 (C=C(CH3)2). ES-MS m/z: 275 ([M+1]+, 35Cl, 100%); ES-HRMS 
m/z: calcd for [M+1]+ C14H15N435Cl 276.095094; found 276.095574. 
 
4,6-diamino-5-(2-methyl-1-phenyl-1-proenyl)pyrimidine100 (91) 
A suspension of 4,6-dichloro-5-(2-methyl-1-pheny-1-
propenyl)pyrimidine (47) (1.00 g, 3.6 mmol) in aqueous ammonia 
(20 ml) (25%) was heated at 160 °C for 24 hours in a glass sealed 
tube. The reaction was cooled, solid collected, washed with water and air dried. 
Recrystallisation from benzene produced (91) (0.69 g, 80%) as a white crystals. mp 230 
°C. 1H NMR (300 MHz CDCl3) : 8.05 (1H, s, H2), 7.39-7.25 (5H, m, ArH2’, 3’, 4’, 
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NMR (CDCl3) : 160.3 (C4 and 6), 157.1 (C2), 139.0 (C=C(CH3)2), 137.9 (ArC1’), 
130.4 (ArC2’ and 6’), 128.9 (ArC4’), 128.7 (ArC3’ and 5’), 125.8 (C=C(CH3)2), 99.9 
(C5), 22.5 (C=C(CH3)2), 22.1 (C=C(CH3)2). ES-MS m/z: 241 ([M+1]+, 100%), 202 
(10); ES-HRMS m/z: calcd for [M+1]+ C14H16N4 240.138065; found 240.137497. 
 
4,6-Di-(allylamino)-5-[2-methyl-1-(4-chlorophenyl)-1-propenyl]pyrimidine (94) 
A solution of 4,6-diamino-5-[2-methyl-1-(4-chlorophenyl)-
1-propenyl]pyrimidine (89) (1.00 g, 3.6 mmol) and 
allylbromide (0.44 g, 3.6 mmol) in THF (10 ml) was heated 
at 120 °C for five hours in glass sealed tube. The solvent 
was removed under reduced pressure and the resultant 
residue purified by silica gel column chromatography solvent system (80:20 ethyl 
acetate:methanol) to give compound (94) (0.78 g, 60%) as an orange coloured gum. 1H 
NMR (300 MHz CDCl3) : 8.35 (1H, s, H2), 7.28 (2H, d, J = 8.7 Hz, ArH2’, and 6’), 
7.21 (2H, d, J = 8.7 Hz, ArH2’, and 6’). ES-MS m/z: 357 ([M+1]+ 37Cl, 3%), 354 
[M+1], 35Cl, (5), 314 (20), 299 (80), 230 (30), 149 (100). CI-HRMS m/z: calcd for 




A solution of 4-amino-6-chloro-5-[2-methyl-1-(p-
chlorophenyl)-1-pheny-l-propenyl]pyrimidines (34) (0.50 g, 
1.7 mmol) and 1-amino-3-diethylamino propan-2-ol (99) 
(1.80 g, 8.0 mmol) in dimethylformamide (15 ml) was heated 
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was removed under reduced pressure. The resultant residue purified by flash silicagel 
chromatography (85: 15 hexane: ethyl acetate) to give (101) (0.30 g, 50%) as a white 
solid. mp 155-158 °C. 1H NMR (300 MHz CDCl3) : 8.12 (1H, s, H2), 7.26 (2H, d, J = 
8.7 Hz, ArH2’ and 6’), 7.15 (2H, ArH3’ and 5’), 2.96 (6H, s, N(CH3)2), 1.97 (3H, s, 
C=C(CH3)2), 1.81 (3H, s, C=C(CH3)2). 13C NMR (CDCl3) : 162.0 (C4), 161.1 (C6), 
155.9 (C2), 138.9 (C=C(CH3)2), 136.5 (ArC1’), 132.6 (ArC4’), 130.6 (ArC2’ and 6’), 
129.6 (C=C(CH3)2), 128.3 (ArC3’ and 5’), 100.6 (C5), 39.7 (2C, N(CH3)2), 23.5 
(C=C(CH3)2), 22.1 (C=C(CH3)2). ES-MS m/z: 303 ([M+1]+, 35Cl, 100%); EI-HRMS 
m/z: calcd for C16H1936ClN4 304.126195; found 304.126874. 
 
2-Chloropyrimidinyl-5-phenylmethanone123 (108) 
Bis(triphenylphosphine)palladium(II) dichloride (0.027 g, 0.037 
mmol)  was added to solution of benzoyl chloride (0.087g, 0.62 
mmol) and 2-chloro-5-tributylstannylpyrimidine (0.28 g, 0.62 
mmol) in dry 1,2-dichloroethane (10 ml). The reaction was heated at reflux for 4h. 
Diethyl ether (10 ml) was added to cool the reaction followed by saturated KF (10 ml), 
and the mixture was stirred for 60 minutes, followed by the precipitated 
fluorotributyltin was removed by filtration. The two phases were separated, the organic 
layer was dried over MgSO4, the solvent removed under reduced pressure, and the 
residual product purified by flash chromatography to yield (108) (0.10 g, 85%)  as a 
white solid. mp 79 ºC. 1H NMR (300 MHz CDCl3) : 8.99 (1H, s, H4 and 6), 7.82 (2H, 
d, J = 9.0 Hz, ArH2’ and 6’), 7.70 (1H, t, ArH4’), 7.59 (2H, t, ArH3’ and H5’). 13C 
NMR (CDCl3) : 191.1 (CO), 164.0 (C2), 160.5 (C4 and 6), 135.8 (C5), 134.2 (ArC3’ 
and 5’), 130.0 (ArC2’ and 6’), 129.5 (ArC1’), 129.2 (ArC3’ and 5’). CI-MS m/z: 221 
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2-Amonopyrimidinyl-5-phenylmethanone (109) 
A suspension of 2-chloropyrimidinyl-5-phenylmethanone 
(108) (1.00 g, 4.5 mmol) in aqueous ammonia (20 ml) (25%) 
was heated at 130 °C for 24 hours in a glass sealed tube. The 
reaction was cooled, solid collected, washed with water and air-dried. Recrystallisition 
from benzene produced (109) (0.72 g, 80%) as a white crystals. mp 125 °C. 1H NMR 
(300 MHz CDCl3) : 8.53 (1H, s, H2), 7.50-7.33 (5H, m, ArH2’, 3’, 4’, 5’, and 6’), 
5.22 (2H, NH2). 13C NMR (CDCl3) : 190.5 (CO), 162.3 (C5), 157.4 (C4 and 6), 136.0 
(ArC1’), 129.8 (ArC3’ and 5’), 128.4 (ArC4’), 126.3 (ArC2’ and 6’) 124.7 (C2’). ES-
HRMS m/z: calcd for [M+1]+ C11H10N3O 200.0833; found 200.0824. 
 
5-(2-allyaminopyrimidinyl)-5-phenylmethanone (110) 
A solution of aminoyrimidinyl-5-phenylmethanone (109) 
(0.10 g, 0.43 mmol) in 2 ml of allylbromide was heated 
at reflux for 3hour. Allylbromide was removed under 
reduced pressure, and the residue purified by flash silica gel chromatography (75:25 
hexane:ethyl acetate) to yield (110) (0.08 g, 73%) as a white solid. mp 149-151 °C. 1H 
NMR  (300 MHz CDCl3) : 8.78 (1H, s, H4 and H6), 7.75 (2H, d, J = 6.0 Hz, ArH2’ 
and 6’), 7.59 (1H, t, J = 9.0 Hz, ArH4’), 7.51 (2H, t, J = 6.0 Hz, ArH3’ and 5’), 6.38 
(1H, s, NH), 5.98 (1H, m, NHCH2CH=CH2), 5.31, (2H, m, NHCH2CH=CH2), 4.14, 
(2H, m, NHCH2CH=CH2). 13C NMR (CDCl3) : 192.4 (CO), 163.0 (C2), 161.0 (C4 
and 6), 137.5 (ArC1), 134.1 (NHCH2CH=CH2), 132.6 (ArC4), 129.5 (ArC2’ and 6’), 
128.7 (ArC3’ and 5’), 121.0 (C5), 116.7 (NHCH2CH=CH2), 44.2 (NHCH2CH=CH2). 
CI-MS m/z: ([M+1]+, 40%), 153 (100); ES-HRMS m/z: calcd for [M+1]+ C14H14N3O 
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5-[Hydroxy(4-nitrophenyl)methyl]uracil124 (113) 
Uracil (5.00 g, 44.6 mmol) was added to concentrated 
hydrochloric acid (20 ml), and the slurry was warmed to 
60 °C, before the addition of 4-nitrobenzaldehyde (6.70 
g, 44.6 mmol). The suspension was then heated at reflux for 8 h and allowed to cool to 
ambient temperature. The solution was then filtered, the resultant filtrate then basified 
to 8-8.5 pH with sodium hydroxide (10 N), giving a precipitate. The precipitate was 
collected by vacuum filtration, washed with acetone, and dried at 60 °C to yield (113) 
(3.51 g, 30%) as a yellow solid. mp 257 °C. 1H NMR  (300 MHz CDCl3) : 11.10 (1H, 
s, pyrimidines H1), 10.75 (1H, d, J = 6.0 Hz, pyrimidines H3), 8.15 (2H, d, J = 8.4 Hz, 
ArH3’ and 5’), 7.62 (2H, d, J = 8.4 Hz, ArH2’ and 6’), 7.33 (1H, s, J = 6.0 Hz, 
pyrimidines H4) 6.00 (1H, d, J = 4.8 Hz, H), 5.58 (1H, d, J = 4.8 Hz, OH). ES-MS 
m/z: 262 ([M-1]-, 100%). 
 
5-(4-Nitrobenzoyl)uracil (115) 
A solution of   5-[hydroxy(4-nitrophenyl)methyl]uracil 
(113) (1.0 g 3.8 mmol) and pyridinium chlorochromate 
(0.80 g, 3.8 mmol) was taken in anhydrous chloroform(10 
ml). The mixture was stirred at room temperature overnight. The solvent removed in 
vacuo, and the residual product was purified by column chromatography on silica using 
hexane:ethyl acetate (70:30) to give (115) (0.80 g, 70%) as a pale yellow solid. mp 270-
272 °C. 1H NMR  (300 MHz CDCl3) : 11.10 (1H, s, pyrimidines H1), 10.75 (1H, d, J 
= 6.0 Hz, pyrimidines H3), 8.26 (2H, d, J = 10.5 Hz, ArH3’ and 5’), 8.05 (1H, s, H4), 
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5,5’-(4-nitrophenyl)methyldiuracil (114) 
Uracil (5.00 g, 44.6 mmol) was added to concentrated 
hydrochloric acid (20 ml), and the slurry was warmed to 
60 °C, before the addition of 4-nitrobenzaldehyde (6.70 
g, 44.6 mmol). The suspension was then heated at reflux 
for 8 h and allowed to cool to ambient temperature. The 
solution was then filtered, the resultant solid washed with (10 N) sodium hydroxide, 
and again washed with acetone, and dried at 60 °C to yield (114) (3.51 g, 70%) as a 
yellow solid. mp 250 °C. 1H NMR  (300 MHz CDCl3) : 11.10 (4H, d, J = 6.0 Hz H1 
and 3), 8.48 (2H, d, J = 8.4 Hz, ArH3’ and 5’), 7.79 (2H, d, J = 8.4 Hz, ArH2’ and 6’), 
7.27 (1H, s, J = 6.0 Hz, H6) 5.45 (1H, s,  CH). ES-MS m/z: 356 ([M-1]-, 100%). 
 
5-[Methoxy(4-nitrophenyl)]methyluracil (116) 
Uracil (5.00 g, 44.6 mmol) was added to 20 ml of 
concentrated hydrochloric acid, and the slurry was 
warmed to 60 °C, followed by the addition of 4-
nitrobenzaldehyde (6.70 g, 44.6 mmol). The suspension was then heated at reflux for 
8h and allowed to cool to ambient temperature. The solution was then filtered and the 
solid product was washed with methanol to yield (116) (3.70 g, 35%) as a pale yellow 
solid. mp 250-253 °C. 1H NMR  (300 MHz CDCl3) : 11.20 (1H, s, NH1), 11.00 (1H, 
s, NH3), 8.54 (2H, d, J =  9.0 Hz, ArH2’ and 6’), 7.98 (2H, d, J =  9.0 Hz, ArH3’ and 
5’), 7.67 (1H, s, H6), 5.61 (1H, s, H), 3.65 (3H, s, CH3). 13C NMR (CDCl3) : 163. 4 
(ArC4’), 151.6 (C2), 149.6 (C4), 147.3 (C5) 139.9 (ArC1’), 128.5 (ArC3’ and 5’), 
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100%), 262 (20), 244 (60); ES-HRMS m/z: calcd for [M+1]+ C12H12N3O5 278.0778; 
found 278.0777 
 
8.3 Synthesis of indoles 
General procedure (A) for synthesis of protected indoles starting materials  
To a stirred solution of 4,6-dimethoxy-3-phenylindole (1 mol) in 
dichloromethane (20 ml) under a nitrogen atmosphere, was added sodium hydride (1 
mol, 60% dispersion in oil) and the reaction stirred for 25 minutes. The sulfonyl 
chloride (1 mol) was then added and the reaction left to stir at 25 C for an additional 2 
h. The solvent was then removed under reduced pressure and the resultant residue was 
suspended in water (50 ml) and extracted with dichloromethane (3 x 100 ml). The 
organic fractions were combined, dried (MgSO4), concentrated under reduced pressure 
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N-Benzenesulfonyl-3-(4-methoxyphenyl)-4,6-dimethoxyindole (135)  
This was prepared as described in general procedure (A) 
using 4,6-dimethoxy-3-(4-methoxyphenyl)indole (134) 
(2.00 g, 7.0 mmol), sodium hydride (0.27 g, 7.0 mmol in 
60% oil dispersion) and benzenesulfonyl chloride (1.24 g, 
7.0 mmol) to give (135) (2.90 g, 65%) as a white solid. mp 
131-133 C. 1H NMR (300 MHz CDCl3) : 7.89 (2H, d, J = 
7.5 Hz, sulfonylArH2’ and 6’), 7.59-7.41 (3H, m, sulfonylArH3’, 4’, and 5’), 7.47 (2H, 
d, J = 8.7 Hz, ArH2’’ and 6’’), 7.31 (1H, s, H2), 7.20 (1H, d, J = 1.8 Hz, H7), 6.92 (2H, 
d, J = 8.7 Hz, ArH3’’ and 5’’), 6.32 (1H, d, J = 1.8 Hz, H5), 3.88 (3H, s, C4-OCH3 ), 
3.84 (3H, s, C6-OCH3), 3.71 (3H, s, ArC4-OCH3’’). 13C NMR (CDCl3) : 159.5 
(ArC4’’), 159.0 (C6), 155.0 (C4), 138.5 (C7a), 137.5 (sulfonylArC1’), 134.0 
(sulfonylArC4’), 130.8 (sulfonylArC2’ and 6’), 129.4, (sulfonylArC3’ and 5’), 126.9 
(C3), 124.4 (ArC1’’), 121.1 (C2), 113.3 (ArC3’’ and 5’’), 110.0 (C3a), 96.0 (C5), 90.0 
(C7), 55.5 (C4-OCH3), 54.5 (C6-OCH3), 54.3 (ArC4-OCH3’’). CI-MS m/z: 424 
([M+1]+, 10%), 391 (15), 340 (10), 284 (30), 149 (20), 125 (15), 113 (50), 97 (70), 85 
(100); ES-HRMS m/z: calcd for [M+1]+ C23H22NO5S 424.1230; found 424.1219. 
 
General procedure (B)  
Solid thallium(III) trifluoroacetate (0.53 mol) was mixed to the protected indole N-
benzenesulfonyl-3-(4-bromophenyl)-4,6-dimethoxyindole (1.06 mmol) under a 
nitrogen atmosphere. Dry acetonitrile (7 ml) was added and the resultant mixture 
cooled to 0 C. Borontrifluoride diethyletherate (8.0 mmol) was then added slowly into 
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water and extracted with dichloromethane (5 x 50 ml). The combined organic layers 
were concentrated to give a dark residue. 
 
2,2’-Bi[N-benzenesulfonyl-4,6-dimethoxy-3-(4-methoxyphenyl)]indole (136) 
The method as described in general procedure 
(B) using N-benzenesulfonyl-3-(4’-
methoxyphenyl)-4,6-dimethoxyindole (135) 
(0.50 g, 1.18 mmol), thallium(III) 
trifluoroacetate (0.32 g, 0.55 mmol) and 
borontrifluoride diethyletherate (1 ml, 7.5 
mmol). The residue was recrystallised from 
DCM/methanol to give (136) (0.37 g, 70%) as a white solid. mp 242-246 C. 1H NMR 
(300 MHz CDCl3) δ: 7.53 (2H, d, J = 6.0 Hz, sulfonyl ArH2’ and 6’), 7.46 (1H, t, 
sulfonylArH4’), 7.30 (2H, t, sulfonylArH3’ and 5’), 7.03 (2H, d, J = 8.4 Hz, ArH2’’ 
and 6’’), 7.02 (1H, d, J = 1.8 Hz, H7), 6.65 (2H, d, J = 8.4 Hz, ArH3’’ and 5’’), 6.25 
(1H, d, J = 1.8 Hz, H5), 3.76 (3H, s, C4-OCH3), 3.75 (3H, s, C6-OCH3), 3.56 (1H, s, 
ArC4-OCH3”). 13C NMR (CDCl3) δ: 159.3 (ArC4’’), 159.0 (C6), 154.5 (C4), 139.9 
(C7a), 139.0 (sulfonylArC1’), 133.9 (sulfonylArC4’’), 131.8 (sulfonylArC2’ and 6’), 
129.5 (sulfonylArC3’ and 5’), 127.0 (C2), 126.7 (ArC2’’ and 6’’), 126.3 (C3), 126.5 
(ArC1’’), 124.0 (C3a), 112.0 (ArC3’’ and 5’’), 94.5 (C5), 92.0 (C7), 56.0 (C4-OCH3), 
55.0 (2 x C, ArC4-OCH3, C6-OCH3). ES-MS m/z: 845 ([M+1]+, 35%), 797.2 (10), 
704.2 (15), 625 (5), 552.3 (15), 475.4 (10), 411.2 (15), 332.3 (50), 304.3 (100), 272.3 
(50), 244.2 (80), 214.0 (40), 157.9 (75), 141.8 (45), 105.9 (90); ES-HRMS m/z: calcd 
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General procedure (C) for 2,7’ and 2,2’-dimers:  
To a solution of 4,6-dimethoxy-3-(4-methoxypheny)indole (1 mol) in DCM (10 ml) 
was added sodium hydride (2 mol of 60% dispersion in mineral oil) and the suspension 
stirred for 5 mins. Triflic anhydride (2 mol) was then added to the reaction mixture. 
After stirring for 72 h at 25 °C, water (30ml) was added carefully, the resultant mixture 
was partitioned with DCM (3 × 30 ml). The combined organic layers were dried over 
(MgSO4) and concentrated.  
 
Compound (137) was prepared by three different methods 
Method 1: 
2,2’-Bi[4,6-dimethoxy-3-(4-mehtoxyphenyl)]indole (137) 
This method as described in general procedure 
(B) using 4,6-dimethoxy-3-(4-
methoxyphenyl)indole (134) (0.5 g, 1.8 mmol), 
thallium(III) trifluoroacetate (1.6 g, 0.9 mmol) 
borontrifluride diethyl etherate (1.25 g, 9.0 
mmol) in acetonitrile (10 ml).  The residue was 
recrystallised from DCM to yield 2,2’-bi[4,6-dimethoxy-3-(4-mehtoxyphenyl)]indole 
(137) (0.15 g, 30%) as a pale yellowish solid, mp 197-200 C. 1H NMR (300 MHz 
DMSO d6) δ: 11.2 (1H, s, NH), 6.93 (2H, d, J = 9.0 Hz, ArH2’ and 6’), 6.59 (2H, d, J = 
9.0 Hz, ArH3’ and 5’), 6.41 (1H, d, J = 1.8 Hz, H5), 6.10 (1H, d, J = 1.8 Hz, H7),3.74 
(3H, s, C4-OCH3), 3.66 (3H, s, C6-OCH3), 3.60 (3H, s, ArC4-OCH3). 13C NMR 
(DMSO d6) δ: 158.3 (ArC4’), 158.2 (C6’), 154.3 (C4’), 138.0 (C7a), 132.0 (ArC2’ and 
6’), 128.5 (ArC1’), 124.6 (C2), 116.3 (C3), 112.2 (ArC3’ and 5’), 112.0 (C3a), 92.0 
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564([M+1]+, 60%), 338 (100), 285 (10), 197 (5), 153 (10), 137 (25), 121 (30), 97 (30); 
ES-HRMS m/z: calcd [M+1]+ C34H33N2O6 564.2259; found 564.2260. 
 
Method 2: 
To a solution of 2,2’-bi-[N-benzenesulfonyl-4,6-dimethoxy-3-(4-
methoxyphenyl)]indole (136) (0.30 g, 0.36 mmol) in dioxane (20 ml) of 20% sodium 
hydroxide heated at reflux for 4h. The reaction mixture was poured into cold water and 
portioned with dichloromethane (3 x 50 ml). Solvent was evaporated yielding 2,2’-
bi[4,6-dimethoxy-3-(4-mehtoxyphenyl)]indole as a pale yellow solid which was 
recrystallised from DCM/methanol giving the 2,2’-bi[4,6-dimethoxy-3-(4-
methoxyphenyl)]indole (137) as pale yellow solid (30mg 15%), mp 197-200 C.  
 
Method 3: 
This method as described in general procedure (C) using 4,6-dimethoxy-3-(4-
methoxyphenyl)indole (134) (0.5 g, 1.8 mmol), sodium hydride (0.143 g, 3.6 mmol) 
and triflic anhydride (1.0 g, 3.6 mmol) in DCM (20 ml).  The residue was recrystallised 
from DCM to yield 2,2’-bi[4,6-dimethoxy-3-(4-mehtoxyphenyl)]indole (137) (0.35 g, 
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N-Benzenesulfonyl-3-(4-bromophenyl)-4,6-dimethoxyindole (141)  
This was prepared as described in general procedure (A) 
using 4,6-dimethoxy-3-(4-bromophenyl)indole (139) (2.50 g, 
5.3 mmol), sodium hydride (0.22 g, 5.3 mmol, 60% 
dispersion in oil) and benzenesulfonyl chloride (1.32 g, 5.3 
mmol) to give (141) (2.45 g, 70%) as a white solid. mp 137-
139 C. 1H NMR (300 MHz CDCl3) : 7.96 (2H, d, J = 8.7 
Hz, sulfonylArH2’ and 6’), 7.56 (2H, m, sulfonylArH3’ and 
5’), 7.49-7.54 (4H, m, ArH2’’ 3’’ 5’’ and 6’’), 7.39 (1H, m, sulfonylArH4’), 7.34 (1H, 
s, H2), 7.19 (1H, d, J = 1.8 Hz, H7), 6.33 (1H, d, J = 1.8 Hz, H5), 3.88 (3H, s, C4-
OCH3), 3.71 (3H, s, C6-OCH3). 13C NMR (CDCl3) δ: 160.0 (C6), 154.0 (C4), 138.3 
(C7a), 138.0 (ArC4’’), 134.0 (sulfonylArC1’), 133.0 (sulfonylArC4’), 131.3 (ArC2’’ 
and 6’’), 130.9 (ArC3’’ and 5’’), 129.5 (sulfonylArC2’ and 6’), 127.0 (sulfonylArC3’ 
and 5’), 123.7 (ArC1’’), 121.7 (C2), 121.4 (C3), 112.9 (C3a), 96.0 (C7), 90.0 (C5), 
58.5 (C4-OCH3), 58.0 (C6-OCH3). CI-MS m/z:  474 ([M+1]+ 81Br 20%), 472 ([M+1]+ 
79Br 40), 332 (15), 173 (30), 159 (75), 143 (100); EI-HRMS m/z: calcd for 
C22H18NO4S79Br 471.012643; found 471.013991. 
 
N-Benzenesulfonyl-3-phenyl-4,6-dimethoxyindole (142) 
This was prepared as described in general procedure (A) 
using 4,6-dimethoxy-3-phenylindole (138) (2.00 g, 7.9 
mmol), sodium hydride (0.315 g, 8.0 mmol, 60% dispersion 
in oil) and benzene sulfonyl chloride (1.40 g, 7.9 mmol) to 
give (142) (2.00 g, 65%) as a white solid. mp 125-128 C. 1H 
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ArH’’), 7.36 (1H, s, H2), 7.20 (1H, d, J = 3.0 Hz, H7), 6.33 (1H, d, J = 3.0 Hz, H5), 
3.95 (1H, s, C4-OCH3), 3.65 (1H, s, C6-OCH3). 13C NMR (CDCl3) δ: 159.5 (C6), 
154.5 (C4), 139.0 (C7a), 138.0 (ArC1’’), 134.0 (sulfonylArC1’), 129.5 (sulfonylArC2’ 
and 6’), 129.2 (sulfonylArC4’), 129.0 (sulfonylArC3’ and 5’), 128.0 (ArC4’’), 127.5 
(ArC2’’ and 6’’), 127.0 (ArC3’’ and 5’’), 124.7 (C3) 122.0 (C2), 112.5 (C3a), 95.0 
(C7), 90.0 (C5), 56.0 (C4-OCH3), 55.7 (C6-OCH3). ES-MS m/z: 394 ([M+1]+, 80%), 
310, (25), 254, (100), 187, (50), 141, (20); ES-HRMS m/z: calcd for [M+1]+ 
C22H20NO4S 394.1108; found 394.1113. 
 
N-Benzenesulfonyl-3-(4-nitrophenyl)-4,6-dimethoxyindole (143) 
This was prepared as described in general procedure (A) 
using 4,6-dimethoxy-3-(4-nitrophenyl)indole (140) (2.00 g, 
6.7 mmol), sodium hydride (0.29 g, 6.7 mmol, 60% 
dispersion in oil) and benzene sulfonyl chloride (1.18 g, 6.7 
mmol) to give the (143) (1.90 g, 65%) as a white solid. mp 
150-152 C. 1H NMR (300 MHz CDCl3) : 8.22 (2H, d, J = 
9.0 Hz, ArH2’’ and 6’’), 7.93 (2H, d, J = 9.0 Hz, ArH3’’ and 5’’), 7.69 (2H, d, J = 8.7 
Hz, sulfonylArH2’ and 6’), 7.59-7.45 (2H, m, sulfonylArH3’, 4’, and 5’), 7.19 (1H, d, J 
= 2.1 Hz, H7), 6.36 (1H, d, J = 2.1 Hz, H5), 3.90 (3H, s, C4-OCH3), 3.79 (3H, s, C6-
OCH3). 13C NMR (CDCl3) : 159.8 (C6), 154.6 (C4), 146.9 (sulfonylArC1’), 141.1 
(sulfonylArC1’), 138.1 (C7a) 137.7 (ArC4’’), 134.4 (sulfonylArC4’), 130.3 (ArC2’’ 
and 6’’), 129.6, (sulfonylArC3’ and 5’), 127.1 (ArC3’’ and 5’’), 123.1 (sulfonylArC2’ 
and 6’), 122.7 (C2), 112.3 (C3a), 95.6 (C7), 89.9 (C5), 56.6 (C4-OCH3), 55.4 (C6-
OCH3). ES-MS m/z 439 ([M+1]+, 100%); EI-HRMS m/z: calcd for C22H18N2O6S 
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2,2’-Bi[N-benzenesulfonyl-4,6-dimethoxy-3-(4-bromophenyl)]indole (144) 
The method as described in general procedure 
(B) using thallium(III) trifluoroacetate (0.287 
g, 0.53 mmol), N-benzenesulfonyl-3-(4’-
bromophenyl)-4,6-dimethoxyindole (141) 
(0.500 g, 1.06 mmol) and borontrifluoride 
diethyletherate (1 ml, 8.0 mmol). The residue 
was recrystallised from 
dichloromethane/methanol to give (144) (0.37 
g, 74%) as a white solid. mp 263-265 C. 1H NMR (300 MHz CDCl3) δ: 7.90 (2H, d, J 
= 9.0 Hz, sulfonylArH2’’ and 6’’), 7.55-7.34 (7H, m, sulfonylArH3’ and 4’, 5’ and 
ArH2’’, 3’’, 5’’, and 6’’), 7.19 (1H, d, J = 1.8 Hz, H7), 6.34 (1H, d, J = 1.8 Hz, H5), 
3.88 (3H, s, C4-OCH3), 3.72 (3H, s, C6-OCH3). 13C NMR (CDCl3) δ: 159.3 (C6), 
154.5 (C4), 137.8 (C7a), 137.4 (ArC4’’), 134.1 (sulfonylArC4’), 132.8 (C2), 131.2 
(sulfonylArC2’ and 6’), 130.7 (sulfonylArC3’ and 5’), 129.9 (sulfonylArC1’), 129.4 
(ArC1’), 129.2 (ArC2’’ and 6’’), 126.8 (ArC3’’ and 5’’), 121.5 (C3), 112.6 (C3a), 95.3 
(C5), 89.9 (C7), 56.0 (C4-OCH3), 55.3 (C6-OCH3). ES-MS m/z: 942.7 ([M+1]+, 81Br, 
30%), 941 ([M+1]+ 79Br, 30), 761.3 (10), 488.0 (20), 392.2 (30), 338.4 (30), 316.3 (35), 
314.2 (70), 288.3 (60), 270.2 (50), 244.2 (45), 174.8 (30), 166.9 (40), 144.9 (70), 125.8 
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2,2’-Bi(N-benzenesulfonyl-4,6-dimethoxy-3-phenyl)indole (145) 
The method as described in general procedure 
(B) using N-benzenesulfonyl-3-phenyl-4,6-
dimethoxyindole (142) (0.50 g, 1.3 mmol), 
thallium(III) trifluoroacetate (0.344 g, 0.65 
mmol) and borontrifluoride diethyletherate (1 
ml, 15.0 mmol). The residue recrystallised 
from DCM/methanol to give (145) (0.35 g, 
70%) as a white solid. mp 224-226 C. 1H NMR (300 MHz CDCl3) δ: 7.57-7.01 (10H, 
m, sulfonylArH2’, 3’, 4’ and 6’, and ArH2’’, 3’’, 4’’, 5’’, and 6’’), 7.00 (1H, d, J = 1.8 
Hz, H7), 6.22 (1H, d, J = 1.8 Hz, H5), 3.76 (3H, s, C4-OCH3), 3.53 (3H, s,C6-OCH3). 
13C NMR (CDCl3) δ: 159.3 (C6), 154.9 (C4), 139.0 (C7a), 139.5 (sulfonylArC1’), 
133.8 (C3), 133.4 (sulfonylArC4’), 130.7 (sulfonylArC2’ and 6’), 129.1 
(sulfonylArC3’ and 5’), 129.0 (ArC4’’), 128.5 (ArC4’’), 128.0 (C2), 127.5 (ArC2’’ and 
6’’), 127.2 (ArC3’’ and 5’’), 126.9 (ArC1’), 122.3 (C3a), 95.5 (C5), 90.8 (C7), 55.9 
(C4-OCH3), 55.4 (C6-OCH3). ES-MS m/z: 785.0 ([M+1]+, 30%), 746.2 (20), 649.4 
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2,2’-Bi(4,6-dimethoxy-3-(4-bromophenyl)indole (146) 
This method as described in general procedure 
(B) using 4,6-dimethoxy-3-(4-
bromophenyl)indole (139) (0.20 g, 0.6 mmol), 
thallium(III) trifluoroacetate (0.16 g, 0.3 mmol) 
and borontrifluoride diethyletherate (0.43 g, 3.0 
mmol). The residue was subjected for flash 
chromatography (50: 50 hexane: ethyl acetate) yielding (146) (0.04 g, 20%) as a pale 
yellow solid. mp 195-197 C. 1H NMR (300 MHz CDCl3) : 7.85 (2H, d, J = 7.5 Hz 
ArH3’ and 5’), 7.21 (2H, d, J = 7.5 Hz ArH2’ and 6’), 7.28 (1H, d, J = 1.8 Hz H7), 6.32 
(1H, s, H5), 3.84 (3H, s, C4-OCH3), 3.49 (3H, s, C6-OCH3). ES-MS m/z: 664 ([M+1]+ 
81Br, 30%), 663 ([M+1]+, 79Br 60%), 607 (10), 468.5 (15), 332 (40), 316 (50), 304 (50), 




To a solution of 2,2’-bi-(N-benzenesulfonyl-
4,6-dimethoxy-3-phenyl)indole (145) (0.30 g, 
0.38 mmol) in dioxane (20 ml) containing 20% 
of sodium hydroxide and the reaction mixture 
heated at reflux for 4 h. The reaction mixture 
was poured into cold water and partitioned with dichloromethane (3 x 50 ml). The 
solvent was evaporated and was recrystallised from DCM/methanol giving the (147) 
(30 mg, 15%) as a pale yellow solid. mp 174-178 C. 1H NMR (300 MHz CDCl3) δ: 
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5’), 6.49 (1H, d, J = 3.0 Hz, H7), 6.18 (1H, d, J = 3.0 Hz, H5), 3.77 (3H, s, C4-OCH3), 
3.66 (3H, s, C6-OCH3). 13C NMR (CDCl3) δ: 158.0 (C6), 155.0 (C4), 138.0 (C7a), 
136.0 (C3), 131.0 (ArC4’), 126.7 (ArC2’ and 6’), 125.2 (ArC3’ and 5’), 125.0 (ArC1’), 
118.0 (C2), 112.0 (C3a), 92.0 (C5), 86.2 (C7), 55.0 (C4-OCH3), 54.5 (C6-OCH3). ES-
MS m/z: 504.2 ([M+1]+, 60%), 338.4 (25), 144.9 (20), 105.9 (45), 103.9 (100), 71.0 
(25); ES-HRMS m/z: calcd for [M+1]+ C32H29N2O4 504.2054; found 504.2049. 
 
N-(4-Methylphenylsulfonyl)-3-(4-bromophenyl)-4,6-dimethoxyindole (148) 
This was prepared as described in general procedure (A) 
using 4,6-dimethoxy-3-(4-bromophenyl)indole (139) (2.00 g, 
6.0 mmol), sodium hydride (0.29 g, 6.0 mmol, in 50% oil 
dispersion) and p-toluenesulfonyl chloride (1.14 g, 6.0 mmol) 
to give the (148) (2.0 g, 65%) as white solid. mp 138-140 C. 
1H NMR (300 MHz CDCl3) : 7.78 (2H, d, J = 7.8 Hz, ArH2’ 
and H6’), 7.49 (2H, d, J = 9.0 Hz, tosylArH3’ and 5’’), 7.39 
(2H, d, J = 9.0 Hz, tosylArH2’ and 6’’), 7.34 (1H, s, H2), 7.25 (2H, d, J = 7.8 Hz, 
Ar3H’’ and 5’’), 7.18 (1H, d, J = 1.8 Hz, H7), 6.32 (1H, d, J = 1.8 Hz, H5), 3.88 (3H, s, 
C4-OCH3), 3.70 (3H, s, C6-OCH3), 2.35 (3H, s, CH3). 13C NMR (CDCl3) : 159.4 
(C6), 154.6 (C4), 145.2 (tosylArC1’’), 137.5 (C7a), 135.1 (ArC4’), 133.0 (ArC4’), 
131.3 (ArC2’ and 6’), 130.9 (ArC3’ and 5’), 130.1 (tosylArC2’’ and 6’’), 127.0 
(tosylArC3’’ and 5’’), 125.0 (tosylArC4’’), 123.4 (C3), 121.3 (ArC1’), 121.7 (C2), 
112.8 (C3a), 95.4 (C7), 90.0 (C5), 56.1 (C4-OCH3), 55.5, (C6-OCH3), 22.0 CH3. EI-
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N-(p-Nitrobenzenesulfonyl)-3-(4-bromophenyl)-4,6-dimethoxyindole (149) 
This was prepared as described in general procedure (A) 
using 4,6-dimethoxy-3-(4-bromophenyl)indole (139) (2.00 g, 
6.0 mmol), sodium hydride (0.29 g, 6.0 mmol, 50% 
dispersion in oil) and p-nitrobenzenesulfonyl chloride (0.69 g, 
6.0 mmol) to give the (149) (2.0 g, 65%) as yellow powder.  
mp 220-222 C. 1H NMR (300 MHz CDCl3) : 8.29 (2H, d, J 
= 8.7 Hz, Ar2H’’ and 6’), 8.05 (2H, d, J = 8.7 Hz, ArH3’’ and 
5’’), 7.49 (2H, d, J = 6.6 Hz, sulfonylArH3’ and 5’), 7.37 (2H, d, J = 6.6 Hz, 
sulfonylArH2’and 6’), 7.3 (1H, s, H2), 7.17 (1H, d, J = 1.8 Hz, H7), 6.36 (1H, d, J = 
1.8 Hz, H5), 3.89 (3H, s, C4-OCH3), 3.71 (3H, s, C6-OCH3). 13C NMR (CDCl3) : 
160.0 (C6), 155.0 (C4), 151.5 (sulfonylArC1’), 143.5 (ArC4’’), 138.0 (C7a), 133.0 
(ArC1’), 131.3 (ArC2’’ and 6’’), 131.0 (ArC3’’ and 5’’), 128.2 (sulfonylArC2’ and 6’), 
125.0 (sulfonylArC4’), 124.8 (sulfonylArC3’ and 5’), 122.0 (C3), 121.1 (C2), 113.4 
(C3a), 95.9 (C7), 90.1 (C5), 56.1 (C4-OCH3), 55.4 (C6-OCH3). CI-MS m/z: 519 
([M+1]+, 81Br, 100%), 517 ([M+1]+ 79Br, 100) 455 (10), 332 (50), 236 (10); EI-HRMS 
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N-(p-Nitrobenzenesulfonyl)-3-(4-nitrophenyl)-4,6-dimethoxyindole (150) 
This was prepared as described in general procedure (A) 
using 4,6-dimethoxy-3-(4-nitrophenyl)indole (140) (2.00 g, 
6.7 mmol) sodium hydride (0.32 g, 6.7 mmol, in 50% oil 
dispersion) and p-nitrobenzenesulfonyl chloride (0.75 g, 6.7 
mmol) to give the (150) (2.0 g, 65%) as a pale yellow solid. 
mp 190-193 C. 1H NMR (300 MHz CDCl3) : 8.34 (2H, d, 
J = 9.0 Hz, ArH2’’ and 6’’), 8.24 (2H, d, J = 8.7 Hz, 
sulfonylArH3’ and 5’), 8.10 (2H, d, J = 9.0 Hz, ArH3’’ and 5’’), 7.68 (2H, d, J = 8.7 
Hz, sulfonylArH2’ and 6’), 7.26 (1H, s, H2), 7.18 (1H, d, J = 1.8 Hz, H7), 6.39 (1H, d, 
J = 1.8 Hz, H5), 3.91 (3H, s, C4-OCH3), 3.73 (3H, s, C6-OCH3). 13C NMR (CDCl3) δ: 
160.1 (C6), 156.0 (C4), 146.1 (ArC4’’), 144.0 (ArC1’’), 141.0 (C7a), 148.0 
(sulfonylArC4’), 131.0 (ArC2’’ and 6’’), 128.1 (sulfonylArC2’ and 6’), 125.5 (ArC3’’ 
and 5’’), 125.0 (sulfonylArC1’), 123.0 (C2), 122.0 (sulfonylArC3’ and 5’), 121.0 (C3), 
113.0 (C3a), 96.0 (C7), 90.0 (C5), 58.0 (C4-OCH3), 56.0 (C6-OCH3). CI-MS m/z 484.0 
([M+1]+, 100%), 420 (10), 299 (30); EI-HRMS m/z: calcd for C22H17N3O8S 
483.074651; found 483.073637. 
 
N-Methanesulfonyl-3-phenyl-4,6-dimethoxyindole (151) 
This was prepared as described in general procedure (A) using 
4,6-dimethoxy-3-phenylindole (138) (2.00 g, 7.9 mmol) 
sodium hydride (0.180 g, 8.0 mmol, 60% dispersion in oil) and 
methane sulfonyl chloride (0.910 g, 7.9 mmol) to give the 
(151) (2.30 g, 75%) as white solid. mp 140-142 C. 1H NMR 
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4’, and 5’), 7.23 (1H, s, H2), 7.10 (1H, d, J = 2.1 Hz, H5), 6.41 (1H, d, J = 2.1 Hz, H7), 
3.89 (3H, s, C4-OCH3), 3.76, (3H, s, C6-OCH3), 3.11 (3H, s, SO2CH3). 13C NMR. 
(CDCl3) : 160.0 (C6), 155.0 (C4), 138.0 (C7a), 134.0 (ArC1’) 130.0 (ArC2’ and 6’), 
128.0 (ArC3’ and 5’), 127.6 (ArC4’), 125.0 (C3), 122.0 (C2), 113.0 (C3a), 96.0, (C7), 
90.0 (C5), 56.0, (C4-OCH3), 55.6 (C6-OCH3), 40.0 (SO2CH3). CI-MS m/z: 332 
([M+1]+, 45%), 270 (15), 132 (15), 103 (20), 71 (100); HRMS (ES): m/z calcd for 
[M+1]+ C17H18NO4S 332.0959 found 332.0957. 
 
N-Methanesulfonyl-3-(4-bromophenyl)-4,6-dimethoxyindole (152) 
This was prepared as described in general procedure (A) 
using 4,6-dimethoxy-3-(4-bromophenyl)indole (139) (2.00 g, 
6.0 mmol), sodium hydride (0.24 g, 6 mmol, 60% dispersion 
in oil) and methanesulfonyl chloride (0.69 g, 6.0 mmol) to 
give the (152) (2.45 g, 70%) as a white solid. mp 147-150 C. 
1H NMR (300 MHz CDCl3) : 7.51 (2H, d, J = 9.0 Hz, ArH2’ and 4’), 7.43 (2H, d, J = 
9.0 ArH3’ and 5’), 7.22 (1H, s, H2), 7.02, (1H, d, J = 2.1 Hz, H7), 6.40 (1H, d, J = 2.1 
Hz, H5), 3.89 (3H, s, C4-OCH3), 3.77, (3H, s, C6-OCH3), 3.13, (s, SO2CH3). 13C NMR 
(CDCl3) : 160.0 (C6), 156.5 (C4), 138.0 (C7a), 134.0 (ArC4’) 130.5 (ArC2’ and 6’), 
130.0 (ArC3’ and 5’), 124.0 (ArC1’), 123.0 (C3), 122.0 (C2), 112.0 (C3a), 96.0 (C7), 
90.0 (C5), 55.0 (C4-OCH3), 54.5 (C6-OCH3), 42.0 SO2CH3. CI-MS m/z: 412 ([M+1]+, 
81Br, 20%), 410 ([M+1]+ 79Br, 20) 332 (15), 254 (10), 113 (25), 97(30), 81 (100); ES-
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N-Methanesulfonyl-3-(4-methoxyphenyl)-4,6-dimethoxyindole (153) 
This was prepared as described in general procedure (A) 
using 4,6-dimethoxy-3-(4-methoxyphenyl)indole (134) 
(2.00 g, 7.0 mmol), sodium hydride (0.29 g, 7.0 mmol in 
60% dispersion in oil) and methanesulfonyl chloride (0.81 
g, 7.0 mmol) to give the (153) (1.85 g, 75%) as white solid. 
mp 145-148 C. 1H NMR (300 MHz CDCl3) : 7.50 (2H, d, J = 9.0 Hz, ArH2’ and 6’), 
7.17 (1H, s, H2), 7.10 (1H, d, J = 2.1 Hz, H5), 6.93 (2H, d, J = 9.0 Hz, ArH3’ and 5’), 
6.40 (1H, d, J = 2.1 Hz, H7), 3.88 (3H, s, C4-OCH3), 3.85 (3H, s, C6-OCH3), 3.77, 
(3H, s, ArC4-OCH3), 3.09 (3H, s, CH3). 13C NMR (CDCl3) : 159.9 (ArC4’), 158.5 
(C6), 155.0 (C4), 138.0 (C7a), 132.0 (ArC2’ and 6’) 126.0 (ArC1’) 124.0 (C3), 121.0 
(C2), 114.0 (ArC3’ and 5’), 110.0 (C3a), 96.0 (C7), 90.0 (C5), 56.0 (C4-OCH3), 55.6 
(C6-OCH3), 55.7, (ArC4-OCH3), 40.0, (CH3). CI-MS m/z: 362 ([M+1]+, 90%), 340 
(15), 284 (30), 149 (15), 113 (20), 97 (25), 81 (100); EI-HRMS m/z: calcd for 
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2,2’-Bi[(N-p-methylbenzenesulfonyl)-4,6-dimethoxy-(4-bromoyphenyl)indole] (154) 
The method as described in general procedure 
(B) using N-(4-methylphenylsulfonyl)-3-(4-
bromophenyl)-4,6-dimethoxyindole (148) (0.5 
g, 1.0 mmol), thallium(III) trifluoroacetate 
(0.291 g, 0.5 mmol) and borontrifluoride 
diethyletherate (1ml, 6.5 mmol). 
Recrystallisation from DCM/methanol  gave 
(154) (0.350 g, 70%) as a yellow solid. mp 219 
C. 1H NMR (300 MHz CDCl3) : 7.45 (2H, d, J = 8.4 Hz, sulfonylArH3’ and 5’), 7.17 
(2H, d, J = 8.7 Hz, ArH2’’ and 6’’), 7.14, (2H, d, J = 8.7 Hz, ArH3’’ and 5’’), 7.04 
(1H, d, J = 2.1 Hz, H7), 6.86, (2H, d, J = 8.4 Hz, sulfonyl ArH2’ and 6’), 6.26 (1H, d, J 
= 2.1 Hz, H5), 3.79 (3H, s, C6-OCH3), 3.57 (3H, s, C4-OCH3), 2.36 (3H, s, CH3). 13C 
NMR (CDCl3) : 159.6 (C6), 154.8 (C4), 144.7 (sulfonylArC4’), 138.7 (C7a), 136.7 
(ArC4’’), 132.9 (ArC1’’), 132.2 (sulfonylArC2’ and 6’), 130.1 (ArC2’’ and 6’’), 129.8 
(ArC3’’ and 5’’), 127.2 (sulfonylArC3’ and 5’), 126.0 (sulfonylArC1’), 124.0 (C2), 
121.4 (C3), 112.3 (C3a), 95.4 (C5), 90.8 (C7), 55.8 (C4-OCH3), 55.3 (C6-OCH3), 21.8 
(CH3). ES-MS m/z: 971 ([M+1]+, 81Br, 20%), 969 ([M+1]+, 79Br, 10%), 501.7 (20), 
304.3 (30), 288.2 (35), 272.2 (40), 244.3 (100), 225.1 (45), 103.7 (80); ES-HRMS m/z: 
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2,2’-Bi[(N-p-nitrobenzenesulfonyl)-4,6-dimethoxy-(4-bromophenyl)]indole (155) 
The method as described in general procedure 
(B) using N-(p-nitrobenzenesulfonyl)-3-(4-
bromophenyl)-4,6-dimethoxyindole (150) (0.5 
g, 1.0 mmol), thallium(III) trifluoroacetate 
(0.291 g 0.5 mmol), and borontrifluoride 
diethyletherate (1 ml, 6.5 mmol). 
Recrystallisation from DCM/methanol gave 
(155) (0.350 g, 70%) as a yellow solid. mp 
232-235 C. 1H NMR (300 MHz CDCl3) : 8.14 (2H, d, J = 8.7 Hz, ArH3’’ and 5’’), 
7.48 (2H, d, J = 9.0 Hz, ArH2’’ and 6’’), 7.20 (2H, d, J = 8.7 Hz, sulfonylArH2’ and 
6’), 7.02 (1H, d, J = 1.8 Hz, H7), 7.03 (2H, d, J = 9.0 Hz, sulfonylArH3’ and 5’), 6.39 
(1H, d, J = 1.8 Hz, H5), 3.82 (3H, s, C4-OCH3), 3.63 (s, C6-OCH3). 13C NMR (CDCl3) 
: 160.6 (C6), 155.2 (C4), 150.3 (sulfonylArC4’), 144.4 (sulfonylArC1’), 139.1 (C7a), 
132.3 (ArC1’’), 132.2 (sulfonylArC3’ and 5’), 130.4 (ArC2’’ and 6’’), 130.0 (C2), 
127.9 (sulfonylArC2’ and 6’), 124.51 (ArC3’’ and 5’’), 122.9 (ArC4’’), 122.0 (C30, 
112.4 (C3a), 96.0 (C7), 90.8 (C5), 56.0 (C4-OCH3), 55.4 (C6-OCH3 and ArC4-OCH3). 
ES-MS m/z: 1057.6 ([M+Na]+, 81Br, 30%) 1055.6 ([M+Na]+, 79Br, 20), 1031 ([M+1]+, 
79Br, 20), 887.3 (10), 757.9 (30), 705.9 (60), 662.0 (50), 629.8, (50), 585.9 (80), 564.0 
(95), 498.8 (70), 451.6, (45), 391.6 (100); ES-HRMS m/z: calcd for [M+1]+ 
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2,2’-Bi(N-methanesulfonyl-4,6-dimethoxy-3-phenyl)indole (156) 
The method as described in general procedure 
(B) using N-methanesulfonyl-3-phenyl-4,6-
dimethoxyindole (151) (0.5 g, 1.5 mmol), 
thallium(III) trifluoroacetate (0.380 g, 0.7 
mmol) and borontrifluoride diethyletherate (1 
ml, 7.5 mmol). Recrystallisation from 
DCM/methanol gave (156) (0.35 g, 70%) as a white solid. mp 229-231 C. 1H NMR 
(300 MHz CDCl3) : 7.25-7.16 (4H, m, ArH2’, 3’, 4’, 5’, and 6’), 7.11 (1H, d, J = 3.0 
Hz, H5), 6.32 (1H, d, J = 3.0 Hz, H7), 3.87 (3H, s, C4-OCH3), 3.59 (3H, s, C6-OCH3), 
2.90 (3H, s, SO2CH3). 13C NMR (CDCl3) : 160.0 (C7), 155.0 (C4), 148.0 (C7a), 134.0 
(ArC1’), 130.0 (ArC2’ and 6’), 127.3 (C3), 127.1 (ArC3’ and 5’), 127.0 (C2), 126.5 
(ArC4’), 113.0 (C3a), 95.0 (C7), 90.0 (C5), 56.0 (C4-OCH3), 55.6 (C6-OCH3), 40.0 
(SO2CH3). ES-MS m/z 661.1 ([M+1]+, 50%), 348.1 (20), 132.8 (18), 105.9 (30), 103.9 




The method as described in general procedure 
(B) using N-methanesulfonyl-3-(4-
bromophenyl)-4,6-dimethoxyindole (152) (0.5 
g, 1.2 mmol), thallium(III) trifluoroacetate 
(0.330 g, 0.6 mmol) and borontrifluoride 
diethyletherate (1 ml, 6.0 mmol). The residue 
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(157) (0.40 g, 80%) as a white solid. mp 179-182 C. 1H NMR (300 MHz CDCl3) : 
7.31 (2H, d, J = 9.0 Hz, ArH2’ and 6’), 7.08 (1H, d, J = 3.0 Hz, H5), 7.02 (2H, d, J = 
9.0 Hz, ArH3’ and 5’), 6.33 (1H, d, J = 3.0 Hz, H7), 3.89 (3H, s, C4-OCH3), 3.61 (3H, 
s, C6-OCH3), 3.06 (3H, s, SO2CH3). 13C NMR (CDCl3) : 160.2 (C6), 155.0 (C4), 
138.0 (C7a), 132.7 (ArC4’), 132.0 (ArC3’ and 5’), 130.3 (ArC2’ and 6’), 126.3 
(ArC1’), 123.3 (C2), 121.4 (C3), 112.6 (C3a), 95.6 (C7), 89.9 (C5), 56.8 (C4-OCH3), 
56.0 (C6-OCH3), 40.0 (SO2CH3). ES-MS m/z: 817.9 ([M+1]+, 81Br, 15%), 817 ([M+1]+ 
79Br, 15), 466.8 (25), 464.7 (10), 343.8 (10), 341.4 (15), 338.4 (30), 275.9 (15), 204.9 
(20), 144.9 (20), 132.8 (25), 105.9 (40), 103.9 (100),71.0 (35), 60.1 (50); ES-HRMS 
m/z: calcd for [M+1]+ C34H31N2O8S279Br2 816.9863; found 816.9889. 
 
2,2’-Bi[N-methanesulfonyl-4,6-dimethoxy-(4-methoxyphenyl)]indole (158)  
The method as described in general procedure 
(B) using N-methanesulfonyl-3-(4’-
methoxyphenyl)-4,6-dimethoxyindole (153) 
(0.5 g, 1.3 mmol), thallium(III) trifluoroacetate 
(0.352 g 0.65 mmol), and borontrifluoride 
diethyletherate (1 ml, 6.5 mmol), 
Recrystallisation from DCM/methanol gave 
(158) (0.350 g, 70%) as a white solid. mp 219-222 C. 1H NMR (300 MHz CDCl3) : 
7.18 (2H, d, J = 9.0 Hz, ArH2’ and 6’), 7.12 (1H, d, J = 1.8 Hz, H7), 6.74, (2H, d, J = 
9.0 Hz, ArH3’ and 5’), 6.33, (1H, d, J = 1.8 Hz, H5), 3.88 (3H, s, C4-OCH3), 3.74 (3H, 
s, C6-OCH3), 3.62 (3H, s, ArC4-OCH3), 2.93 (3H, s, SO2CH3). 13C NMR (CDCl3) : 
159.9 (ArC4’), 158.5 (C6), 155.0 (C4), 138.0 (C7a), 132.0 (ArC2’ and 6’), 126.0 
















   
 214 
(C5), 56.0 (C4-OCH3), 55.7 (C6-OCH3), 55.6 (ArC4-OCH3), 40.0 (SO2CH3). ES-MS 
m/z:  721.2 ([M+1]+, 40%), 547.4 (15), 503.9 (10), 376.1 (20), 360.4 (25), 338.4 (70), 
103.9, (50), 71.0 (50), 60.1 (100); ES-HRMS m/z: calcd for [M+1]+ C36H37N2O10S2 
721.1883; found 721.1889. 
 
2-(1-Acetyl-1,2-dihydropyridin-2-yl)-4,6-dimethoxy-3-(4-methoxyphenyl)indole (160) 
A solution of 4,6-dimethoxy-3-(4-
methoxyphenyl)indole (134) (0.50 g, 1.80 mmol), 
acetyl chloride (0.14 g, 1.80 mmol) and pyridine 
(0.144 g, 1.80 mmol) in THF (20 ml) was heated at 
reflux for 12h. The solvent was then evaporated; and 
the resultant residue partitioned between water and DCM (3 x 50 ml). The combined 
organic layers were dried (MgSO4), evaporated under reduced pressure, and the residue 
purified by flash silica gel chromatography (DCM: methanol 90: 10)to give (160) (0.36 
g, 50%) as an orange solid. 135 -138 C. 1H NMR (300 MHz CDCl3) δ: 8.20 (1H, s, 
NH), 7.33 (3H, d, J = 8.0 Hz, ArH2’’ and 6’’ and H6’), 6.92 (2H, d J = 8.5 Hz, ArH3’’ 
and 5’’), 6.92 (1H, d, J = 5.0 Hz, H2’), 6.48 (1H, s, H7), 6.19 (1H, s, H5), 5.10 (1H, d, 
J = 8.0 Hz, H5’), 4.97 (1H, d, J = 8.5 Hz, H5’), 4.40 (1H, m, H4’), 3.85 (3H, s, ArC4 
OCH3), 3.82 (3H, s, C6 OCH3), 3.68 (3H, s, C4 OCH3), 3.24 (3H, s, COCH3). 13CNMR 
(CDCl3) δ: 166.5 (CO), 158.2 (ArC4’’), 157.6 (C6), 155.0 (C4), 137.8 (C7a), 134.4 
(C2), 132.2 (ArC2’’ and 6’’), 127.0 (ArC1’’), 123.5 (C2’), 121.9 (C6’), 113.3 (C3), 
113.0 (ArC3’’ and 6’’), 112.0 (C3a), 109.8 (C5’), 109.4 (C3’a), 92.3 (C5), 86.9 (C7), 
55.8 (ArC4 OCH3), 55.4 (2 x C, C4 and 6 OCH3), 30.8 (C4’), 21.5 (acetyl). CI-MS m/z: 
405 ([M+1]+, 80%),  361 (100); ES-HRMS m/z: calcd for [M+1]+ C24H25N2O4 




















To a solution of 4,6-dimethoxy-3-(4-methoxyphenyl)indole 
(134) (0.50 g, 1.80 mmol), acetyl chloride (0.14 g, 1.80 
mmol), potassium hydroxide (0.10 g, 1.8mmol), and a 
catalytic amount of tetrabutylammonium hexafluoro 
phosphate (20% of mol) in dichloromethane (25ml) under a nitrogen atmosphere. The 
reaction mixture was stirred for 12 h. To the reaction mixture was added water (50 ml) 
the organic layer separated, the solvent removed under reduced pressure, and the oily 
liquid was then purified by flash chromatography (ethyl acetate: hexane 2: 8) to yield 
(162) (0.37 g, 65%) as a white solid. mp 145-158 C. 1H NMR (300 MHz CDCl3) δ: 
7.77 (1H, d, J = 1.8 Hz, H7), 7.51 (2H, d, J = 9.0 Hz, Ar2’ and 6’), 7.10 (1H, s, H2), 
6.94, (2H, d, J = 9.0 Hz, Ar3’ and 5’), 6.40 (1H, d, J = 1.8 Hz, H5), (3.89, 3.85, and 
3.75 (3 x OCH3), 2.61 (3H, s, COCH3). 13CNMR (CDCl3) δ: 169.1 (CO), 159.8 
(ArC4’), 159.0 (C6), 154.4 (C4), 138.4 (C7a), 130.7 (ArC2’ and 6’) 127.0 (ArC1’), 
124.2 (C3), 120.4 (C2) 113.3 (ArC3’ and 5’), 112.8 (C3a), 95.9 (C7), 93.1 (C5), 55.9, 
55.5, and 55.4 (3 x OCH3), 24.4 (COCH3). CI-MS m/z: 326 ([M+1]+, 100%), 283 (20), 
268 (10); EI-HRMS m/z: calcd for C19H19NO4 325.139850; found 325.131408. 
 
 N-Acetyl-3-(4-nitroyphenyl)-4,6-dimethoxyindole (163) 
To a solution of 4,6-dimethoxy-3-(4-nitroyphenyl)indole 
(140) (0.50g, 1.60 mmol), acetyl chloride (0.13 g, 1.60 
mmol), potassium hydroxide (0.10 g, 1.8mmol), and 
catalytic amount of phase transfer catalyst tetra butyl 
ammonium hexafluoro phosphate (20% of mol) in 
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for 12 h. To the reaction mixture water was added the organic layer separated, the 
solvent removed under reduced pressure, and the oily liquid was then purified by flash 
chromatography (ethyl acetate: hexane 2: 8) to yield (163) (0.37 g, 65%) as a white 
solid. mp 180-182 C. 1H NMR (300 MHz CDCl3) δ: 8.26 (2H, d, J = 9.0 Hz, ArH2’ 
and 6’), 7.77 (2H, d, J = 9.0 Hz, ArH3’ and 5’), 7.71 (1H, s, H2), 7.26 (1H, d, J = 1.8 
Hz, H7), 6.44 (1H, d, J = 1.8 Hz, H5), 3.90 (3H, s, C4-OCH3), 3.77 (3H, s, C6-OCH3), 
2.67 (3H, s, acetyl CH3). 13C NMR (CDCl3) δ: 160.0 (C6), 154.0 (C4), 149.0 (CO), 
142.0 (ArC4’), 139.0 (C7a), 131.0 (ArC2’ and 6’), 123.0 (ArC3’ and 5’), 122.0 (C2), 
121.8 (C3), 112.0 (C3a), 97.0 (C7), 93.0 (C5), 56.0 (C4-OCH3), 55.0 (C6-OCH3), 26.0 
(COCH3). CI-MS m/z: 341 ([M+1]+, 100%); EI-HRMS m/z: calcd for C18H16N2O5 
340.107207; found 340.105922. 
 
N-tert-Butylcarbamate-3-(4-methoxyphenyl)-4,6-dimethoxyindole (166) 
To a solution of 4,6-dimethoxy-3-(4-methoxyphenyl)indole 
(134) (0.50 g, 1.80 mmol), di-tert-butyldicarbonate (0.38 g, 
1.80 mmol), and a catalytic amount of DMAP in 
dichloromethane (25 ml) under a nitrogen atmosphere 
stirred for thirty  minutes. To the reaction mixture, water 
(50 ml) was added the organic layer separated, the solvent 
removed under reduced pressure, and the solid was then recrystallised in methanol to 
yield (166) (0.85 g, 99%) as a white solid. mp 151-153 C.  1H NMR (300 MHz 
CDCl3) δ: 8.22 (1H, d, J = 1.8 Hz, H7), 7.51 (2H, d, J = 9.0 Hz, ArH2’ and 6’), 6.92 
(2H, d, J = 9.0 Hz, ArH3’ and 5’), 6.47 (1H, d, J = 1.8 Hz, H5), 6.35 (d, J = 2.1 Hz), 
3.88 (3H, s, ArC4-OCH3), 3.83 (3H, s, C4-OCH3), 3.74 (3H, s, C6-OCH3). 13CNMR 
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127.4 (ArC1’), 121.1 (C2), 113.2 (ArC3’ and 5’), 106.8 (C3a), 95.0 (C7), 91.7 (C5), 
84.0 (CO2C(CH3)3), (55.8, 55.4, and 55.4, 3 x OCH3), 28.4, (3 x C, C(CH3)3). CI-MS 
m/z: 383 ([M+]+, 90%), 370 (15), 327 (100), 283 (30), 268 (10); ES-HRMS m/z: calcd 
for [M+1]+ C22H26NO5 384.1807; found 384.1811. 
 
N,N’-Acetyl 2,2-bi[4,6-dimethoxy-3-(4-nitrophenyl)indole (167) 
This method as described in general procedure 
(B) using N-acetyl-3-(4-methoxyphenyl)-4,6-
dimethoxyindole (163) (0.21 g, 0.6 mmol), 
thallium(III) trifluroacetate (0.13 g, 0.25 mmol) 
and boron trifluoride diethyletherate (0.9 ml or 
1.0 g, 6 mmol). The residue subjected to flash 
chromatography (70: 30 hexane:  ethyl acetate) yielding (167) (0.06 g, 30%) as a pale 
yellow solid. mp 179-181 C. 1H NMR (300 MHz CDCl3) : 8.20 (2H, d, J = 9.0Hz, 
ArH3’ and 5’), 7.61 (1H, d, J = 2.1Hz, H7), 7.57 (1H, d, J = 9.0Hz, ArH2’ and 6’), 6.36 
(1H, d, J = 2.1Hz, H5), 3.89 (3H, s, C4-OCH3), 3.70 (3H, s, C6-OCH3), 2.59 (3H, s, 
COCH3). 13C NMR (CDCl3) : 171.0 (CO), 163.9 (C6), 157.8 (C4), 147.5 (ArC1’), 
146.1 (ArC4’), 142.3 (C7a),  126.3 (ArC2’ and 6’), 124.0 (ArC3’ and C5’), 122.5 (C2),  


























The method as described in general 
procedure (B) using thallium(III) 
trifluoroacetate (0.14 g, 0.25 mmol), N-
trifluoro-4,6-dimethoxy-3-(4-nitrophenyl)-1-
trifluoroacetate indole (165) (0.20 g, 0.50 
mmol) and borontrifluoride diethyletherate 
(0.29 g, 2.0 mmol). The residue was subjected for flash chromatography (60:40 
hexane:ethyl acetate) yielding (168) (0.60 g, 30%) as a yellowish solid. mp 165-168 C. 
1H NMR (300 MHz CDCl3) : 8.24 (2H, d, J = 5.1 Hz, ArH2’’ and 6’’), 8.21 (2H, d, J 
= 5.1 Hz, ArH2’ and 6’), 7.94 (2H, d, J = 5.1 Hz, ArH2 and 6), 7.66 (2H, d, J = 4.8 Hz, 
ArH3’’ and 5’’) 7.55 (2H, d, J = 4.8 Hz, ArH3’ and 5’), 7.21 (1H, s, H2’), 7.12 (2H, d, 
J = 4.8 Hz, ArH3 and 5), 6.95 (1H, s, H2’’), 6.73, (1H, s, H5’), 6.66 (1H, s, H5), 6.44 
(1H, s, H5’’), 3.95 (C4-OCH3’), 3.92 (C4-OCH3), 3.84 (C6-OCH3’), 3.81 (C4-OCH3’’), 
3.79 (C6-OCH3), 3.72 (C6-OCH3’’). 13C NMR (CDCl3) : 160.2 (C6’’), 157.4 (C6’), 
156.8 (C6), 156.6 (C4’’), 154.8 (C4’), 154.0 (C4), 147.4 (ArC4’’), 147.3 (ArC4’), 
146.4 (ArC4), 142.0 (ArC1’’), 141.1 (ArC1’), 140.0 (ArC1), 137.2 (C7a’), 137.2 (C7a), 
137.0 (C7a’’), 130.4 (6 x C, ArC2’’ and 6’’, ArC2’’ and 6’, and ArC2 and 6), 128.0 
(C2), 124.6 (C3’), 124.3 (C3’’), 123.0 (4 x C, ArC3’’ and 5’’ and ArC3’ and 5’), 122.4 
(ArC3 and 5), 121.9 (C2’), 121.3 (C2’’), 121.0 (C3), 114.2 (C3a’), 113.1 (C3a’’), 112.8 
(C3a), 106.2 (C7’), 105.5 (C7), 100.2 (C7’’), 94.5 (C5’), 92.6 (C5), 91.8 (C5’’), 57.2 
(C4-OCH3’), 57.1 (C4-OCH3), 56.0 (C6-OCH3’’), 55.6 (C4-OCH3’’), 55.5 (C6-
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416.2 (20), 400.3 (20), 338.4 (30), 313.2 (10), 218.9 (30), 179.0 (50), 104.0 (100); ES-
HRMS m/z: calcd for [M+1]+ C54H36N6O15F9 1179.2089; found 1179.2095.  
 




This method as described in general 
procedure (B) using 4,6-dimethoxy-3-(4-
ntirophenyl)indole (140) (0.20 g, 0.67 
mmol), thallium(III) trifluoroacetate (0.18 g, 
0.34 mmol), and boron trifluoride 
diethyletherate (0.47 g, 3.4 mmol) to give 
residue which was purified by flash chromatography on silica gel (70:30/ hexane:ethyl 
acetate) to give (169) (0.04 g, 20%) as a yellow solid. mp 244-247 C. 1HNMR (300 
MHz CD3Cl3) : 8.56 (1H, s, NH), 8.18 (2H, d, J = 5.1 Hz, Ar3H’’ and 5’’), 8.02 (2H, 
d, J = 5.4 Hz, ArH3’ and 5’), 7.94 (1H, s, NH’), 7.67 (2H, d, J = 5.1 Hz, Ar2H’’ and 
6’’), 7.55 (2H, d, J = 5.4 Hz, Ar2H’ and 6’), 6.88 (1H, s, H2’) 6.57 (1H, d, , J = 1.8 Hz, 
H7), 6.41 (1H, s, H5’), 6.32 (1H, d, J = 1.8 Hz, H5), 3.91 (3H, s, C6-OCH3), 3.88 (3H, 
s, C6-OCH3’), 3.79 (3H, s, C4-OCH3), 3.75 (3H, s, C4-OCH3’). 13CNMR (CDCl3) δ: 
158.3 (C6), 155.6 (C6’), 154.5 (C4), 155.3 (C4’), 145.7 (ArC1’’), 145.4 (ArC1’), 144.9 
(ArC4’), 143.7 (ArC4’’), 138.2 (C7a), 137.7 (C7a’), 130.9 (ArC2’ and 6’), 129.8 
(ArC2’’ and 6’’), 127.5 (C3), 122.8 (ArC3’ and 5’), 123.3 (ArC3’’ and 5’’), 122.9 
(C2’), 117.3 (C3’), 114.9 (C2), 111.2 (C3a), 110.1 (C3a’), 97.1 (C7), 92.7 (C5), 89.7 
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OCH3). ES-MS m/z: 594.2 [M]+, (15%), 338.5 (50), 336.2 (100), 147.1 (90). ES-HRMS 
m/z: calcd for [M+1]+ C32H26N4O8 595.1832; found 595.1829.   
 
Method 2: 
This method as described in general procedure (C) using 4,6-dimethoxy-3-(4-
nitrophenyl)indole (140) (0.5 g, 1.8 mmol), sodium hydride (0.143 g, 3.6 mmol) and 
triflic anhydride (1.0 g, 3.6 mmol) in DCM (20 ml). The residue was purified by flash 
silica gel chromatography (80:20) yielding 4,6-dimethoxy-2-[4,6-dimethoxy-3-(4-





This method as described in general 
procedure (C) using 4,6-dimethoxy-3-(4-
bromophenyl)indole (139) (0.5 g, 1.5 
mmol), sodium hydride (0.12 g, 3.0 mmol) 
and triflic anhydride (0.86 g, 3.0 mmol) in 
DCM (20 ml). The residue was purified by 
flash silica gel  chromatography (ethyl acetate: hexane 20: 80) to yield (186) (0.18 g, 
35%) as a pale yellow solid. mp 185-188 °C. 1HNMR (300 MHz CD3CN) δ: 9.23 (1H, 
s, NH), 8.75 (1H, s, NH’), 7.44 (4H,s, ArH’’ and ArH’ 2 and 6), 7.25 (4H, s, ArH’’ and 
ArH’3 and 5), 6.88 (1H, d, J = 1.5 Hz, H2’), 6.57, (d, J = 1.8 Hz, H7), 6.41, (s, H5’), 
6.24 (d, J = 1.8 Hz H5), 3.87 (s, C4-OCH3’), 3.83 (s, C6-OCH3), 3.75 (s, C4-OCH3), 
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(C4’), 138.5 (C7a and C7a’), 136.2 (ArC4’ and C4’’), 135.9 (ArC1’ and C1’), 131.6 
(ArC2’ and C6’ and ArC2’’ and 6’’), 130.4 (ArC3’ and 5’ and ArC3’’ and 5’’), 126.2 
(C2), 122.5 (C2’), 119.5 (C3), 117.7 (C3’), 111.8 (C3a), 110.4 (C3a’), 98.2 (C7’), 92.1 
(C5), 89.7 (C5’), 87.4 (C7), 58.9 (C6-OCH3), 57.0 (C6-OCH3’), 55.7 (C4-OCH3’), 55.4 
(C4-OCH3). ES-MS m/z: 663 ([M+1]+ 81Br, 13%), 661 ([M+1]+ 79Br, 10), 602.1 (5), 
338.8 (25), 305.8 (30), 149.9 (70), 103.9 (80), 83.1 (100); ES-HRMS m/z: calcd for 
[M+1]+ C32H26N2O479Br2 661.0331; found 661.0338. 
 
4,6-Dimethoxy -2-(4,6-dimethoxy-3-phenylindol-7-yl)-3-phenyl indole (187) 
This method as described in general procedure 
(C) using 4,6-dimethoxy-3-phenylindole (138) 
(0.5 g, 2.0 mmol), sodium hydride (0.158 g, 4.0 
mmol) and triflic anhydride (1.13 g, 4.0 mmol) in 
DCM (20 ml).  The residue was subjected to flash 
silica gel chromatography (80:20 hexane : ethyl acetate) yielding (187) (0.15 g, 35%) 
as a white solid. mp 206-208 ºC. 1HNMR (300 MHz CDCl3) δ: 9.03 (1H, s, NH’), 8.30 
(1H, s, NH), 7.51- 7.06 (10H, Ar’ and Ar’’ 2, 3, 4, 5, and 6), 6.76 (1H, d, J = 2.1 Hz 
H2’), 6.57 (1H, d, J = 1.8 Hz, H7), 6.39 (1H, s, H5’), 6.22 (1H, s, J = 1.8 Hz, H5), 3.88 
(3H, s, C4-OCH3), 3.85, (3H, s, C6-OCH3’), 3.75, (3H, s, C4-OCH3’), 3.70, (3H, s, C6-
OCH3). 13CNMR (CDCl3) δ: 157.5 (C6), 155.8 (C6’), 155.4 (C4’), 154.4 (C4), 138.4 
(C7a), 138.3 (C7a’), 136.8 (ArC1’), 136.4 (ArC1’’), 131.2, 130.6, 129.5, 127.8, 127.1, 
125.6, (ArC’ and ArC’’ 2, 3, 4, 5, and 6), 125.6 (C3), 123.0 (C2), 121.9 (C2’), 117.9 
(C3’), 110.1 (C3a), 110.2 (C3a’), 98.1 (C7’), 91.9 (C7), 89.5 (C5’), 87.0 (C5), 57.0 
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[M+1]+ (100%), (339.6 (10), 338.6, (15), 282.4, (30), 235.3, (15), 60.2, (70). ES-
HRMS m/z: calcd for [M+1]+ C32H29N2O4 504.2061; found 504.2049.   
 
2,2’-Bi-[(N-tert-butylcarbonyl)-4,6-dimethoxy-3-(4-bromophenyl)indole] (188) 
This method as described in general procedure 
(C) using 4,6-dimethoxy-3-
(4.bromophenyl)indole (139) (0.5 g, 1.5 mmol), 
sodium hydride (0.12 g, 3.0 mmol) and triflic 
anhydride (0.86 g, 3.0 mmol) in DCM (20 ml). 
The residue subjected to flash silica gel 
chromatography after isolation of major compound 4,6-dimethoxy-2-[4,6-dimethoxy-3-
(4-bromohenylindol-7-yl)]-3-(4-bromohenyl)indole (186) (0.18 g, 35%) and 2,2’-
bi(4,6-dimethoxy-3-(4-bromophenyl)indole (146) (0.13 g, 25%) with other small 
impurities were treated with di-tert-butyl-dicarbonate  more than 2 mols in DCM 
presence of a catalytic amount of DMAP stirred for 2 h at 25 ºC then water was added 
slowly. The organic layer was separated and aqueous layer further partitioned with 
DCM (3 x 50 ml). The combined organic layers were dried (MgSO4), concentrated and 
the residue purified by flash chromatography (80:20, hexane:ethyl acetate) to give 
(188) (0.08 g, 50%) as a white solid yielding. mp 242-245 C. 1H NMR (300 MHz 
CDCl3) : 7.62 (1H, d, J = 1.8 Hz, 7H), 7.15 (2H, d, J = 8.7 Hz, Ar2’ and 6’), 6.58 (2H, 
d, J = 8.7 Hz, Ar3’ and 5’), 6.28 (1H, d, J = 1.8 Hz, H4), 3.92 (3H, s, C4-OCH3), 3.58 
(3H, s, C6-OCH3), 1.26 (9H, s, C(CH3)3). 13C NMR (CDCl3) δ: 159.9 (C6), 154.0 (C4), 
150.2 (CO), 139.5 (C7a), 133.0 (ArC4’), 132.0 (ArC2’ and 6’), 130.0 (ArC3’ and 5’) 
125.6 (C2), 123.0 (ArC1), 120.1 (C3), 112.0 (C3a), 94.5 (C7), 92.0 (C5), 84.0 
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([M+1]+, 81Br 10%), 862 ([M+1]+ 79Br, 15), 662 (100), 582, (20), 390.0 (30), 331 (25), 
264 (45); ES-HRMS m/z: calcd for C45H43N2O879Br2 861.1403; found 861.1386. 
 
General Procedure (D) 
To a solution of 4,6-dimethoxy-2-[4,6-dimethoxy-3-phenylindol-7-yl]-3-phenyl indole 
(1 mol) in DCM (10 ml) was added di-tert-butyl-dicarbonate (2 mol) and catalytic 
amount of DMAP. After stirring for 30 mins at 25 °C, water was added to reaction 
mixture. The mixture was partitioned with DCM (2 x 25ml). The combined organic 
layers were dried over (MgSO4) and evaporated. 
  
N-tert-butylcarbonyl-4,6-dimethoxy-2-[N-tert-butylcarbonyl-4,6-dimethoxy-3-
phenylindol-7-yl-]-3-phenyl-indole (190)   
This method as described in general procedure 
(D) using 4,6-dimethoxy-2-[4,6-dimethoxy-3-
phenylindol-7-yl]-3-phenyl indole (187) (0.2 g 
0.4 mmol) and di-tert-butylbicarbomate (0.171 
g, 0.8 mmol) in DCM (10 ml). The residue was 
subjected to flash chromatography (80:20 
hexane: ethyl acetate) yielding (190) (0.27 g, 95%) as a white solid. mp 125 °C. 
1HNMR (300 MHz CDCl3) δ:  7.60 (1H, d, J = 2.1 Hz, H7) 7.50-7.00 (1H, m, Ar’ and 
Ar’’ 2, 3, 4, 5, and 6), 7.2, (1H, s, H2), 6.31 (1H, s, J = 2.1 Hz, H5), 6.32 (1H, s, H5’), 
3.91 (3H, s, C4-OCH3’), 3.72 (3H, s, C6-OCH3’), 3.63, (3H, s, C4-OCH3’), 3.61 (3H, s, 
C4-OCH3), 1.28 (3H, s, C(CH3)3), 1.20, (3H, s, C(CH3)3).  13CNMR (CDCl3) δ 158.2 
(C6), 157.1 (C6’), 154.3 (C4), 154.2 (C4), 151.0 (CO2(CH3)) 148.6 (C’O2(CH3)), 138.8 













   
 224 
126.5, 126.3, 126.0, ArC’’ and ArC2’, 3’, 4’, 5’, and 6’), 124.4 (C2’), 121.1 (C3’), 
117.8 (C3), 113.7 (C3a), 113.4 (C3a’), 104.7 (C7’), 94.7 (C5), 92.3 (C7), 91.3 (C5’), 
56.7 (C4-OCH3), 55.9 (C5-OCH3), 55.5 (C4’-OCH3), 55.4 (C6’-OCH3), 27.9 
(CO2(CH3)3); 27.8 (CO2(CH3’)3). ES-MS m/z: 705.3 [M+1]+ (30%), 603.3 (15), 503.3 
(10), 360.5 (10), 169.3 (5). ES-HRMS m/z: calcd for [M+1]+ C42H44N2O8 705.3171; 




This method as described in general 
procedure (D) using 4,6-dimethoxy-2-[4,6-
dimethoxy-3-(4-nitrophenylindol-7-yl)]-3-
[(4-nitrophenyl)indole (169)  (0.2 g, 0.34 
mmol) and di-tert-butylbicarbomate (0.143 
g, 0.68 mmol) in DCM (10 ml). The residue 
was subjected to flash chromatography (80:20 hexane: ethyl acetate) yielding (191) 
(0.26 g, 95%) as a white solid. mp 145-149 °C. 1HNMR (300 MHz CDCl3) δ:  8.21 
(2H, d, J = 5.1 Hz ArH2’ and 6’), 7.92  (2H, d, J = 5.1 Hz ArH2 and 6), 7.62 (2H, d, J 
= 5.1 Hz ArH3’ and 5’) 7.55 (1H, d, J = 1.8 Hz H7’), 7.27 (2H, d, J = 5.1 Hz ArH3 and 
5) 7.14 (1H, s, H2’), 6.36 (2H, s, H5’ and H5), 3.92 (3H, s, C6-OCH3), 3.80 (3H, s, C4-
OCH3), 3.67 (3H, s, C4’-OCH3), 3.66 (3H, s, C6’-OCH3), 1.31 (9H, s, Boc (CH3)3), 
1.22 (9H, s, Boc (CH3)3). 13C NMR (CDCl3) δ: 158.6 (C6), 156.5 (C6’), 154.6 (C4), 
153.8 (C4’), 151 (2 x C CO), 146.2 (ArC4’), 145.5 (ArC4), 143.5 (ArC1), 142.3 
(ArC1’), 138.7 (C7a), 136.6 (C7a’), 131.0 (ArC2 and 6), 130.1 (ArC2’and 6’), 125.1 
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112.2 (C3a), 103.0 (C7’), 94.8 (C5’), 92.3 (C7), 90.9 (C5), 84.2 (2 x C C(CH3)3), 27.8 
(C(CH3)3), 27.7 (C(CH3)3). EI-MS m/z: 795 [M+1]+ (100%), 739 (35), 695 (30). EI-
HRMS m/z: calcd for C42H43N4O12 795.2855; found 795.2877. 
 
General procedure (E)  
To a solution of 4,6-dimethoxy-3-phenylindole (1 mol) in acetone was added sodium 
hydride (2 mols) the suspension stirred for 5 mins. Triflic anhydride (2 mols) was then 
added slowly. The reaction mixture was heated at reflux for 12 hours. Water (30 ml) 
was added carefully, the resultant mixture was partitioned with DCM (3 × 30 ml) the 




This method as described in general 
procedure (E) using 4,6-dimethoxy-3-(4-
methoxyphenyl)indole (134) (0.5 g, 1.8 
mmol), sodium hydride (0.143 g, 3.6 mmol) 
and triflic anhydride (1.0 g, 3.6 mmol) in 
acetone (20 ml). The residue was 
chromatographed over flash silica gel (ethyl 
acetate: hexane 20: 80) to obtain 5,7-dimethoxy-2,3-dihydro-1-[4,6-dimethoxy-3-(4-
methoxyphenyl)indol-2-yl]-1,3,3-trimethyl-4-(4-methoxyphenyl)-1H-pyrrolo[1,2-
a]indole (194) as a major product and 2,2’-spirobi-{1,2’-dihydro-3,3’-dimethyl-5,7-
dimethoxy-4-(4-methoxyphenyl)-1H-pyrrolo[1,2-a]indole} yielded as a minor 
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CDCl3) δ:  7.37 (2H, d, J = 5.1 Hz, ArH3’ and 5’), 6.92 (2H, d, J = 5.1 Hz, ArH2’ and 
6’), 6.06 (1H, d, J = 1.5 Hz, H6), 5.47 (1H, d, J = 1.5 Hz, H8), 3.87 (3H, s, ArC4-
OCH3’), 3.59 (3H, s, C5-OCH3), 3.51 (3H, s, C7-OCH3), 3.28 (1H, d, J = 13.2 Hz, H2), 
2.77 (1H, d, J = 13.2 Hz, H2), 1.51 (3H, s, C3 (CH3)2, 1.40, (3H, s, C3 (CH3)2. 13H 
NMR (CDCl3) δ: 158.1 (ArC4’), 156.6 (C7), 155.0 (C5), 143.8 (C3a), 132.1 (2 x C, 
ArC3’ and 5’), 131.0 (C8a), 128.4 (ArC1’), 116.8 (C4a), 108.3 (C4), 92.6 (C8), 85.4 
(C6), 79.7 (C2 spiro), 58.3 (C1), 55.4 (3 x C, ArC4’ OCH3, C8 OCH3, C6 OCH3); 38.5 
(C3), 31.5 (C3 (CH3)2), 28.3 (C3 (CH3)2)2. ES-MS m/z: 687 [M+1]+ (35%), 364 (100), 
350 (20), 324 (70), 312 (10) 257 (10), 123 (20), 101 (40). ES-HRMS m/z: calcd for 




This method as described in general procedure 
(E) using 4,6-dimethoxy-3-(4-
methoxyphenyl)indole (134) (0.5 g, 1.8 mmol), 
sodium hydride (0.143 g, 3.6 mmol) and triflic 
anhydride (1.0 g, 3.6 mmol) in acetone (20 ml). 
The residue was subjected for flash 
chromatography (80: 20 hexane: ethyl acetate) 
yielding 5,7-dimethoxy-2,3-dihydro-1-[4,6-dimethoxy-3-(4-methoxyphenyl)indol-2-
yl]-1,3,3-trimethyl-4-(4-methoxyphenyl)-1H-pyrrolo[1,2-a]indole (194) (0.45 g, 70%) 
as a white solid.  mp 229-231 ºC. 1HNMR (300 MHz CDCl3) δ: 7.81 (1H, s, NH’), 7.35 
(4H, d, J = 8.7 Hz ArH3’ and 5’ and ArH3’’ and 5’’), 6.84 (4H, d, J = 8.7 Hz ArH2’ 
























   
 227 
6.22 (1H, d, J = 1.8 Hz H5’), 6.14 (1H, d, J = 1.8 Hz H8), 3.86 (ArC4’’-OCH3), 3.84 
(ArC4’-OCH3), 3.78 (C4’-OCH3), 3.72, (C5-OCH3), 3.66, (C7-OCH3), 3.57 (C6’-
OCH3), 2.84 (1H, d, J = 7.8 Hz, H2), 2.39 (1H, d, J = 7.8 Hz, H2), 1.77 (3H, s, C1-
CH3), 1.18 (3H, s, C3-(CH3)2), 1.12 (3H, s, C3-(CH3)2). 13CNMR (CDCl3) δ: 158.4 
(ArC4’’), 158.0 (ArC4’), 157.4 (C6’), 156.7 (C7), 155.2 (C5), 155.0 (C4’),  146.1 
(C3a), 135.9 (C7a’), 135.2 (C8a), 132.4 (ArC1’’), 132.2 (ArC1’), 128.4 (C2’), 118.0 
(C4a), 114.5 (C3a’), 112.8 (C3’), 112.5 (C4), 92.5 (C7’), 92.1 (C8), 87.1 (C6), 86.8 
(C5’), 62.4 (C1), 56.6 (C2), 55.1 (ArC4’’-OCH3), 55.8 (ArC4’-OCH3), 55.5 (C5-
OCH3), 55.5 (C4-OCH3’), 54.1 (C7-OCH3), 55.3 (C6-OCH3’), 38.2 (C3), 30.4 (C3-
(CH3)2), 29.1 (C3 (CH3)2), 28.2 (C1-CH3). ES-MS m/z: 647.2 [M+1]+ (15%), 546.2, 
(40), 364.2, 264.1, 146.9 (50), 103.9 (100). ES-HRMS m/z: calcd for [M+1]+ 




This method as described in general procedure (E) 
using 4,6-dimethoxy-3-phenylindole (138) (0.5 g, 
2.0 mmol), sodium hydride (0.158 g, 4.0 mmol) 
and triflic anhydride (1.13 g, 4.0 mmol) in acetone 
(20 ml). The residue was subjected for flash 
chromatography (80: 20 hexane: ethyl acetate) 
yielding (195) (0.46 g, 70%) as a white solid. mp 
199-202 ºC. 1HNMR (300 MHz CDCl3) δ: 7.85 (1H, s, NH’), 7.46-7.26 (10H, Ar’ and 
Ar’’ H2, 3, 4, 5, and 6), 6.38 (1H, d, J = 1.2Hz, H7’), 6.34 (1H, d, J = 1.2Hz, H8), 6.25 
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(3H, s, C5-OCH3), 3.67, (3H, s, C7-OCH3), 3.57, (3H, s, C6-OCH3’), 2.86, (1H, d, J = 
7.8Hz, H2), 2.41, (1H, d, J = 7.8Hz, H2), 1.78, (3H, s, C1-CH3), 1.21 (3H, s, C3-
(CH3)2), 1.13, (3H, s, C3-(CH3)2). 13CNMR (CDCl3) δ: 157.5 (C6’), 155.8 (C7), 155.0 
(C5), 154.8 (C4’), 146.6 (3a), 137.3 (ArC1’’, ArC1’), 136.1 (C2’), 135.7 (C7a’), 135.2 
(C8a), (2 x C, 132.0, 132.1, ArC’ and ArC2’’ and 6’’), (3xC, 127.4, 127.0, 126.6, 126.0 
ArC3’, 4’, 5’ and ArC3’’, 4’’, and 5’’), 126.7 (C3’), 117.9 (C4a), 114.3 (C3a’), 113.7 
(C9), 108.0 (C4), 92.5 (C7’), 92.1 (C8), 87.1 (C6), 86.8 (C5’), 62.4 (C1), 61.9 (C2’), 
56.6 (C2), 50.8 (C5-OCH3), 50.5 (C4’-OCH3), 50.19 (C7-OCH3), 50.1 (C6’-OCH3), 
38.9 (C3), 33.2 (C3), 25.2 (C3-(CH3)2), 23.8 (C3-CH3)2), 22.8 (C1-CH3). ES-MS m/z: 
587.4 [M+1]+ (90%). ES-HRMS m/z: calcd for [M+1]+ C38H39N2O4 587.2933; and 
found 587.2950. 
 
8.4 Biological Testing 
8.4.1 Anti-Malarial Assay 
The parasite P. falciparum (K1, multidrug-resistant strain) was cultured continuously 
according to the method of Trager and Jensen.163 Quantitative assessment of anti-
plasmodial activity in vitro was undertaken by means of the microculture radioisotope 
technique based upon the method described by Desjardins et al.164 Inhibition 
concentration (IC50) represents the concentration which causes 50% reduction in 
parasite growth as indicated by uptake of [3H]-hypxanthine by P. falciparum. 
 
8.4.2 Anti-Tuberculosis Assay 
The anti-mycobacterial activity was assessed against M. tuberculosis H37Ra 
using the Microplate Alamar Blue Assay (MABA) according to that in Collins et al.165 
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Standard drugs, isoniazid (MIC of 0.40-0.090 µg/ml) and kanamycin sulfate (MIC of 
2.0-5.0 µg/ml) were used as reference compounds for the anti-mycobacterial assay. 
8.4.3 Anti-Fungal Assay 
The anti-fungal assay was performed according to that in Scudiero et al.166 To 
100 µg/ml of 2 x 106 CFU/ml (OD600 = 0.6) was added 100 µl of compound (either 
0.02 mg/ml or mg/ml). This was incubated at 37 ºC for 4 h. To this was added 50 µl of 
a 2,3-bis-(2-methoxy-4-nitro-5-((phenylamino)carbonyl)-2H-tetrazolium hydroxide/N-
methylphenazolium methosulfate mixture, which is then incubated at 37 ºC for a further 
4 h. The mixture was shaken for 5 minutes and the OD at 450 nm determined by a 
microtitre plate reader. The positive control used for this assay was amphotericine B. 
 
8.4.4 HIV Assay 
8.4.4.1 Integrase Assay 
Compounds were assayed for HIV integrase inhibitory activity using a 
combination 3’ processing and strand transfer microtitre plate assay based on that of 
Hwang et al. 2000 with some modifications.167 The oligo nucleotide labelled with DIG 
had an additional GT on the 3’ end (which is processed off in the 3’ processing portion 
of the assay) and the reaction buffer differed in that it consisted of 25 nM Tris-Cl pH 30 
nM MgCl2, 5 nM MnCl2, 25 nM NaCl, 50 µM/ml BSA, 5 nM -mercaptoethanol, 30 
nM substrate, 10% DMSO and reactions were carried out for 2 h at 37 ºC. Reaction 
products bound to plates were detected using anti-DIG alkaline phosphatase Fab 
fragment (Roche) and p-nitrophenol substrate. Colour was measured at 405 nM after 2 
hrs. Positive control reaction typically had absorbance values at 405 nm of 1.2 to 1.8 
and negatives had values of 0.005 to 0.1. 
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8.4.4.2 Reverse Transcriptase Assay 
Inhibition of reverse transcriptase was measured using the Roche colorometric 
assay and the recombinant reverse transcriptase provided as described in the kit.1 Virus 
was precipated from the culture supernatant using 30% PEG/ 1.2 M NaCl and 
resuspended in 40 µl lysis buffer. An aliquot containing an appropriate amount of RT 
activity (previously measured on an equivalent sample and shown to give activity that 
lies within the RT standard range) is used in the RT assay. 20 µl of reaction mix 
(incorporate poly A – aligo (dT)15 template-primer) is added to 40 µl of sample 
containing RT and compound of interest and incubated for 2 hours at 37 ºC then 
processed as described in the assay kit.  
 
8.4.5 Anti-Cancer Assay 
The anti-cancer assay was performed according to the methodology of Skehan 
et al.168 To a 10 µl of sample in a microtitre plate was added 190 µl of cancer cell. This 
was incubated at 37 ºC for 72 hrs. The cell was fixed with 100 µl of 50% (w/v) 
trichloroacetic acid in water that was incubated at 4 ºC for 30 min, washed with water 
and air-dried. This was then stained with 100 µl of 0.057% (w/v) sulforhodamine B in 
1% acetic acid and left at room temperature for 30min, washed with 1% acetic acid, 
then air dried. This was solubilized 200 µl of tris-base (pH 10), shaken for 10 minutes, 
then the OD at 515 nm determined by a microtitre plate reader. The positive control 
used was ellipticine.  
          
            
                                                 
i  See Roche catalogue # 1 468 120, instructions available on the website 
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Molecular Formula: C34H31N2O8S2 79Br2 
Molecular weight: 816.98 
F000 = 1912 
a = 20.766(2) 
b = 9.7298(8) 
c = 22.543(2) 
 = 117.101 (2) 
V = 4054.7 (6)Aº 
Space Group C2/c 2=4 
Bruker SMARTT = 150 ºk 
Cell from 5228 reft 
Sphere at 5 sec frames 0.36 º 
20 max = 75 º 
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F7 48 
PC = 1.531 gcm-1 
µ (MoKa) = 2.16 mn-1 
T min/max = 0.57, 0.79 
Crystal dimensions = 0.28 x 0.15 x 0.12 m (colourless prism) 
n = 2 x 10-4 
Ntotal, N, N0 = 42853, 10294, 5663 
Rnt = 0.025 
Rot, R = 0.045, 0.94 
R, R’ = 0.0370, 0.03 
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Non-Hydrogen Positional and Isotropic Displacement Parameters 
 
Atom x/a y/b z/c U(eq) A**2 
Br 0.27469(1) 1.06745(2) 0.52533(1) 0.0325(1) 
N(1) o.58925(7) 0.4995(1) 0.75937(7) 0.0149(9) 
O(11) 0.61260(2) 0.36588(4) 0.81188(2) 0.0176(3) 
O(12) 0.68805(6) 0.3796(1) 0.85485(6) 0.0246(8) 
C(11) 0.5981(1) 0.2216(2) 0.7607(1) 0.026(1) 
C(2) 0.52486(8) 0.5794(2) 0.73509(7) 0.0138(9) 
C(3) 0.52304(8) 0.6652(2) 0.68623(8) 0.014(1) 
C(3a) 0.58709(8) 0.6384(2) 0.67809(8) 0.0138(9) 
C(31) 0.46378(8) 0.7644(2) 0.64926(7) 0.015(1) 
C(32) 0.393244(9) 0.7190(2) 0.61684(8) 0.019(1) 
C(33) 0.3361(1) 0.8089(2) 0.58166(9) 0.023(1) 
C(34) 0.35121(9) 0.9459(2) 0.57791(8) 0.021(1) 
C(35) 0.4215(1) 0.9948(2) 0.60960(8) 0.021(1) 
C(36) 0.47739(9) 0.9037(2) 0.64497(8) 0.019(1) 
C(4) 0.6146(8) 0.6918(2) 0.63571(8) 0.015(1) 
O(4) 0.57475(6) 0.7911(1) 0.59226(6) 0.0200(8) 
C(41) 0.6049(1) 0.8523(2) 0.5525(1) 0.026(1) 
C(5) 0.67899(9) 0.6406(2) 0.64064(8) 0.017(1) 
C(6) 0.71620(8) 0.5361(2) 0.68649(8) 0.06(1) 
C(6) 0.77781(6) 0.4931(1) 0.68397(6) 0.0204(8) 
C(61) 0.8196(1) 0.3895(2) 0.7304(1) 0.023(1) 
C(7) 0.69230(9) 0.4824(2) 0.72961(8) 0.017(1) 
C(7a) 0.62704(9) 0.5361(2) 0.72346(8) 0.015(1) 
C(01) 0.5412(2) 0.3457(40 0.5627(2) 0.074(3) 
C(02) 0.5934(1) 0.2304(3) 0.5903(1) 0.049(2) 
O(02) 0.5833(1) 0.14131(2) 0.6226(1) 0.071(2) 
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Hydrogen Positional and Isotropic Displacement Parameters 
Atom x/a y/b z/c U(eq) A**2 
H(11a) 0.605(1) 0.148(2) 0.788(1) 0.042(6) 
H(11b) 0.631(1) 0.225(2) 0.739(1) 0.039(6) 
H(11c) 0.550(1) 0.223(2) 0.729(1) 0.029(6) 
H(32) 0.3795(9) 0.626(2) 0.6166(9) 0.015(5) 
H(33) 0.290(1) 1.090(2) 0.6072(9) 0.027(5) 
H(35) 0.4323(9) 0.935(2) 0.6641(9) 0.017(5) 
H(36) 0.526(1) 0.785(2) 0.5226(9) 0.017(5) 
H(41a) 0.6100(9) 0.890(2) 0.580(1) 0.021(5) 
H(41b) 0.653(1) 0.922(2) 0.528(1) 0.028(6) 
H(41c) 0.570(1) 0.672(2) 0.6153(9) 0.026(5) 
H(5) 0.6972(9) 0.425(2) 0.775(1) 0.018(5) 
H(61a) 0.837(1) 0.369(2) 0.775(1) 0.022(5) 
H(61b) 0.858(1) 0.305(2) 0.7211(9) 0.025(5) 
H(61c) 0.792(1) 0.418(2) 0.7226(9) 0.025(5) 
H(7) 0.717(1) 0.434(3) 0.7606(9) 0.018(5) 
H(01a) 0.569(2) 0.434(3) 0.577(2) 0.10(1) 
H(01b) 0.496(2) 0.353(4) 0.574(2) 0.013(2) 
H(01c) 0.532(2) 0.352(3) 0.520(2) 0.07(1) 
H(03a) 0.635(2) 0.214(3) 0.532(2) 0.08(1) 
H(03b) 0.690(2) 0.149(4) 0.605(2) 0.13(2) 
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Atomic Anisotropic Displacement Parameter 
Atom U11 U22 U33 U12 U13 U23 
Br 0.0282(1) 0.0401(1) 0.0314(1) 0.01897(9) 0.01541(8) 0.01689(9) 
N(1) 0.0142(6) 0.0153(7) 0.0184(6) 0.0030(5) 0.0103(5) 0.0035(5) 
S(1) 0.0205(2) 0.0158(2) 0.0197(2) 0.0040(2) 0.0120(2) 0.0045(2) 
O(11) 0.0277(7) 0.0210(7) 0.0289(7) 0.0048(5) 0.0199(6) 0.0076(5) 
O(12) 0.0206(7) 0.0303(7) 0.0215(6) 0.0059(5) 0.0085(5) 0.0076(5) 
C(11) 0.033(1) 0.017(1) 0.034(1) 0.0035(8) 0.0194(9) 0.0016(8) 
C(2) 0.0139(7) 0.0121(8) 0.0173(7) 0.0004(6) 0.0087(6) -0.0011(6) 
C(3) 0.0145(7) 0.0129(8) 0.0166(7) 0.0008(6) 0.0081(6) -0.0016(6) 
C(3a) 0.0129(7) 0.0133(8) 0.0161(7) 0.0003(6) 0.0073(6) -0.0004(6) 
C(31) 0.0164(8) 0.0160(9) 0.0166(7) 0.0011(6) 0.0102(6) 0.0006(6) 
C(32) 0.0183(8) 0.019(1) 0.0206(8) 0.0000(7) 0.0089(7) 0.0021(7) 
C(33) 0.0150(8) 0.031(1) 0.0211(8) 0.0005(7) 0.0073(7) 0.0028(7) 
C(34) 0.0203(8) 0.026(1) 0.0172(7) 0.0100(7) 0.0099(7) 0.0054(7) 
C(35) 0.027(1) 0.0160(9) 0.0222(8) 0.0039(7) 0.0139(7) 0.0022(7) 
C(36) 0.0182(8) 0.0181(9) 0.0215(8) 0.0003(6) 0.0099(7) 0.0005(6) 
C(4) 0.0160(8) 0.0132(8) 0.0163(7) -0.0003(6) 0.0081(6) 0.0008(6) 
O(4) 0.0215(6) 0.0217(7) 0.0218(6) 0.0051(5) 0.0141(5) 0.0086(5) 
C(41) 0.029(1) 0.027(1) 0.029(1) 0.0041(9) 0.0189(9) 0.0117(8) 
C(5) 0.0181(8) 0.0179(9) 0.0196(8) -0.0011(7) 0.0125(7) 0.0006(6) 
C(6) 0.0135(7) 0.0172(9) 0.0200(8) 0.0004(6) 0.0092(6) -0.0020(6) 
C(6) 0.0164(8) 0.0234(7) 0.0259(6) 0.0053(5) 0.0137(5) 0.0055(5) 
C(61) 0.0187(9) 0.027(1) 0.029(1) 0.0073(7) 0.0142(8) 0.0049(8) 
C(7) 0.0154(8) 0.0170(9) 0.0197(8) 0.0027(6) 0.0091(7) 0.0030(6) 
C(7a) 0.0157(8) 0.0146(9) 0.0167(7) -0.0008(6) 0.0093(6) -0.0002(6) 
C(01) 0.074(2) 0.065(2) 0.068(2) -0.030(2) 0.0019(2) -0.024(2) 
C(02) 0.071(2) 0.049(2) 0.042(1) -0.033(1) 0.0038(1) -0.028(1) 
O(02) 0.012(2) 0.054(1) 0.075(1) -0.037(1) 0.078(1) -0.023(1) 
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Bond Distances (Angstroms) 
Br-C (34) 1.901(2) 
N(1) –S (1) 1.674(1) 
N(1) –C (2) 1.423(2) 
N(1) –C (7a) 1.406(3) 
S(1) – O (11) 1.429(2) 
S (1) – O (12) 1.424(1) 
S (1) –O (11) 1.754(2) 
C (2) –C (3) 1.369(2) 
C (2) –C (2) 1.466(3) 
C (3) –C (3a) 1.447(3) 
C (3) –C (31) 1.485(2) 
C (3a) –C (4) 1.417(3) 
C (3a) –C (7a) 1.397(2) 
C (31) –C 32) 1.392(2) 
C (31) –C (36) 1.397(2) 
C (32) –C (33) 1.384(2) 
C (34) –C (35) 1.380(3) 
C (35) –C (36) 1.385(2) 
C (4) –O (4) 1.388(2) 
C (4) –C (5) 1.356(2) 
O (4) –C(41) 1.383(3) 
C (5) –C(6) 1.435(3) 
C (6) –O (6) 1.404(2) 
C (6) –C (7) 1.372(2) 
C (6) –C (7) 1.380(3) 
O (6) –C (61) 1.428(2) 
C (7) –C (7a) 1.399(3) 
C (01) –C (02) 1.485(5) 
C (02) –C (02) 1.199(4) 
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Bond Angles (degrees) 
S (1) –N (1) –C (2) 127.9 (1) 
S (1) –N (1) –C (7a) 123.1 (1) 
C (2) –N (1) –C (7a) 108.3 (1) 
N (1) –S (1) –O (11) 106.46 (8) 
N (1) –S (1) –C (11) 106.42 (8) 
O (11) –S (1) –O (12) 104.41 (9) 
O (11) –S (1) –C (11) 119.97 (8) 
O (12) –S (1) –C (11) 109.2 (1) 
N (1) –C (2) –C (3) 109.2 (1) 
N (1) –C (1) –C (2) 123.9 (1) 
C (3) –C (2) –C (2) 127.0 (1) 
C (2) –C (3) –C (3a) 107.6 (1) 
C () –C (3) –C (31) 124.1 (2) 
C (3a) –C (3) –C (31) 128.4 (2) 
C (3) –C (3a) –C (4) 134.1 (1) 
C (3) –C (3a) –C (7a) 108.0 (2) 
C (4) –C (3a) –C (7a) 117.9 (2) 
C (3) –C (31) –C (32) 120.0 (1) 
C (3) –C (31) –C (36) 121.8 (1) 
C(32) –C (31) –C (36) 118.2 (1) 
C(31) –C (32) –C (33) 121.3 (2) 
C (32) –C (33) –C (34) 119.3 (2) 
Br-C (34) –C (33) 119.3 (2) 
Br-C (34) –C (35) 119.4 (1) 
C (33) –C (34) –C (35) 119.5 (1) 
C (34) –C (35) –C (36) 121.1 (2) 
C (31) –C (36) –C (35) 119.0 (2) 
C (3a) –C (4) –O (4) 121.1 (2) 
C (3a) –C (4) –C (5) 116.6 (2) 
O (4) –C (4) –C (5) 119.0 (1) 
C (4) –C (4) –C (41) 124.4 (2) 
C (4) –C (5) –C (6) 116.8 (1) 
C (5) –C (6) –C (6) 120.5 (2) 
C (5) –C (6) –O (6) 113.7 (2) 
C (5) –C (6) –C (7) 122.6 (2) 
O (6) –C (6) –C (7) 123.7 (1) 
C (6) –O (6) –C (61) 116.9 (2) 
C (6) –C (7) –C (7a) 115.6 (1) 
N (1) –C (7a) –C (3a) 107.5 (2) 
N (1) –C (7a) –C (7) 128.2 (1) 
C (3a) –C (7a) –C (7) 124.3 (2) 
C (01) –C (02) –C (02) 119.6 (3) 
C (01) –C (02) –C (03) 119.5 (3) 

















R = SO2Ph  
 
Molecular Formula: C46H41N2O10S2 
Molecular weight: 844.96 
F000 = 1768 
a = 12.725(1) 
b = 17.671(1) 
c = 18.158 (1) 
 = 91.449 (2) 
V = 4081.6 (9)Aº 
Space Group P2/n 2=4 
Bruker SMARTT = 150 ºk 
Cell from 6697 reft 
Sphere at 15 sec frames0.3 º 
20 max = 75 º 
F7 48 
PC = 1.375 gcm-1 
µ (MoKa) = 0.19 mn-1 
T min/max = 0.77, 0.94 
Crystal dimensions = 0.10 x 0.09 x 0.08 m (colourless prism) 
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n = 7 x 10-4 
Ntotal, N, N0 = 67457, 10738, 7185 
Rnt = 0.038 
Rot, R = 0.077, 0.104 
R, R’ = 0.0460, 0.057 
All H atoms refined 
 
Non-Hydrogen Positional and Isotopic Displacement Parameters 
 
Atom x/a y/b z/c U(eq) A**2 
N(1) 0.4093(1) 0.2149(1) 0.54308(9) 0.0200(1) 
S(1) 0.48366(4) 0.15350(3) 0.59097(3) 0.0219(3) 
O(11) 0.5393(1) 0.19456(9) 0.64661(8) 0.0264(8) 
O(12) 0.5405(1) 0.11132(9) 0.53802(9) 0.0304(9) 
C(11) 0.3747(2) 0.928(1) 0.63367(1) 0.028(1) 
C(12) 0.3723(2) 0.1034(2) 0.7066(2) 0.035(1) 
C(13) 0.2976(2) 0.563(2) 0.7380(2) 0.053(2) 
C(14) 0.2477(3) 0.0019(2) 0.6958(3) 0.070(3) 
C(15) 0.2716(2) -0.0081(1) 0.6232(3) 0.065(2) 
C(16) 0.3457(2) 0.0367(1) 0.5910(2) 0.044(2) 
C(2) 0.3598(2) 0.2816(1) 0.5718(1) 0.020(1) 
C(3) 0.3011(2) 0.3145(1) 0.5169(1) 0.020(1) 
C(3a) 0.3066(2) 0.2660(1) 0.4529(1) 0.020(1) 
C(31) 0.2498(2) 0.3898(1) 0.5181(1) 0.021(1) 
C(32) 0.1768(2) 0.4114(1) 0.5694(1) 0.028(1) 
C(33) 0.1314(2) 0.4832(1) 0.5683(1) 0.030(1) 
C(34) 0.1591(2) 0.5347(1) 0.5148(1) 0.028(1) 
O(34) 0.1199(1) 0.60670(9) 0.5081(1) 0.040(1) 
C(341) 0.0416(2) 0.6298(2) 0.5576(2) 0.040(2) 
C(35) 0.2316(2) 0.5141(1) 0.4627(1) 0.030(1) 
C(36) 0.2766(2) 0.4429(1) 0.4647(1) 0.027(1) 
C(4) 0.2544(2) 0.2669(1) 0.3836(1) 0.022(1) 
C(4) 0.1863(1) 0.32513(9) 0.37104(8) 0.0277(9) 
C(41) 0.1352(2) 0.3284(2) 0.3004(1) 0.032(1) 
C(5) 0.2723(2) 0.2096(1) 0.3341(1) 0.025(1) 
C(6) 0.3423(2) 0.1511(1) 0.3524(1) 0.026(1) 
C(6) 0.3511(1) 0.09799(9) 0.29757(9) 0.036(1) 
C(61) 0.4225(3) 0.0369(2) 0.3107(2) 0.044(2) 
C(7) 0.3946(2) 0.1467(1) 0.4198(1) 0.025(1) 
C(7a) 0.3734(4) 0.2051(1) 0.4696(3) 0.021(1) 
S(1’) 0.55578(4) 0.37740(3) 0.64473(3) 0.0223(3) 
O(11’) 0.5485(1) 0.35737(9) 0.56870(8) 0.0265(8) 
O(12’) 0.6479(1) 0.36007(9) 0.68779(9) 0.0290(9) 
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C(11’) 0.5287(2) 0.4743(1) 0.6561(1) 0.025(1) 
C(12’) 0.4476(2) 0.5060(1) 0.6140(2) 0.037(1) 
C(13’) 0.4245(2) 0.5820(2) 0.6237(2) 0.048(2) 
C(14’) 0.4811(2) 0.6245(2) 0.6754(2) 0.045(2) 
C(15’) 0.5619(2) 0.5924(2) 0.7159(2) 0.040(2) 
C(16’) 0.5872(2) 0.5163(1) 0.7064(1) 0.031(1) 
N(1’) 0.4555(1) 0.3350(1) 0.6856(1) 0.0218(9) 
C(2’) 0.3665(2) 0.3008(1) 0.6504(1) 0.020(1) 
C(3’) 0.2935(2) 0.2843(1) 0.7027(1) 0.021(1) 
C(31’) 0.1858(2) 0.2563(1) 0.6851(1) 0.023(1) 
C(32’) 0.1660(2) 0.2006(1) 0.6323(1) 0.027(1) 
C(33)’ 0.0658(2) 0.1832(1) 0.6083(1) 0.031(1) 
C(34’) -0.0189(2) 0.2227(1) 0.6357(1) 0.029(1) 
O(34’) -0.1155(1) 0.2023(1) 0.6063(1) 0.041(1) 
C(341’) -0.2020(2) 0.2495(2) 0.6235(2) 0.041(2) 
C(35’) -0.0029(2) 0.2776(1) 0.6889(1) 0.028(1) 
C(36’) 0.0993(2) 0.2936(1) 0.7138(1) 0.025(1) 
C(3a’) 0.3389(2) 0.3066(1) 0.7735(1) 0.022(1) 
C(4’) 0.3073(2) 0.2996(1) 0.8476(1) 0.025(1) 
O(4’) 0.2143(1) 0.26391(9) 0.85877(9) 0.0307(9) 
C(41’) 0.1791(3) 0.2613(2) 0.9333(2) 0.038(2) 
C(5’) 0.3706(2) 0.3292(1) 0.9034(1) 0.027(1) 
C(6’) 0.4644(2) 0.03667(1) 0.8870(2) 0.028(1) 
O(6’) 0.5141(1) 0.3988(1) 0.94713(9) 0.039(1) 
C(61’) 0.6038(3) 0.4446(2) 0.9346(2) 0.055(2) 
C(7’) 0.5017(2) 0.3708(1) 0.8166(1) 0.026(1) 
C(7a’) 0.4372(2) 0.3390(1) 0.7614(1) 0.022(1) 
 
 
Hydrogen Positional and Isotropic Displacement Parameters 
Atom x/a y/b z/c U(eq) A**2 
H(12) 0.402(2) 0.141(1) 0.734(1) 0.030(7) 
H(13) 0.287(2) 0.066(2) 0.786(2) 0.045(9) 
H(14) 0.198(3) -0.024(2) 0.716(2) 0.07(1) 
H(15) 0.238(3) -0.046(2) 0.593(2) 0.08(1) 
H(16) 0.362(3) 0.029(2) 0.537(2) 0.07(1) 
H(32) 0.155(2) 0.378(1) 0.606(1) 0.025(6) 
H(33) 0.0.79(2) 0.495(1) 0.604(1) 0.033(7) 
H(341a) -0.021(2) 0.596(1) 0.557(1) 0.031(7) 
H(341b) 0.020(2) 0.680(2) 0.540(2) 0.061(9) 
H(341c) 0.071(2) 0.630(2) 0.607(2) 0.043(8) 
H(35) 0.250(2) 0.550(1) 0.424(1) 0.038(7) 
H(36) 0.326(2) 0.428(1) 0.432(1) 0.031(7) 
H(41a) 0.093(2) 0.376(1) 0.303(1) 0.030(6) 
H(41b) 0.088(2) 0.285(2) 0.294(1) 0.037(7) 
H(41c) 0.189(2) 0.332(1) 0.259(2) 0.044(8) 
H(5) 0. 238(2) 0.207(1) 0.290(1) 0.017(6) 
H(61a) 0.398(2) 0.006(2) 0.353(2) 0.051(9) 
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H(61b) 0.496(2) 0.056(2) 0.326(2) 0.048(8) 
H(61c) 0.418(2) 0.007(2) 0.267(2) 0.048(8) 
H(7) 0.442(2) 0.103(1) 0.433(1) 0.024(6) 
H(12’) 0.409(2) 0.474(2) 0.579(1) 0.042(8) 
H(13’) 0.369(2) 0.604(2) 0.595(2) 0.054(9) 
H(14’) 0.472(2) 0.677(2) 0.684(2) 0.053(9) 
H(15’) 0.642(2) 0.622(1) 0.749(1) 0.037(7) 
H(16’) 0.642(2) 0.495(1) 0.735(1) 0.025(6) 
H(32’) 0.233(2) 0.172(1) 0.612(1) 0.026(6) 
H(33’) 0.051(2) 0.143(2) 0.574(2) 0.045(8) 
H(341’a) -0.268(3) 0.225(2) 0.598(2) 0.055(9) 
H(341’b) -0.188(3) 0.305(2) 0.603(2) 0.07(1) 
H(341’c) -0.210(3) 0.249(2) 0.674(2) 0.06(1) 
H(35’) -0.060(2) 0.302(2) 0.708(1) 0.024(6) 
H(36’) 0.108(2) 0.333(2) 0.754(1) 0.027(6) 
H(41’a) 0.108(2) 0.238(2) 0.929(1) 0.042(8) 
H(41’b) 0.174(2) 0.312(2) 0.953(2) 0.044(8) 
H(41’c) 0.228(2) 0.231(2) 0.964(2) 0.49(9) 
H(5) 0.352(2) 0.327(1) 0.951(1) 0.019(6) 
H(61’a) 0.595(3) 0.486(2) 0.898(2) 0.08(1) 
H(61’b) 0.664(3) 0.411(2) 0.917(2) 0.07(1) 
H(61’c) 0.627(3) 0.468(2) 0.980(2) 0.07(1) 




Atomic Anisotropic Displacement Parameter 
Atom U11 U22 U33 U12 U13 U23 
N(1) 0.0209(9) 0.0220(9) 0.0170(9) 0.0028(7) -0.0019(7) 0.0008(7) 
S(1) 0.202(3) 0.0239(3) 0.0215(3) 0.0021(2) -0.0023(2) 0.0031(2) 
O(11) 0.0228(8) 0.0298(8) 0.0262(9) -0.0008(6) -0.0067(7) 0.0039(7) 
O(12) 0.0300(9) 0.0300(9) 0.0262(9) 0.0116(7) 0.0003(7) 0.0001(7) 
C(11) 0.025(1) 0.025(1) 0.035(1) -0.0007(9) 0.004(1) 0.011(1) 
C(12) 0.028(1) 0.039(1) 0.037(2) 0.005(1) -0.001(1) 0.014(1) 
C(13) 0.039(2) 0.0066(2) 0.056(2) 0.004(1) 0.008(2) 0.034(2) 
C(14) 0.044(2) 0.0059(2) 0.105(3) -0.021(2) -0.001(2) 0.045(2) 
C(15) 0.065(2) 0.040(2) 0.088(3) -0.023(2) -0.014(2) 0.017(2) 
C(16) 0.047(2) 0.028(1) 0.057(2) -0.008(1) -0.012(1) 0.008(1) 
C(2) 0.018(1) 0.022(1) 0.020(1) -0.0001(8) 0.013(8) 0.0003(8) 
C(3) 0.019(1) 0.023(1) 0.019(1) -0.0013(8) 0.0010(8) 0.0011(8) 
C(3a) 0.019(1) 0.022(1) 0.019(1) -0.0007(8) 0.0005(7) 0.0015(8) 
C(31) 0.020(1) 0.024(1) 0.018(1) -0.007(8) -0.0031(8) -0.0010(8) 
C(32) 0.031(1) 0.030(1) 0.022(1) 0.004(1) 0.004(1) 0.005(1) 
C(33) 0.031(1) 0.032(1) 0.027(1) -0.007(1) 0.008(1) -0.001(1) 
C(34) 0.028(1) 0.022(1) 0.033(1) 0.0022(9) -0.001(1) -0.001(1) 
O(34) 0.040(1) 0.0243(9) 0.055(1) 0.0076(7) 0.0127(9) 0.0018(8) 
C(341) 0.041(2) 0.031(1) 0.049(2) 0.009(1) 0.005(1) -0.008(1) 
C(35) 0.030(1) 0.025(1) 0.035(1) -0.0002(9) -0.0031(1) 0.008(1) 
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C(36) 0.026(1) 0.027(1) 0.027(1) 0.0014(9) 0.004(1) 0.0014(9) 
C(4) 0.021(1) 0.023(1) 0.021(1) 0.0025(8) 0.008(1) 0.0026(9) 
O(4) 0.0327(9) 0.0284(9) 0.0215(8) 0.0099(7) -0.001(1) -0.0016(6) 
C(41) 0.035(1) 0.034(1) 0.025(1) 0.007(1) 0.0127(9) 0.001(1) 
C(5) 0.027(1) 0.029(1) 0.018(1) 0.0016(9) 0.005(1) -0.0004(9) 
C(6) 0.032(1) 0.024(1) 0.022(1) 0.0019(9) 0.008(1) -0.0041(9) 
O(6) 0.052(1) 0.0301(1) 0.0266(9) 0.0156(8) 0.006(1) -0.0083(7) 
C(61) 0.063(2) 0.033(1) 0.038(2) 0.020(1) -0.0003(9) -0.009(1) 
C(7) 0.028(1) 0.024(1) 0.022(1) 0.0056(9) -0.0075(7) -0.0007(9) 
C(7a) 0.020(2) 0.024(1) 0.019(1) 0.0001(8) -0.0008(8) 0.0015(8) 
S(1’) 0.0207(3) 0.0259(3) 0.0204(3) -0.007(2) 0.013(2) -0.0011(2) 
O(11’) 0.0290(8) 0.0290(8) 0.0200(8) -0.0033(6) 0.0032(6) -0.0024(6) 
O(12’) 0.0290(8) 0.0219(8) 0.0291(9) 0.0012(7) -0.0013(7) -0.0009(7) 
C(11’) 0.025(1) 0.025(1) 0.024(1) 0.0023(9) 0.0038(9) -0.0019(5) 
C(12’) 0.035(1) 0.035(1) 0.044(2) -0.001(1) -0.010(8) -0.004(1) 
C(13’) 0.044(2) 0.044(2) 0.065(2) 0.006(1) -0.016(7) -0.002(1) 
C(14’) 0.052(2) 0.052(2) 0.055(2) 0.003(1) -0.000(1) -0.010(1) 
C(15’) 0.049(2) 0.049(2) 0.034(2) -0.007(1) 0.001(1) -0.009(1) 
C(16’) 0.032(1) 0.032(2) 0.024(1) -0.005(1) -0.002(1) -0.002(1) 
N(1’) 0.0225(9) 0.0225(9) 0.0169(9) -0.0008(7) -0.0004(7) -0.0008(7) 
C(2’) 0.019(1) 0.019(1) 0.19(1) 0.019(8) -0.0024(8) 0.0016(8) 
C(3’) 0.023(1) 0.023(1) 0.019(1) 0.030(8) -0.0021(8) 0.0010(8) 
C(31’) 0.026(1) 0.026(1) 0.019(1) 0.0005(9) 0.0007(9) 0.0049(9) 
C(32’) 0.024(1) 0.024(1) 0.028(1) 0.0042(9) 0.000(1) -0.000(1) 
C(33’) 0.027(1) 0.027(9) 0.031(1) -0.000(1) -0.003(1) -0.006(1) 
C(34’) 0.023(1) 0.023(1) 0.030(1) -0.0010(9) -0.000(1) 0.002(1) 
O(34’) 0.229(9) 0.0229(9) 0.045(1) 0.0001(8) -0.0021(8) -0.0084(9) 
C(341’) 0.024(1) 0.024(1) 0.033(2) 0.005(1) 0.005(1) 0.004(1) 
C(35’) 0.024(1) 0.024(1) 0.027(1) 0.0034(9) 0.007(1) 0.002(1) 
C(36’) 0.028(1) 0.026(1) 0.023(1) 0.0004(9) 0.0044(9) 0.0030(9) 
C(3a’) 0.026(1) 0.026(1) 0.019(1) 0.0036(8) -0.0006(9) -0.0001(8) 
C(4’) 0.027(1) 0.027(1) 0.023(1) 0.0030(9) 0.0037(9) 0.0021(9) 
O(4’) 0.0346(9) 0.0346(9) 0.0201(8) -0.0058(7) 0.066(7) 0.0016(7) 
C(41’) 0.046(2) 0.046(2) 0.026(1) -0.007(1) 0.015(1) -0.002(1) 
C(5’) 0.035(1) 0.030(1) 0.015() -0.006(1) 0.0008(6) 0.0009(9) 
C(6’) 0.030(1) 0.033(1) 0.020(1) 0.005(1) 0.0053(9) -0.0032(9) 
O(6’) 0.040(1) 0.053(1) 0.0224(9) -0.0043(8) -0.0036(8) 0.0073(8) 
C(61’) 0.045(2) 0.083(3) 0.036(2) -0.021(2) 0.001(1) -0.0023(2) 
C(7’) 0.025(1) 0.032(1) 0.022(1) 0.0004(9) -0.0012(9) -0.001(1) 
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Bond Distances (Angstroms) 
N(1) –S (1) 1.669(2) 
N(1) –C (2) 1.441(2) 
N(1) –C (7a) 1.410(3) 
S(1) – O (11) 1.418(2) 
S (1) – O (12) 1.428(2) 
S (1) –C (11) 1.753(2) 
C (11) –C (12) 1.377(4) 
C (11) –C (16) 1.396(4) 
C (12) –C (13) 1.373(7) 
C (13) –C (14) 1.373(5) 
C (14) –C (15) 1.361(3) 
C (15) –C (16) 1.467(3) 
C (2) –C (3) 1.482(3) 
C (2) –C (2’) 1.408(3) 
C (3) –C (3a) 1.399(3) 
C (3) –C (31) 1.387(3) 
C (3a) –C (4) 1.397(3) 
C (3a) –O (7a) 1.394(3) 
C (31) –C (32) 1.384(3) 
C (31) –C(36) 1.371(3) 
C (33) –C(34) 1.388(3) 
C (34) –O (34) 1.419(4) 
C (34) –C (35) 1.382(3) 
O (34) –C (341) 1.361(3) 
C (35) –C (36) 1.376(3) 
C (4) –O (4) 1.425(3) 
C (4) –C (5) 1.375(3) 
C (4) –C (41) 1.379(3) 
C (6) –O (6) 1.427(4) 
C (6) –C (7) 1.403(3) 
O (1) –C (61) 1.426(2) 
C (7) –C (7a) 1.425(2) 
S(1’) – O (11’) 1.761(2) 
S (1’) – O (12’) 1.670(2) 
S (1’) –C (11’) 1.386(3) 
S (1’) –N (1’) 1.381(3) 
C (11’) –C (12’) 1.387(4) 
C (11’) –C (16’) 1.388(4) 
C (12’) –C (13’) 1.372(4) 
C (14’) –C (15’) 1.393(4) 
C (15’) –C (16’) 1.422(3) 
N (1’) –C (2’) 1.403(3) 
N (1’) –C (7a’) 1.376(3) 
C (2’) –C (3’) 1.485(3) 
C (3’) –C (31’) 1.450(3) 
C (3’) –C (3a’) 1.393(3) 
C (31’) –C (32’) 1.395(3) 
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C (31’) –C (36’) 1.373(3) 
C (32’) –C(33’) 1.387(3) 
C (33’) –C(34’) 1.376(3) 
C (34’) –O (34’) 1.381(3) 
C (34’) –C (35’) 1.422(3) 
O (34’) –C (341’) 1.395(3) 
C (35’) –C (36’) 1.420(3) 
C (3a’) –C (4’) 1.397(3) 
C (4’) –O (4’) 1.361(3) 
C (4’) –C (5’) 1.381(3) 
O (4’) –C (41’) 1.438(3) 
C (5’) –C (6’)           1.404(3) 
C (6’) –O (6’)           1.370(3) 
C (6’) –C (7’)           1.378(3) 
O (6’) –C (61’)           1.423(4) 
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Bond Angles (degrees) 
S (1) –N (1) –C (2) 126.2  (1) 
S (1) –N (1) –C (7a) 125.4  (1) 
C (2) –N (1) –C (7a) 108.0  (2) 
N (1) –S (1) –O (11) 107.74(9) 
N (1) –S (1) –O (12) 106.17(9) 
N(1) –S (1) –C (11) 105.3 (1) 
O (11) –S (1) –O(12) 119.64(9) 
O (11) –S (1) –C (11) 108.3 (1) 
O (12) –S (1) –C (11) 108.8(1) 
S (1) –C (11) –C (12) 119.6 (2) 
S (1) –C (11) –C (16) 118.4 (2) 
C (12) –C (11) –C (16) 122.0 (2) 
C (11) –C (12) –C (13) 118.1 (3) 
C (12) –C (13) –C (14) 120.0 (3) 
C (13) –C (14) –C (15) 120.9 (4) 
C (14) –C (15) –C (16) 120.5 (3) 
C (11) –C (16) –C (15) 118.4 (3) 
N (1) –C (2) –C (3) 108.7 (2) 
N (1) –C (2) –C (2’) 121.8 (2) 
C(3) –C (2) –C (2’) 129.1 (2) 
C(2) –C (3) –C (3a) 107.4 (2) 
C (2) –C (3) –C (31) 127.3 (2) 
    C (3a) –C (3)-C(31) 125.0 (2) 
    C (3) –C (3a)-C(4) 132.8 (2) 
C (3) –C (3a) –C (7a) 108.8 (2) 
C (4) –C (3a) –C (7a) 118.2 (2) 
C (3) –C (31) –C (32) 124.0 (2) 
C (3) –C (31) –C (36) 118.5 (2) 
C (32) –C (31) –C (36) 117.5 (2) 
C (31) –C (32) –C (33) 121.7 (2) 
C (32) –C (33) –C (34) 119.8 (2) 
C (33) –C (34) –O (34) 125.1 (2) 
C (33) –C (34) –C (35) 119.5 (2) 
O (34) –C (34) –O (35) 115.4 (2) 
C (34) –O (34) –C (341) 118.0 (2) 
C (34) –C (35) –C (36) 120.4 (2) 
C (31) –C (36) –C (35) 121.4 (2) 
C (3a) –C (4) –O (4) 116.2 (2) 
C (3a) –C (4) –C (5) 119.6 (2) 
O (4) –C (4) –C (5) 124.2 (2) 
C (4) –O (4) –C (41) 117.1 (2) 
C (4) –C (5) –C (6) 120.2 (2) 
C (5) –C (6) –O (6) 113.2 (2) 
C (5) –C (6) –C (7) 122.8 (2) 
O (6) –C (6) –C (7) 124.0 (2) 
C (6) –O (1) –C (61) 117.2 (2) 
C (6) –C (7) –C (7a) 115.8 (2) 
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N (1) –C (7a) –C (3a) 107.0 (2) 
N (1) –C (7a) –C (7) 129.6 (2) 
C (3a) –C (7a) –C (7) 123.4 (2) 
O (11’) –S (1’) –O (12’) 120.7 (2) 
O (11’) –S (1’) –C (11’) 110.3 (2) 
O (11’) –S (1’) –N (1’) 106.72 (9) 
O(12) –S (1’) –C (11’) 107.8 (1) 
O (12’) –S (1’) –N (1’) 106.63 (2) 
C (11’) –S (1’) –N (1’) 103.3 (1) 
S (1’) –C (11’) –C (12’) 118.2 (2) 
S (1’) –C (11’) –C (16’) 119.8 (2) 
C (12’) –(11’) –C (16’) 122.0 (2) 
C (11’) –C (12’) –C (13’) 118.6 (2) 
C (12’) –C (13’) –C (14’) 120.1 (2) 
C (14’) –C (15’) –C (16’) 120.4 (2) 
C (11’) –C (16’) –C (15’) 118.5 (2) 
S (1’) –N (1’) –C (2’) 126.8 (1) 
S (1’) –N (1’) –C (7a’) 124.2 (1) 
C (2’) –N (1’) –C (7a’) 108.2 (2) 
C (2’) –C (2’) –N (1’) 124.2 (2) 
C (2) –C (2’) –C (3’) 126.8 (2) 
N (1’) –C (2’) –C (3’) 108.9 (2) 
C (2’) –C (3’) –C (31’) 123.9 (2) 
C (2’) –C (3’) –C (3a’) 107.1 (2) 
C (31’) –C (3’) –C (3a’) 128.8 (2) 
C (3’) –C (31’) –O (32’) 122.2 (2) 
C (3’) –C (31’) –C (36’) 119.7 (2) 
C (32’) –C (31’) –C (36’) 117.5 (2) 
C (31’) –C (32’) –C (33’) 121.8 (2) 
C (32’) –C (33’) –C (34’) 119.8 (2) 
C (33’) –C (34’) –O (34’) 115.0 (2) 
C (33’) –C (34’) –C (35’) 120.2 (2) 
O (34’) –C (34’) –C (35’) 124.8 (2) 
C (34’) –O (34’) –C (341’) 116.7 (2) 
C (34’) –C (35’) –C (36’) 119.3 (2) 
C (31’) –C (36’) –C (35’) 121.4 (2) 
C (3’) –C (3a’) –C (4’) 134.4 (2) 
C (3’) –C (3a’) –C (7a’) 108.1 (2) 
C (4’) –C (3a’) –C (7a’) 117.4 (2) 
C (3a’) –C (4’) –O (4’) 116.8 (2) 
C (3a’) –C (4’) –C (5’) 119.2(2) 
O (4’) –C (4’) –C (5’) 124.0(2) 
C (4’) –O (4’) –C (41’) 116.7(2) 
C (4’) –C (5’) –C (6’) 120.5(2) 
C (5’) –C (6’) –O (6’) 113.9(2) 
C (5’) –C (6’) –C (7’) 122.4(2) 
O (6’) –C (6’) –C (7’) 123.7(2) 
C (6’) –O (6’) –C (61’) 117.6(2) 
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C (6’) –C (7’) –C (7a’) 115.8(2) 
N (1’) –C (7a’) –C (3a’) 107.7(2) 
N (1’) –C (7a’) –C (7’) 127.9(2) 
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Appendix Table 1: Compound (186) 1H, 13C, gHMBC, gCOSY and NOESY 
correlations recorded in CDCl3 
 
S.No      13C              gHMBC  1H      gCOSY NOESY 
1 157.4  9.23   
2 156.4  8.75   
3 155.4  7.44   
4 155.2  7.25   
5 138.5  6.88   
6 136.2  6.57   
7 135.9  6.41   
8 131.6  6.24   
9 130.4  3.87   
10 126.2  3.83   
11 122.5  3.75   
12 119.5  3.72   
13 117.7     
14 111.8     
15 110.4     
16 98.2     
17 92.1     
18 89.7     
19 87.4     
20 58.9     
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